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ABSTRACT 
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous 
system. In around 85% of cases, the disease progresses through two distinct 
stages: relapsing-remitting MS (RRMS) is driven by repeated bouts of 
demyelination caused by autoimmune inflammation; and progressive MS, in which 
inflammation gives way to neurodegenerative processes that lead to axonal loss 
and the steady accumulation of disability. There is no cure for MS and the majority 
of disease-slowing treatments target the immune response in RRMS. These 
interventions are ineffective in progressive MS and other treatment options are 
extremely limited. Understanding the mechanisms underlying neurodegeneration 
in MS is critically important to developing therapeutics for progressive disease. 
Fibroblast growth factor 9 (FGF9) has recently been implicated in the 
pathogenesis of MS. FGF9 inhibits myelination and promotes the production of 
inflammatory chemokines. This led to the hypothesis that FGF9 is involved in 
remyelination failure and may promote neurodegeneration via tissue remodelling 
and inflammatory pathways. FGF signaling is complex and the findings in MS 
raised many questions: what cells respond to FGF9 in MS? Why is FGF9 
expression induced in the first place? Can FGF9 cause demyelination as well as 
inhibit myelination? This thesis has focused on the roles of FGF9 in MS and tried 
to answer these questions. 
Through in vitro models, astrocytes, oligodendrocytes, and macrophages were 
shown to express feedback inhibitors of FGF signaling when treated with FGF9. 
Astrocytes produced FGF9 in response to hypoxic stress, macrophages 
expressed FGF9 when polarized towards an anti-inflammatory phenotype, 
suggesting hypoxia, and repair processes may drive FGF9 expression in the CNS. 
FGF9 did not cause demyelination in vitro but over-expression in vivo induced 
severe demyelination over the course of several months. Oligodendrocytes 
exposed to FGF9 failed to differentiate properly when the factor was removed 
which led to aberrant myelination. Long-term treatment with FGF9 induced axonal 
pathology, potentially via deficits in axon-transport. Over-expression of FGF9 in rat 
cortex also produced an axonal pathology, which suggests chronic exposure is 
detrimental to neurons. Together, these findings indicate that increased levels of 
FGF9 are detrimental to myelination and neurons in the CNS. Demyelination, and 
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axonal pathology are hallmarks of MS and these studies provide evidence that 
FGF9 can mediate these processes in in vitro and in vivo models. 
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1 GENERAL INTRODUCTION 
1.1 General introduction to multiple sclerosis 
1.1.1 Historical perspective of multiple sclerosis 
The earliest known description of symptoms thought to be caused by multiple 
sclerosis (MS) comes from 12th century Iceland; from the account of a woman that 
suffered transient paresis and vision loss (Holmøy, 2006). The first descriptions  
and illustrations of MS lesions come from Sir Robert Carswell, a Professor of 
pathology in the early 19th Century (Compston, 1988). Carswell described the 
hallmarks of lesions of the brain and spinal cord but did not identify MS as a 
disease in its own right (Murray, 2009). This had to wait a further 40 years until the 
French neurologist, Professor Jean-Martin Charcot collated clinical and 
pathological descriptions of the disease he named “sclerose en plaque” 
(Compston, 1988). Charcot described three clinical symptoms that were used in 
the early diagnosis of MS: nystagmus, intention tremor, and telegraphic speech, 
known as Charcot’s neurological triad. Charcot also described cognitive symptoms 
of MS such as memory loss, difficulty grasping new concepts, and emotional 
disturbances (Özakbaş, 2015). This marked the beginning of defining diagnostic 
guidelines for MS which now draw extensively on magnetic resonance imaging 
(MRI) based criteria and cerebrospinal fluid (CSF) findings, as well as 
symptomology (Polman et al., 2011). 
The development of effective treatments for MS followed these improvements in 
disease diagnosis. High dose, intravenous steroid therapy replaced 
adrenocorticotropic hormone based treatments (Eisen and Norris, 1969) in the 
1970’s and is still used in the treatment of clinically severe acute relapses (Milligan 
et al., 1987, Caster and Edwards, 2015). However, the first treatments to show 
real efficacy in reducing relapse frequency were β-interferons which became 
available in the 1990’s (Ebers, 1998). There are currently a dozen approved 
immunomodulatory treatments for relapsing-remitting MS (RRMS) (Table 1.1), but 
their efficacy remains limited by large numbers of non-responders and their failure 
to halt accumulation of disability in patients with progressive forms of the disease.  
 
Chapter 1 – General Introduction 3 
 
 
 
 
 
(Hauser et al., 2017, Myhr and Mellgren, 2009, Tumani, 2008, Kieseier, 2011, 
Neuhaus et al., 2001, Fox, 2006, Hutchinson, 2007, Khatri, 2016, Gandoglia et al., 
2017, Havrdova et al., 2015, Linker and Haghikia, 2016, Lycke, 2015)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 1
.1
. 
C
u
rr
e
n
tl
y
 a
p
p
ro
v
e
d
 t
re
a
tm
e
n
ts
 f
o
r 
m
u
lt
ip
le
 s
c
le
ro
s
is
 
Chapter 1 – General Introduction 4 
 
The introduction of these immunomodulatory treatments can be traced back 
studies in the 1930’s that lead to the development of experimental autoimmune 
encephalitis (EAE) as an animal model for MS (Chaudhuri and Behan, 2005).  
EAE is a CD4+ T-cell mediated autoimmune disease that reproduces many of the 
clinical and pathological features of RRMS in which disease activity is driven by 
inflammatory activity in the central nervous system (CNS). Unfortunately, other 
pathological mechanisms appear to be responsible for disease activity in 
progressive forms of MS for which there are currently no effective treatments 
available.   
1.1.2 Pathogenesis of multiple sclerosis 
Several demyelinating diseases of the CNS share common features with, and can 
be difficult to differentiate from, classical MS. Neuromyelitis optica, for example, 
produces inflammatory demyelinating lesions and has a relapsing disease course, 
but mostly affects the optic nerves and spinal cord while sparing the brain 
(Wingerchuk et al., 1999). Acute disseminated encephalomyelitis causes 
widespread CNS inflammation and demyelination but occurs as a single bout of 
inflammation and is triggered by infections or immunization although the 
mechanism responsible is still unknown (Sanderson et al., 2017). Classification 
and diagnosis of the different demyelinating diseases is still difficult due to the 
overlapping mechanisms of damage and the unknown triggers in most cases. 
Several hypotheses for the cause of MS have been proposed such as vitamin 
deficiency, hygiene, infections, vaccination, gut microbiota, etc. yet the trigger or 
triggers remain a mystery. It has however, become clear that a combination of 
genetic susceptibility and environmental factors determine ones likelihood of 
developing the disease. If one twin has MS, a monozygotic twin has a 30% chance 
of developing MS while a dizygotic twin has only a 7.5% chance (Willer et al., 
2003). Having two affected parents carries a higher risk of developing MS than 
having just one, 25% vs 15% respectively (Robertson et al., 1997). These 
observations point towards a clear genetic component and genome-wide 
association studies have identified over 50 susceptibility genes for MS (Lin et al., 
2015). The majority of these genes are involved in the immune system with the 
strongest association in human leukocyte antigen (HLA) genes (Olerup and Hillert, 
1991). HLA genes are highly variable amongst the population as they transcribe 
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components of the major histocompatibility complex (MHC) class I and II, which 
mediate antigen presentation between antigen presenting cells, and B and T cells. 
Polymorphisms in interleukin receptor genes and in the myelin oligodendrocyte 
glycoprotein (MOG) have also been associated with a greater susceptibly to MS 
(Hafler et al., 2007, Lin et al., 2015).  
Prevalence of MS generally increases further north and south from the equator 
and in the last few decades, rates of MS have increased drastically in some areas 
pointing to the involvement of strong environmental factors. In Canada for 
example, the female to male ratio has increased over the last half century to 
exceed 3.2 : 1 (Orton et al., 2006). Several studies focusing on different 
populations have shown migration from a high-risk area to a low-risk area 
correlates with a decrease in risk for MS and vice versa (Elian et al., 1990, 
Hammond et al., 2000). These studies indicate that sun exposure may be a factor 
in the latitudinal gradient of MS prevalence. This is supported by extensive 
studies, which demonstrate a strong correlation between high levels of vitamin D 
and a reduced risk of MS (Riccio and Rossano, 2017, Munger et al., 2006, Alharbi, 
2015). The most substantial environmental risk factor so far identified is Epstein-
Barr virus (EBV) infection in childhood or early adulthood associated with a 15 - 
and 30 - fold increased risk of MS respectively (Levin et al., 2003). The 
mechanisms linking MS with EBV infection are still not fully understood but B and 
T cells in MS lesions have been independently implicated. In one study the vast 
majority of MS brains contained infiltrating B cells infected with EBV while brains 
with other inflammatory diseases did not (Serafini et al., 2007). T cells from MS 
patients with MS-linked MHCII alleles recognise EBV and myelin basic protein 
(MBP) peptides suggesting molecular mimicry may lead to an autoimmune 
response against myelin (Lang et al., 2002). None of these factors can account for 
all cases of MS or the underlying mechanisms that facilitate disease. Especially 
lacking is evidence for the causes of progressive forms of MS, which mainly lack 
inflammatory components that most of the genetic and environmental risk factors 
are associated with. 
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1.1.2.1 Relapsing remitting multiple sclerosis 
RRMS accounts for about 85% of MS cases diagnosed and mostly strikes people 
in their 20s with around 5% of cases occurring in children (Özakbaş, 2015). RRMS 
normally presents as clinically isolated syndrome (CIS) in which patients present 
with one or more neurological symptoms such as optic neuritis and numbness in 
the extremities. If patients with CIS also have lesions or white matter (WM) 
abnormalities detectable by MRI, they have a 60 - 80% chance of developing MS 
within 5 years vs 20% for CIS patients without detectable lesions (Fisniku et al., 
2008). Patients that develop MS will typically experience relapses every 1.5 years 
but the frequency is highly variable and can be reduced with current treatments. 
95% of MS patients have white matter lesions detectable by MRI and 90% have 
evidence of intrathecal antibody synthesis, detected as oligoclonal bands on gel 
electrophoresis of CSF (Polman et al., 2011). 
Patients with RRMS develop spontaneous and erratic neurological symptoms 
accompanied by the appearance of inflammatory lesions in the corresponding 
brain or spinal cord region. Patients will then go through periods of remission 
where symptoms may partially or totally disappear, this is more common in early 
stages of disease and over the course of 20 - 30 years patients will accumulate a 
variety of disabilities and cognitive impairments.  
Although the trigger of MS is unknown, pathogenesis is thought to begin with the 
entry of self-reactive T cells into the CNS. CD4+ T helper-17 (Th17) cells secrete 
IL-17 and -22, which activate endothelial cells of the blood-brain barrier (BBB) to 
upregulate integrin expression (Kebir et al., 2007, Tzartos et al., 2008). Circulating 
monocytes as well as CD8+ T cells, B cells, and plasma cells are recruited into the 
CNS via the activated BBB and inflammatory lesions begin to develop. Infiltrating 
immune cells become activated and in turn secrete a variety of inflammatory 
cytokines, which activate and recruit resident microglia into the lesion. B cells and 
plasma cells secrete antibodies that opsonise myelin and axons, and are detected 
as oligoclonal bands in CSF. Antibody deposition further opsonises myelin and 
facilitates damage via complement activation as serum proteins cross the 
damaged BBB (Lucchinetti et al., 2000). Monocytes and microglia secrete tumour 
necrosis factor α (TNFα) and nitric oxide (NO), which kills oligodendrocytes (OLs) 
and impairs mitochondrial function respectively (Nakazawa et al., 2006, Zajicek et 
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al., 1992, Lan et al., 2017). NO can kill neurons directly, as well as via 
mitochondrial impairment (Smith et al., 2001, Dutta et al., 2006). CD8+ T cells are 
the predominant T cell population in MS lesions but their role in disease is still 
controversial as different groups find they have pathological and beneficial 
functions depending on the experimental model used (Sinha et al., 2015). This 
combination of inflammatory pathological mechanisms results in extensive loss of 
mature OLs, degradation of myelin sheathes and damage to underlying axons 
(Bitsch et al., 2000). 
Myelin debris is phagocytosed by infiltrating macrophages, which become laden 
with lipids and take on an anti-inflammatory phenotype; they are termed foamy 
macrophages due to their appearance in histology (Boven et al., 2006, Brück et 
al., 1995). At this stage remyelination may occur, as the brain’s resident 
oligodendrocyte precursor cell (OPC) population migrate into lesions and mature 
(Chandran et al., 2008). The new OLs ensheath denuded axons and account for 
the appearance of so-called shadow plaques, partially remyelinated lesions 
observed in histology of MS brains. Remyelination is highly variable in the 
population with only 20% of RRMS patients exhibiting extensive remyelination, 
which was correlated with longer disease duration and life expectancy, suggesting 
that remyelination is protective in MS (Patrikios et al., 2006). Although 
remyelination has long been considered a therapeutic target, there are currently 
no approved treatments for RRMS that enhance or promote remyelination. 
1.1.2.2 Progressive multiple sclerosis 
Within 20 years of disease onset, most RRMS patients will transition into 
secondary progressive MS (SPMS) (Tutuncu et al., 2013). In around 10% of 
patients, disease is progressive from the onset, known as primary progressive MS 
(PPMS) (Tutuncu et al., 2013). Primary progressive MS (PPMS) shares many 
similarities with SPMS and some key distinctions, however from here they will be 
referred to together as progressive MS unless otherwise stated. Progressive MS is 
characterised by a steady worsening of symptoms without periods of recovery and 
the majority of disability associated with MS is acquired during progressive stages 
of disease (Nandoskar et al., 2017).  
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In SPMS, the change in clinical symptoms reflects the shift from inflammatory to 
neurodegenerative mechanisms that drive pathogenesis. This also renders the 
majority of RRMS treatments, which target the immune system, ineffective against 
progressive forms of MS. The trigger for progressive MS is unknown, however the 
strongest risk factor is age; onset of progressive MS occurs at 40 – 50 years old, 
regardless of whether the patient had RRMS or the age of the patient when 
disease first presented (Tutuncu et al., 2013). 
New lesions can develop in progressive MS and relapses can occur but the main 
drivers of disease are lesion expansion and diffuse white matter pathology. Around 
5% of patients present with progressive MS but also suffer relapses that may or 
may not recover (Trapp and Nave, 2008). Post-mortem progressive MS brains 
display two major types of lesion, chronic-active and chronic-inactive lesions 
(Prineas et al., 2001). Chronic active lesions consist of an inactive lesion core 
surrounded by a slowly expanding, active rim. The active rim resembles acute 
lesions in composition; activated macrophages and microglia are numerous and 
actively phagocytose myelin breakdown products (Lucchinetti et al., 2000). OL 
numbers are reduced and lymphocytes are present in the active rim, and 
penetrate beyond the rim into normal appearing white matter (NAWM). Grey 
matter (GM) lesions are uncommon in RRMS but become more frequent in 
progressive MS and are more strongly associated with disability progression than 
white matter pathology (Calabrese et al., 2012). The core of chronic-active lesions 
is hypocellular, containing mainly reactive astrocytes, a few scattered lymphocytes 
and myeloid cells and few if any OLs. Axonal pathology is more apparent in 
chronic-active lesions than acute lesions in which axons are mostly spared 
(Frischer et al., 2009). Some remyelination can occur in the chronic-active lesion 
rim and is sometimes observed throughout the lesion, however it is rarer in 
progressive MS than RRMS (Lassmann et al., 1997). 
Chronic-inactive lesions, also known as burnt-out lesions have a sharply 
demarcated border between demyelinated areas and NAWM. These lesions are 
quiescent and lymphocytes and myeloid cells are sparsely distributed throughout 
the rim and core (Frischer et al., 2009). Chronic-inactive lesions are mainly 
composed of reactive astrocytes that form a fibrotic scar. OLs are very rare in 
chronic-inactive lesions and axon numbers are reduced by up to 80% (Wilson et 
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al., 2006, Frischer et al., 2009). These lesions do not undergo remyelination and 
inflammatory damage has for the most part ceased, hence the term ‘burnt-out’. 
Another hallmark of progressive MS is diffuse white matter injury. Activated 
microglia, reactive astrocytes, and scattered lymphocytes are found throughout the 
white matter and cortex in progressive MS patients (Allen et al., 2001). 
Quantitative real-time polymerase chain reaction (qPCR) studies found that a 
mixture of pro- and anti-inflammatory genes, such as Il-10, Il-1β, Stat4, Stat6, and 
Csf1 are upregulated in white matter in progressive MS (Zeis et al., 2008). These 
changes are believed to contribute to diffuse myelin injury, axonal death, and 
general atrophy associated with progressive MS (Ceccarelli et al., 2007, 
Kutzelnigg et al., 2005). Around 50% of SPMS and 30% PPMS patients have a 
variable degree of meningeal inflammation (Choi et al., 2012). This is 
characterised by infiltration of T cells, B cells and macrophages in the meninges. 
Meningeal inflammation correlates with greater cortical demyelination, subpial 
lesion load, loss of neurites, and microglia activation in the cortex. Patients with 
more severe meningeal inflammation have a shorter disease course with more 
rapid accumulation of disability and earlier death. Interestingly, B-cell follicular 
structures, containing T- and B-cells, are found in the meninges of over 40% of 
SMPS patients, but they are not seen in PPMS (Magliozzi et al., 2007). Meningeal 
B-cell follicles were associated with earlier onset of MS and more severe disease; 
they were also always adjacent to cortical lesions, suggesting they may contribute 
to lesion development through production of inflammatory cytokines and 
antibodies.  
Besides low-grade inflammation, several neurodegenerative mechanisms have 
been implicated in the pathogenesis of progressive MS. The most obvious cause 
of neurodegeneration in SPMS is from repeated bouts of inflammatory 
demyelination and axonal injury that occurs in RRMS leaving irreparable damage 
in an aged CNS. Loss of OLs and myelin sheathes leaves axons without the 
trophic support they need to survive and so axonal loss occurs (Nave, 2010). Loss 
of myelin also leaves axons more vulnerable to direct damage and more 
susceptible to metabolic stressors. Demyelinated axons have a greater 
requirement for adenosine triphosphate (ATP) as Na+ ion channels, normally 
concentrated at the nodes or Ranvier, become spread out along the axon, making 
it harder to maintain the correct ion gradients for neurotransmission (Nave and 
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Trapp, 2008). This, combined with chronic mitochondrial dysfunction as a result of 
NO production by activated microglia and reactive astrocytes, contribute to axonal 
loss (Trapp and Stys, 2009). A further consequence of Na+ imbalance is increased 
Ca++ levels, which can cause axon degeneration and contributes to deficits in ATP 
production (Trapp and Stys, 2009). In the aged brain, release of reactive iron 
species from dying OLs and microglia causes oxidative damage of surrounding 
cells and contributes to neurodegeneration (Lassmann et al., 2012). Most of the 
neurodegenerative mechanisms associated with progressive MS feed into each 
other and therefore perpetuate and amplify damage. By promoting remyelination, it 
is thought that axons will be protected from downstream degeneration. 
1.2 The fibroblast growth factor signaling family 
Research into the fibroblast growth factor (FGF) signaling has its roots in 1939 
when it was discovered that brain extracts were particularly good inducers of 
proliferation in  periosteal fibroblasts (Trowell and Willmer, 1939). Nearly half a 
century later a protein in bovine pituitary extracts was shown to be mitogenic for 
3T3 mouse fibroblasts in vitro (Armelin, 1973), but, it was not until 1983 this factor 
was purified and named basic-FGF, now known as FGF2 (Lemmon and 
Bradshaw, 1983). Subsequently, several other FGFs were identified as 
oncogenes, endothelial cell growth factors, and tumour-promoting factors (Itoh, 
2007). Genetic studies eventually led to the consolidation of these factors into one 
family based on their high sequence homology (Beenken and Mohammadi, 2009). 
The first fibroblast growth factor receptor (FGFR) was purified from chicken 
embryos using a tagged, truncated FGF2 protein (Lee et al., 1989). The peptide 
sequence of the purified chicken FGFR was used to generate a complementary 
deoxyribonucleic acid (DNA) clone that was found to have high sequence 
homology with human and mouse versions of the same gene, now known to 
encode for FGFR1 (Lee et al., 1989). Stimulation of these receptors with purified 
FGFs resulted in phosphorylation and subsequent tyrosine-kinase activity (Huang 
and Huang, 1986, Coughlin et al., 1988). Screening of a chicken embryo 
complementary DNA (cDNA) library led to the identification of additional FGFRs, 
which were then also identified in human, and mouse by homology-based cloning 
(Pasquale, 1990a, Keegan et al., 1991, Partanen et al., 1991). 
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Since their discovery, the secreted FGFs have been found in all organs and 
tissues in the developing embryo with more limited expression in the adult (Sekine 
et al., 1999, Xu et al., 1998, Fon Tacer et al., 2010). FGF signaling is now known 
to be involved in the induction and patterning of germ layers, organogenesis and 
morphogenesis, cell migration, differentiation, survival, and wound healing (Ornitz 
and Itoh, 2015). FGF signaling occurs in simple invertebrates such as 
Caenorhabditis elegans, Drosophila, as well as all vertebrate species, but is 
absent in unicellular organisms such as Escherichia coli (E.coli) (Itoh, 2007, Itoh 
and Ornitz, 2011). These findings support the hypothesis that FGF signaling 
developed through metazoan evolution to mediate body patterning of multicellular 
organisms (Itoh, 2007, Itoh and Ornitz, 2011). 
Due to their prominent roles in development, mutations in genes involved in FGF 
signaling have been shown to cause a wide variety of developmental disorders 
that can impact every organ in the body (Itoh and Ornitz, 2011). Dysregulated FGF 
signaling is also a well-known facet of cancer development and is normally 
associated with a worse prognosis (Turner and Grose, 2010). During wound 
healing and tissue repair in the adult, FGFs are upregulated and mediate cell 
proliferation, differentiation and angiogenesis. Although roles for FGF signaling in 
developmental disorders and cancer are now well established, its involvement in 
the pathogenesis of inflammatory, autoimmune and acquired neurological 
diseases remains controversial. Its effects are likely to be context-dependent, as it 
is influenced by cross-talk with other signaling pathways associated with 
inflammation and tissue repair. Nonetheless, recent research identifies FGFs as 
promising therapeutic targets in cardiovascular disease, osteoarthritis, 
neurodegenerative disorders and neuropsychiatric conditions (Beenken and 
Mohammadi, 2009, Kiyota et al., 2011, Aurbach et al., 2015).  
1.2.1 Fibroblast growth factor ligands 
There are 22 FGFs expressed in humans, which are classified into two families, 
secreted and intracrine FGFs (iFGFs). The iFGFs do not signal through FGFRs 
and function mainly as co-factors for voltage gated sodium channels (Zhang et al., 
2012). The secreted FGFs are grouped into five paracrine-acting subfamilies and 
one endocrine-acting subfamily based on their structural similarities and 
evolutionary history. The paracrine FGF subfamilies and their interactions with 
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FGFRs are summarized in Figure 1.1. The endocrine-FGF subfamily evolved only 
in vertebrates and is involved in the regulation of bile acid, energy, phosphate, and 
vitamin D metabolism, their dysfunction being associated with a variety of 
metabolic diseases (Itoh et al., 2015). Knock out (KO) studies of endocrine FGFs 
in mice demonstrate they are also required for the normal morphogenesis of some 
organs such as the heart and inner ear (Vincentz et al., 2005, Lysaght et al., 
2014). As well as circulating throughout the body to affect distant cell populations, 
endocrine FGFs require a distinct protein co-factor known as the Klotho receptors 
in order to initiate signaling (Itoh et al., 2015).  
The paracrine FGFs share a regular globular β-trefoil core composed of 12 β-
strands whereas endocrine FGFs lack the β-11 strand and so have an atypical β-
trefoil (Goetz and Mohammadi, 2013). Paracrine FGFs are first expressed in the 
inner cell mass during the earliest stage of embryonic development, before 
implantation into the endometrium (Yamanaka et al., 2010). Paracrine, also known 
as canonical, FGF signaling then facilitates organogenesis and morphogenesis 
throughout the embryo via the formation of tightly controlled ligand gradients (Pera 
et al., 2014, Xu et al., 2000) established by their interactions with heparan 
sulphate proteoglycans (HSPGs). HSPGs are co-factors for paracrine FGF-
signaling found on the surface of all cells and in the extracellular matrix 
(Mohammadi et al., 2005). 
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Figure 1.1 Ligand-receptor interactions of the canonical FGFs. Canonical FGFs are 
paracrine/autocrine signaling molecules and require heparan sulphates to activate 
FGFRs. Receptor preference is indicated by the weight of the lines linking ligands and 
receptors. Data is derived from experiments using Baf3 cells transfected with FGFR 
splice variants, and treated with FGFs, using mitogenic activity as a readout to determine 
binding specificity  (Zhang et al., 2006). 
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1.2.2 Fibroblast growth factor receptors 
FGFs function as ligands for cell surface receptor tyrosine kinases (RTKs) known 
as FGFRs. Humans express four distinct FGFR genes which are all highly related 
with over 50% identical amino acid sequence (Johnson and Williams, 1993, 
Pasquale, 1990b). FGFRs are single pass transmembrane receptors with three 
extracellular immunoglobulin-like domains termed D1 - D3 with functional linker 
domains between each, and an intracellular tyrosine kinase domain (Groth and 
Lardelli, 2002). FGFRs 1 - 3 can undergo two different alternative splicing events; 
the first occurs when the exons encoding the D1 and D1 - D2 linker domains are 
not transcribed so these domains are absent from the final, truncated receptor 
(Mohammadi et al., 2005, Yeh et al., 2003). Real-time binding studies demonstrate 
truncated FGFRs have the same or higher binding affinity for FGFs and HSPGs 
compared to their full-length isoforms and retain biological activity (Olsen et al., 
2004, Mohammadi et al., 2005). Structural studies revealed the D1 and D1-D2 
linker domains interact with the D2-D3 region to occlude the portion of the receptor 
involved in FGF and HSPG-binding (Olsen et al., 2004). In this way, the D1 and 
the D1-D2 linker serves as an auto-inhibitory mechanism that regulates ligand-
binding specificity and promiscuity. 
A second possible splicing event in FGFR expression involves the D3 domain; the 
exon encoding the N-terminal portion of D3 is termed IIIa and two alternative 
exons, termed IIIb and IIIc, encode the C-terminal portion (Schlessinger, 1991, 
Yeh et al., 2003). Expression of each alternative exon is tissue specific: epithelial 
tissues tend to express the IIIb isoforms of FGFRs (FGFR1b – FGFR3b) and 
mesenchymal tissues express the IIIc isoforms (FGFR1c – FGFR3c) (Orrurtreger 
et al., 1993). This alternative splicing event was shown to affect ligand binding 
affinity when Miki et al observed that FGF7 will exclusively bind to FGFR2b and 
not FGFR2c (Miki et al., 1991). Subsequently, Yeh et al showed FGF10, which is 
also highly specific for FGFR2b, induces a conformational change in D2 of the 
spliced receptor which contributes to ligand binding, suggesting alternative splicing 
in the D3 domain may enhance or diminish the interaction of ligand with other 
domains of the receptor, further increasing ligand-receptor specificity (Yeh et al., 
2003). The crystal structures of FGF/ FGFR complexes reveal that interactions 
between the N-terminal region of FGF ligand and the alternatively spliced regions 
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of D3 (IIIb or IIIc) confer ligand specificity and mutations in these regions that 
results in aberrant ligand binding are responsible for some human skeletal 
disorders (Plotnikov et al., 2000). These discoveries effectively increased the 
number of FGFRs with distinct ligand binding capabilities from four to seven. 
Further examples of alternatively spliced receptors with different ligand-binding 
affinities led to the realization that mesenchymal FGFRs were specific for FGF 
ligands secreted by epithelial tissues and vice versa. This provided the basis for 
paracrine FGF signaling loops that regulate complex developmental processes; for 
example, branching and budding of lung epithelia is coupled to proliferation of lung 
mesenchymal cells via bi-directional FGF9 and FGF10 signaling (Colvin et al., 
2001, Sekine et al., 1999). Normal organogenesis and tissue morphogenesis 
depend on the establishment of these paracrine-signaling loops; i.e. mesenchymal 
and epithelial tissues produce a variety of FGF ligands that could be promiscuous 
and bind to FGFRs on the cells that secreted them, which is prevented by the 
expression of alternatively spliced FGFRs on each type of tissue. 
1.2.3 Fibroblast growth factor signaling pathways 
FGFR activation involves two FGF ligands interacting with two receptor monomers 
at the cell surface, with each FGF interacting with both receptors at the same time 
(Mohammadi et al., 2005). Binding occurs at the D2-D3 domains of the FGFR and 
the formation of the ligand-receptor complex causes two FGFRs to dimerize (Ueno 
et al., 1992); this brings the intracellular tyrosine kinase domains into close contact 
and allows them to transphosphorylate each other (Mohammadi et al., 2005). 
FGFRs have six tyrosine residues that are sequentially phosphorylated in order to 
fully activate the tyrosine kinase domain. In this state, FGFRs can recruit CRKL, 
an adapter protein with several Src homology (SH2) and SH3 domains, required 
for the recruitment of signaling proteins to the plasma membrane (Pawson et al., 
1993, Seo et al., 2009). Activated FGFR and CRKL phosphorylate and activate 
FGFR substrate 2α (FRS2α), an adapter protein that is constitutively bound to 
FGFR monomers at the plasma membrane (Wang et al., 1996, Ong et al., 2000). 
Despite its name, FRS2α has been shown to play a role as an adaptor molecule 
for other growth factors such as epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF), vascular endothelial growth factor (VEGF), nerve growth 
factor, and neurotrophic factors (Lax et al., 2002, Kouhara et al., 1997, Xu and 
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Goldfarb, 2001, Chen et al., 2014). Phosphorylated FRS2α contains multiple 
binding sites for SH2 domains of other signaling proteins, and so acts as a docking 
protein on which multiprotein signaling complexes can be formed (Ong et al., 
2000).  Activated FRS2α recruits and activates proteins required for initiation of the 
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein 
kinase B (PI3K-AKT) signaling cascades (Kouhara et al., 1997). FGFRs possess 
two additional tyrosine residues which, when phosphorylated, activate two other 
signaling pathways. Signal transducer and activator of transcription (STAT) 
signaling is initiated when tyrosine 677 is phosphorylated and phospholipase Cγ1 
(PLCγ1) is bound to the receptor by phosphorylated tyrosine 766 (Dudka et al., 
2010, Mohammadi et al., 1992). Which pathways will be activated by FGF 
signaling is dependent on a number of variables: the specific FGF ligand and 
receptor involved, the availability of ligand and receptor at the cell membrane, and 
the influence of downstream regulators and cross-regulation between each 
signaling pathway (Ornitz and Itoh, 2015). A schematic diagram of the three FGF-
signaling pathways and the signaling cascades involved is shown in Figure 1.2. 
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Figure 1.2 Simplified FGF Signaling Schematic. Red arrows denote inhibition, green 
arrows denote promotion of expression. Heparan sulphates are represented in yellow, 
phosphate groups are purple. Heparan sulphate and bound FGF interact with D2 and D3 
domains of two FGFRs, which leads to transphosphorylation of intracellular tyrosine kinase 
domains. Activated RTKs phosphorylate FRS2α, GRB2, and PLCγ1. Activation of each 
signaling cascade leads to transcription of distinct sets of genes. Several inhibitory 
mechanisms (shown in grey) regulate FGF signaling; Sef interacts with FGFRs directly to 
prevent FRS2α phosphorylation. Sproutys are activated by MAPK signaling which they 
regulate by interacting with GRB2 at the membrane or with RAF. DUSPs form part of the 
negative feedback loop of MAPK signaling as they are phosphorylated and activated my 
MAPK proteins. Sproutys, DUSPs, Sef, XFLRT3, and various other FGF signaling 
regulators are induced at the transcriptional level by MAPK signaling. 
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1.2.3.1 MAPK signaling 
When activated, FRS2α recruits and activates the adapter protein growth factor 
receptor-bound 2 (GRB2), which in turn recruits either GRB2‑associated binding 
protein 1 (GAB1) or the guanine nucleotide exchange factor son of sevenless 
(SOS) (Kouhara et al., 1997, Ong et al., 2000). Activated SOS in turn activates 
membrane-bound Ras, which initiates the mitogen-activated protein kinase 
(MAPK) signaling cascade (Katoh and Katoh, 2006). FGF signaling can lead to 
activation of ERK1/2, JNK and p38 MAP kinases (Tsang and Dawid, 2004, House 
et al., 2005). MAPK signaling leads to the phosphorylation and activation of the 
ETS (E26 transformation-specific) family of transcription factors (TFs). ETS TFs 
can then enter the nucleus and induce the expression of genes involved in cell 
proliferation, growth, and survival (Mccubrey et al., 2000). MAPK is the pathway 
most commonly activated by FGF signaling. 
1.2.3.2 PI3K-AKT pathway 
If GRB2 binds to GAB1 instead of SOS, PI3K is recruited and activated, which 
leads to downstream phosphorylation of AKT (Lamothe et al., 2004). AKT inhibits 
a number of apoptotic signaling pathways; for example, AKT phosphorylates 
caspase 9, which inhibits activation of caspase 3 (Fujita et al., 1999). AKT also 
phosphorylates the forkhead box class O transcription factors, which prevents 
them from transcribing death-receptor ligands and Bcl2 family members by forcing 
them to exit the nucleus (Fu and Tindall, 2008, Zhang et al., 2011). Another 
protein phosphorylated and inactivated by AKT is tuberous sclerosis complex 2 
(TSC2), a tumour suppressor gene that regulates cell growth and size (Manning 
and Cantley, 2007). Phosphorylation of TSC2 by AKT causes it to lose its GTPase 
activating protein activity which constitutively inhibits mammalian target of 
rapamycin complex 1 (mTORC1) (Durán and Hall, 2012). mTORC1 is a protein 
complex that determines whether the intracellular environment (amino acid, 
oxygen, and growth factor concentrations, etc.) is favourable towards growth, and 
if so, activates protein synthesis which leads to cell growth and proliferation 
(Manning and Cantley, 2007, Rafalski and Brunet, 2011). Carballada et al. showed 
PI3K-AKT signaling is required for mesoderm induction in xenopus embryos, and 
acts in parallel with MAPK signaling to do so (Carballada et al., 2001). FGF 
signaling is often observed to activate the MAPK and PI3K-AKT signaling 
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pathways in parallel to enhance cell growth and proliferation while preventing 
apoptosis. 
1.2.3.3 PLCγ signaling  
The phospholipase C- γ (PLCγ) signaling pathway is initiated when PLCγ is 
recruited directly to phosphorylated FGFR (Mohammadi et al., 1992). Active PLCγ 
hydrolyzes phosphatidylinositol-4,5-diphosphate to inositol 1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG). DAG activates protein kinase C which then 
phosphorylates and activates regulators of cell motility, such as the actin filament 
reorganisation protein, myristoylated alanine-rich C kinase substrate (Hartwig et 
al., 1992). IP3 functions by inducing the release of calcium ions from intracellular 
stores which activates calcineurin, that in turn, dephosphorylates and activates the 
transcription factor nuclear factor of activated T cells (NFAT) (Hogan et al., 2003). 
NFAT is then able to enter the nucleus and initiate the transcription of genes 
involved in cell motility and migration (Li et al., 2011). The PLCγ pathway was 
shown to regulate motility and migration downstream of FGF signaling when PLCγ 
binding site on FGFRs were blocked in neurons and neurite outgrowth was 
inhibited  (Hall et al., 1996). 
1.2.3.4 STAT signaling 
SH2 domain-containing STAT1, 3, and 5 are recruited to the plasma membrane 
and phosphorylated by the FGFR tyrosine kinase (Ornitz and Itoh, 2015, Hart et 
al., 2000). Phosphorylated STATs combine to form hetero- or homodimers which 
translocate to the nucleus and induce gene transcription (Hebenstreit et al., 2005). 
STATs are typically regarded as downstream mediators of interferon and immune 
mediated signaling, however they are also known to induce genes associated with 
cell proliferation, differentiation, migration, and apoptosis (Kuzet and Gaggioli, 
2016, Au-Yeung et al., 2013). The roles of STATs in FGF signaling are still 
controversial as it has been difficult to delineate the effects of STAT activation 
from other pathways induced by FGFRs as several pathways are usually activated 
in concert. 
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1.2.3.5 FGFs in the nucleus 
FGFs and FGFRs have been visualised in the nuclei of some cell types where 
they regulate gene expression (Planque, 2006). Endocytosis and degradation of 
ligands and receptors is a common regulatory mechanism in cell signaling, 
however some FGFs have been shown to persist inside the cell for over 24 hours 
(Wiedłocha and Sørensen, 2004). FGFR1 and FGFs 1, 2, and 3 have been 
visualised in the nuclei of a variety of cell types but no other FGF ligands or 
receptors, suggesting these abilities are not shared between all FGF family 
members (Planque, 2006). Several high and low molecular weight (MW) isoforms 
of FGF1 and FGF2 can be expressed depending on the where translation is 
initiated on the genes (Iberg et al., 1989). High MW isoforms are not secreted and 
can enter the nucleus directly from the cytoplasm of the cell in which they have 
been translated. Low MW isoforms of bind to FGFR1 at the cell surface and 
translocate to the nucleus via importin β, under the control of PI3K signaling and 
the chaperone protein, heat shock protein-90 (Reilly and Maher, 2001, Małecki et 
al., 2004, Wesche et al., 2006). The nuclear isoform of FGF3 contains three 
polycationic sequences, lacked by the secreted isoform, that mediate entry into the 
nucleus (Antoine et al., 1997). In the nucleus, FGFR1 binds to CREB-binding 
protein and  ribosomal S6 kinase 1 (RSK1) which recruit RNA (ribonucleic acid) 
polymerases, modify histones and induce gene transcription (Stachowiak et al., 
2003, Fang et al., 2005, Hu et al., 2004). Cyclin D1, c-jun, neuron specific enolase, 
and microtubule associated protein-2 genes are all upregulated by nuclear FGFR1 
and are essential for neuronal differentiation (Stachowiak et al., 2003, Reilly and 
Maher, 2001). The mechanisms by which nuclear FGF1, 2, and 3 regulate gene 
expression are less well understood although there is some evidence they interact 
with TFs and RSK2 (Soulet et al., 2005, Sheng et al., 2005). High levels of nuclear 
FGFs are features of some cancers, and are associated with a poor prognosis 
(Joy et al., 1997, Fukui et al., 2003). Overexpression of high MW FGF2 is 
sufficient to transform cultured primary cells and stimulate their proliferation 
(Couderc et al., 1991). Interestingly, nuclear and secreted FGF3 have been found 
to have opposing effects on cell proliferation (Antoine et al., 1997). Results from 
cancer studies show that nuclear FGFs enhance the expression of genes 
associated with cell survival and proliferation which contributes to tumour 
progression (Planque, 2006).  
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1.2.4 Regulation of FGF signaling  
1.2.4.1 Heparan sulphates 
(Moscatelli, 1987) discovered that cells express high and low affinity receptors for 
FGFs. The high affinity receptors are FGFRs and low affinity receptors are 
heparan sulphates. Heparan sulphates are linear glycan polymers that are 
expressed in all tissues, in the extracellular matrix (ECM) and on the surface of 
cells where they modulate cell surface receptor-ligand interactions (Bernfield et al., 
1999). Heparan sulphates are bound to cell membranes via core proteins such as 
transmembrane proteins as in the syndecans or through 
glycosylphosphatidylinositol-anchored core proteins as in the glypicans (Fransson 
et al., 2004, Tkachenko et al., 2005); these proteins and the bound heparan 
sulphates comprise the heparan sulphate proteoglycan.  
Heparan sulphate had previously been reported to enhance FGF signaling in 
epithelial cells (Thornton et al., 1983) and (Yayon et al., 1991) showed heparan 
sulphate was absolutely required for FGF signaling through the use of mutant 
heparan sulphate-deficient cells. Heparan sulphate is required for the formation of 
a stable 2:2 symmetric dimer between FGFs and FGFRs. Stable dimer formation 
allows each FGF to interact with both receptors and the receptors to interact with 
each other via the D3 domains (Schlessinger et al., 2000).  
Heparan sulphates are composed of repeating disaccharides of N‑substituted 
glucosamine and glucuronic acid (Bernfield et al., 1999, Sasisekharan and 
Venkataraman, 2000). The glucosamine in heparan sulphate can be either N-
acetylated or N-sulphated. N-acetylated glucosamine does not undergo 
modification whereas N-sulphated glucosamine can undergo a variety of 
modifications, such as  2-O-, 3-O-, and 6-O- sulphation, and C5-epimerization 
(Perrimon and Bernfield, 2000). These modified sites interact with FGFs and the 
D2 domains of FGFRs via hydrogen bonds (Schlessinger et al., 2000, Gallagher, 
2001). The golgi enzymes, N-deacetylase, uronosyl C5-epimerase, and the N-
sulphotransferases, modify heparan sulphate in a tissue specific manner to 
generate heparan sulphates with unique fine structures (Habuchi et al., 1998, 
Rosenberg et al., 1997).  
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Heparan sulphates have a distinct pattern of expression during embryogenesis 
and development, which affect FGF-FGFR interactions (Allen and Rapraeger, 
2003). The fine structure determines heparan sulphates affinity for FGFs, which 
regulates how far FGFs can diffuse from their site of secretion. In this way, 
heparan sulphates mediate and maintain complex FGF signaling-gradients, which 
are vital for normal morphogenesis during development. The requirement for these 
three components: heparan sulphate, FGF ligand, and FGFR, to be compatible, 
allows for multiple ligands and receptors to be expressed in the same vicinity 
without the danger of promiscuous signaling. This tertiary layer of regulation by 
heparan sulphates also allows for more intricate and complex signaling without the 
need for additional ligands or receptors. 
1.2.4.2 Sproutys 
A number of positive and negative regulators of FGF signaling have been 
discovered in xenopus, zebrafish, and drosophila (Tsang and Dawid, 2004). The 
first to be identified were the Sproutys (Hacohen et al., 1998), antagonists of RTK 
signaling (Frank et al., 2009). There are four Sprouty isoforms, all of which are 
highly conserved in vertebrates and all of which inhibit MAPK signaling 
downstream of FGFR but upstream of ERK, the major protein phosphorylating 
component of the MAPK pathway. PLCγ signaling can also induce Sprouty 
expression, and is in turn regulated by Sproutys (Akbulut et al., 2010, Abe and 
Naski, 2004). Gain- and loss-of-function experiments in mice and chicks show 
FGF signaling induces Sprouty gene expression through MAPK (Minowada et al., 
1999, Chambers and Mason, 2000). Sproutys have a conserved tyrosine 
phosphorylation site and cysteine-rich domain which allows them to translocate to 
the plasma membrane when activated by MAPK signaling (Lim et al., 2002). 
Sproutys function by inhibiting MAPK signaling at two points in the pathway: 
Sprouty can bind to Grb2 at the membrane to prevent it from binding SOS which 
prevents Ras activation, and Sprouty can also interact downstream with Raf to 
attenuate signaling (Hanafusa et al., 2002, Sasaki et al., 2003).  
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1.2.4.3 DUSPs 
The mammalian genome encodes over 60 members of the dual-specificity 
phosphatase (DUSP) family, all of which have an intrinsic ability to 
dephosphorylate tyrosine or serine/threonine kinases (Alonso et al., 2004, Owens 
and Keyse, 2007). Eleven members of the DUSP family comprise the MAPK 
phosphatase subfamily, which regulate components of the MAPK pathway in 
different cellular compartments. Throughout this thesis, only the MAPK 
phosphatase DUSPs are discussed and they are simply referred to as DUSPs. 
DUSP1 dephosphorylates p38 in the nucleus, while DUSP6 dephosphorylates 
ERK in the cytosol (Patterson et al., 2009). DUSPs are phosphorylated and 
activated by MAPK signaling and are therefore feedback inhibitors of MAPK 
(Brondello et al., 1999). DUSPs 1, 5, and 6, are early response genes to FGF 
signaling (Branney et al., 2009). DUSP6 expression is only induced in response to 
FGFR1 or FGFR2 signalling and strongly correlates with the pattern of active FGF 
signaling during embryonic development (Urness et al., 2008, Li et al., 2007).  
1.2.4.4 Extracellular FGF signaling regulators 
Several proteins act in the ECM or at the plasma membrane to positively or 
negatively regulate FGF signaling. FGF-binding protein 1 (FGFBP1) is a secreted 
protein that can bind to heparan sulphate and FGF1, 2, 7, 10, and 22 (Wu et al., 
1991). FGFBP1 was originally identified as an inhibitor of FGF signaling, but has 
since been shown to enhance ligand-receptor interactions and promote 
angiogenesis and wound healing (Rosenberg et al., 1997, Tassi et al., 2011). 
XFLRT3 is a member of a leucine-rich-repeat transmembrane protein family that 
interacts with FGFRs to propagate MAPK signaling (Böttcher et al., 2004). 
XFLRT3 expression is induced by FGF signaling and inhibited by MAPK signaling 
regulators. Sef (similar expression to FGF) is another transmembrane protein that 
interacts with the FGFR, but Sef inhibits signaling by blocking phosphorylation of 
FRS2α (Tsang et al., 2002). Sef-b is a splice-isoform of Sef which lacks the 
transmembrane portion of the protein and inhibits MAPK signaling in the cytosol. It 
accomplishes this by binding to and preventing ERK1/2 from dissociating from the 
MEK complex and entering the nucleus (Preger et al., 2004). FGFRL1 (fibroblast 
growth factor receptor like 1) is a transmembrane protein structurally similar to 
other FGFRs but lacking intracellular tyrosine kinase activity (Trueb et al., 2003). 
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FGFRL1 acts as a decoy receptor and can be shed from the membrane to bind 
FGFs in the ECM (Steinberg et al., 2010). Interestingly, the intracellular domain of 
FGFRL1 contains an SH2 binding motif that can bind SHP-1 and induce MAPK 
signaling without ligation. This suggests that FGFRL1 can also function as a non-
tyrosine kinase signaling receptor (Silva et al., 2013). 
1.3 Fibroblast growth factors in the central nervous 
system 
1.3.1 FGF1, 2, and 9 in CNS development  
FGF1 expression begins late in mouse CNS development on embryonic day 11 
(E11) and does not peak until adulthood (Elde et al., 1991, Alam et al., 1996, Ford-
Perriss et al., 2001). In vitro experiments have shown that downregulating FGF1 
expression in cultured retinal cells was detrimental to neuronal differentiation and 
survival (Désiré et al., 1998). Treating PC12 cells with FGF1 activated MAPK and 
STAT3 signaling which led to enhanced neurite outgrowth, suggesting FGF1 may 
be involved in neuronal differentiation and maintenance in vivo (Lin et al., 2009).  
FGF2 stimulates proliferation of neural crest cells, which go on to make up most of 
the peripheral nervous system in the embryo (Murphy et al., 1994). FGF2 is the 
most abundantly expressed FGF in the CNS during development and in the adult 
(Woodbury and Ikezu, 2014). Like FGF1, FGF2 is produced by neurons but the 
majority is derived from astrocytes during development and adulthood (Woodbury 
and Ikezu, 2014). In early stages of CNS development FGF2 is a proliferative and 
survival factor for neuroepithelial cells (Arakawa et al., 1990, Murphy et al., 1990). 
Several studies have also shown that FGF2 stimulates differentiation of 
neuroepithelial cells into neurons and astrocytes (Murphy et al., 1990, Baron et al., 
2012, Dono et al., 1998, Qian et al., 1997). FGF2 also induces expansion of 
dopaminergic and GABAergic neuronal precursor cells while delaying their 
differentiation (Bouvier and Mytilineou, 1995, Deloulme et al., 1991). FGF2 further 
affects neuronal development by enhancing axonal branching and neurite 
outgrowth (Kalil et al., 2000, Morrison et al., 1986). FGF2 promotes the 
proliferation of oligodendrocyte precursor cells (OPCs) and increases their 
expression of platelet-derived growth factor receptor (PDGFR), which binds 
PDGFα, the most important mitogen and survival factor for early OPCs (Mckinnon 
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et al., 1990). FGF2 is a chemoattractant for OPCs, and transgenic OPCs 
expressing a truncated FGFR1 failed to migrate after transplantation into neonatal 
rat brain (Osterhout et al., 1997, Mckinnon et al., 1993). A schematic diagram of 
OL lineage development and interactions with FGFs at each stage can be seen in 
Figure 1.3. 
FGF9 is expressed at high levels early in murine CNS development (E10 - 14) and 
is mainly localized to developing motor neurons in the spinal cord, for which it is an 
important survival factor (Nakamura et al., 1999, Nakamura et al., 1997, Kanda et 
al., 1999, Garcès et al., 2000). In vitro studies have also shed some light on the 
roles of FGF9 in glial cell development; FGF9 promoted the proliferation and 
survival of neural progenitor cells while inhibiting their differentiation into neurons 
and glia (Lum et al., 2009). Differentiation to all cell types was reduced following 
FGF9 treatment but astrocyte differentiation was markedly reduced; these results 
suggest FGF9 may be involved in maintenance of the progenitor cell populations. 
The effect on astrocyte differentiation is particularly interesting as FGF9 promotes 
proliferation in already differentiated astrocytes (Naruo et al., 1993) demonstrating 
how FGF signaling can have different effects at different stages of lineage 
progression. 
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Figure 1.3 Schematic diagram of FGF signaling events throughout oligodendrocyte 
differentiation. Grey arrows denote inhibition; black arrows denote promotion. OLs 
proceed through three major developmental stages from migratory and proliferative 
precursor cells to mature, myelinating oligodendrocytes. These stages are accompanied by 
changes in FGFR expression and interactions with members of the FGF signaling pathway. 
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1.3.2 Roles of FGFs in the adult CNS  
1.3.2.1 FGF and FGFR expression in the adult CNS 
After development, the FGFs involved in regionalisation and patterning of the CNS 
are down regulated. In the healthy adult CNS only FGF1, 2, and 9 are known to be 
constitutively expressed and their functions in homeostasis are still not fully 
elucidated. FGF1 is produced by neurons in the adult, and unlike other FGFs, 
FGF1 expression increases throughout development and peaks in adulthood (Elde 
et al., 1991, Alam et al., 1996). FGF2 is also produced by neurons in the adult 
CNS but the majority is astrocyte-derived and it is expressed mainly in sites of 
neurogenesis (Woodward et al., 1992). FGF2 is a known mitogen for 
neuroprogenitor cells (which express FGFR1) in the subventricular zone (SVZ) 
and subgranular zone (Ohkubo et al., 2004, Woodward et al., 1992, Werner et al., 
2011). Like in development, FGF9 is mainly produced by neurons, particularly 
motor neurons and is expressed at higher levels in the spinal cord and brain stem 
(Kanda et al., 1999). FGF9 is also produced by white matter astrocytes in the 
spinal cord and by CNPase-positive OLs in the white matter of the cerebellum and 
corpus callosum (Nakamura et al., 1999).  
The major CNS cell types, neurons, astroglia, OLs and microglia have different 
FGFR expression profiles. Neurons, the first cell type to differentiate in the 
developing CNS, express FGFR1 while exclusively retinal neurons also express 
FGFR4 (Fuhrmann et al., 1999). Astrocytes are the most abundant cell type in the 
CNS and constitutively express FGFRs 1, 2, and 3 (Miyake et al., 1996, Choubey 
et al., 2017). Oligodendrocyte lineage cells are responsible for ensheathing axons 
in insulating myelin and express variable levels of FGFRs depending on their 
stage of maturation (Fortin et al., 2005). OPCs only express FGFR1 but as OPCs 
differentiate, they transiently express FGFR3, which is lost by the time the cells 
have fully matured, and begun producing myelin. Mature OLs express FGFR2 
specifically on the myelin sheath; FGFR1 is still expressed but at a reduced level 
compared to OPCs. OLs and astrocytes express the IIIc isoform of each FGFR 
(Miyake et al., 1996). While different CNS cell types express different 
combinations of FGFRs, RNA sequencing data has shown that by far, astrocytes 
have the highest level of expression of FGFRs compared to neurons, OLs, and 
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microglia, suggesting that they will be the main target of FGF signaling in the CNS 
(Zhang et al., 2014). 
Since concomitant expression of several FGFs occurs during development and in 
the adult CNS, altering FGFR expression as OLs mature allows them to temporally 
regulate FGF signaling. Fortin et al demonstrated that signaling through FGFR3 by 
FGFs 8 and 17 inhibits OPC maturation, while FGF2 stimulated OPC proliferation 
via FGFR1 (Fortin et al., 2005). FGF9 appeared to have no effect on OPCs but 
enhanced process elongation in mature OLs via FGFR2 (Furusho et al., 2012). 
Several studies have shown that FGF2 stimulates OPC proliferation while 
inhibiting their maturation and subsequent myelination. FGF2 has also been 
shown to have detrimental effects on mature OLs in which it induces 
downregulation of expression of myelin-associated genes and re-entry into the cell 
cycle (Bansal and Pfeiffer, 1997, Zhou et al., 2006). Most of the studies that have 
shown FGF2 to be an inhibitor of myelination have done so using pure OL 
cultures. A study by Mayer et al found that the inhibition of OL differentiation by 
FGF2 was overcome in the presence of astrocytes (Mayer et al., 1993). These 
findings demonstrate that the outcome of FGF signaling is often context 
dependant and cells will react to FGFs differently depending on their stage of 
maturation. 
1.3.2.2. FGFs in adult CNS homeostasis 
FGF1-null mice appear phenotypically normal; They have no deficiencies in 
embryonic development, adulthood, old age, or reproduction (Miller et al., 2000). 
This suggests absence of FGF1 can be functionally compensated for by other 
FGFs or growth factors. However, FGF1 has been shown to regulate some neuron 
and OL functions. Treating rat hippocampal slices with FGF1 reduced the basal 
amplitude of spikes and facilitated generation of long-term potentiation (Sasaki et 
al., 1994). Subcutaneous injections of FGF1 improved learning and long-term 
memory in senescence-accelerated mice and preserved medial septum 
cholinergic neurons (Sasaki et al., 1999). These findings suggest FGF1 
contributes to learning and memory formation. FGF1 signaling through FGFR1 
and FGFR2 has also been shown to regulate the thickness of myelin sheathes 
produced by OLs. OLs lacking FGFR1 and FGFR2 genes had had reduced 
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expression of myelin genes and thinner myelin sheathes, which was associated 
with reduced MAPK signaling (Furusho et al., 2012). 
FGF2 serves some of the same functions in the adult CNS as it does in the 
embryonic CNS and is a proliferative and survival factor at sites of neurogenesis. 
FGF2 is produced by neurons and astrocytes throughout the CNS but it is 
expressed at highest levels in the hippocampus, striatum, SVZ, and subgranular 
zone, all areas with populations of neuroprogenitor cells (Ohkubo et al., 2004, 
Woodbury and Ikezu, 2014). Subcutaneous injection of FGF2 in mice stimulated 
proliferation in these sites (Wagner et al., 1999). Cultured hippocampal cells 
treated with FGF2 proliferate and express genes associated with neuronal and 
glial cell differentiation (Gage et al., 1995). Neurons derived from these precursors 
go on to exclusively populate the granule cell layer. Neuroprogenitor cells from the 
striatum can also differentiate into neurons, astrocytes, and OLs when treated with 
FGF2. The concentration of available FGF2 determined this cell fate decision with 
lower concentrations favouring neuronal differentiation and higher levels favouring 
glial cell development (Dono et al., 1998, Qian et al., 1997, Gritti et al., 1996).  
FGF2 regulates neuronal morphology and is the most potent enhancer of axon 
branching currently known. In vitro cortical neurons treated with FGF2 have larger 
growth cones and three times more axon branching than untreated neurons (Patel 
and Mcnamara, 1995, Kalil et al., 2000). This is thought to increase the complexity 
of axonal trees in development and regulate axonal remodelling in the adult CNS 
(Ramirez et al., 1999). FGF2 is also involved in neuronal signaling and, like FGF1, 
lowers the threshold required to induce long-term potentiation (Ishiyama et al., 
1991). In vitro experiments and injury models have shown that FGF2 has a variety 
of effects on glial cells but its roles in homeostasis are still unclear.  
The functions of FGF9 in the healthy adult CNS are unclear. Its expression is 
mostly detected in the brainstem and spinal cord where it is thought to provide 
tonic signaling to spinal cord motor neurons (Kanda et al., 1999). Like FGF2, 
FGF9 is a mitogen and survival factor for neuroprogenitor cells, but is less potent 
and inhibits their differentiation into neurons and glia (Lum et al., 2009). 
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1.4 Fibroblast growth factors in multiple sclerosis 
1.4.1 Localisation of FGFs in MS lesions 
In situ hybridisation and immunohistological studies of tissue biopsies and post-
mortem MS brains have identified three FGFs that are upregulated in and around 
lesions: FGF1, 2, and 9. In healthy control brains FGF1 staining was observed in 
subsets of cortical neurons and OL lineage cells throughout the white matter 
(Eckenstein, 1994, Mohan et al., 2014). In MS lesions of the grey matter, neuronal 
FGF1 expression was comparable to controls. FGF1 staining was also observed in 
OLs in the NAWM surrounding MS lesions, particularly lesions that have 
undergone remyelination. Hypertrophic astrocytes in remyelinated lesions tended 
to be FGF1-positive whereas astrocytes in demyelinated areas and NAWM were 
mostly FGF1-negative. In active and chronic active lesions a subset of IBA1+ 
microglia/macrophages expressed FGF1. Double staining for lymphocyte markers 
in lesions with high numbers of perivascular infiltrates showed that both T and B 
cells express FGF1 (Mohan et al., 2014). In all cases where FGF1 staining was 
observed, only subsets of each cell type displayed FGF1 expression, suggesting it 
is a feature of different subsets of cells. 
FGF2 concentrations in CSF from MS patients peaks during a relapse suggesting 
it is involved in the pathogenesis of the disease (Sarchielli et al., 2008). FGF2 is 
detected at higher levels in the serum and CSF of MS patients than healthy 
controls. FGF2 levels were highest during relapses in RRMS and correlated with 
higher lesion loads in SPMS (Sarchielli et al., 2008, Harirchian et al., 2012). In MS 
lesions, FGF2 expression has been observed in damaged neurons, astrocytes, 
macrophages, and microglia, with the highest levels in active lesions and the 
penumbra of chronic lesions (Mizuno, 2014, Albrecht et al., 2002, Albrecht et al., 
2003, Clemente et al., 2011). Perivascular astrocytes located near lesions were 
FGF2-positive suggesting that it is involved in breakdown of the BBB. Astrocytes 
are the main source of FGF2 in the healthy CNS and the same appears to be true 
in MS, however it is only upregulated in actively demyelinating lesions and does 
not appear to be present in chronic inactive lesions with little inflammation 
(Clemente et al., 2011). 
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In healthy control brains, FGF9 staining is observed in neurons and infrequently in 
astrocytes and OLs in white matter (Todo et al., 1998). FGF9 staining appears as 
diffuse background immunoreactivity thought to be due to FGF9 in axons and 
dendrites of neurons, and bound to cells and components of the ECM. In MS 
brains, there is generally higher intensity of diffuse FGF9 immunoreactivity in the 
NAWM. Higher levels of FGF9 expression were seen in active lesions and chronic 
active lesion rims compared to inactive lesions and inactive cores of chronic 
lesions (Lindner et al., 2015). However, unlike FGF2, FGF9 staining was present 
in chronic lesions, albeit to a lesser extent than observed in actively demyelinating 
lesions. FGF9 staining colocalized with markers for OLs, OPCs, and astrocytes in 
active lesions and NAWM. Like FGF1, only subsets of each cell type were found to 
be FGF9-positive: around 50% of astrocytes in active lesions and the surrounding 
periplaque stained for FGF9 and occasional NogoA+ OL lineage cells at the rim of 
actively demyelinating lesions were FGF9-positive (Lindner et al., 2015). 
1.4.2 Roles of FGFs in MS pathogenesis 
1.4.2.1 FGF1 
qPCR analysis found that FGF1 was the most highly expressed myelination-
regulatory factor in remyelinated MS lesions (Han et al., 2008, Mohan et al., 2014). 
Levels of FGF1 expression in demyelinated areas were lower than in control brain 
white matter. Treating dissociated spinal cord cultures and cerebellar slice cultures 
with FGF1 accelerated myelination and remyelination respectively, however 
treating isolated OLs inhibited their differentiation. This suggests promotion of 
myelination by FGF1 was an indirect effect and transcriptional profiling revealed 
that FGF1-treated astrocytes increased expression of CXCL8 and LIF (Leukaemia 
inhibitory factor). Both of these factors are known to enhance OPC recruitment 
and myelination respectively. Lesions in a cuprizone-demyelination model 
displayed reduced levels of FGF1 expression (Berghoff et al., 2017). When these 
mice were treated with dietary cholesterol, levels of FGF1 increased in astrocytes, 
and in vitro, FGF1 was shown to enhance OPC differentiation.  
In a rat spinal cord injury (SCI) model, injection of FGF1 into the injury site resulted 
in significantly greater functional recovery 28 days after injury (Tsai et al., 2008). 
Proteomic analysis showed proteins associated with axonal survival and 
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regeneration were upregulated in FGF1-treated rats while proteins involved in 
astrocyte activation, scar formation and inflammation were reduced. Together, 
these data suggest that FGF1 is beneficial in demyelinating disease and is likely 
involved in the remyelination observed early in MS. Several studies have shown 
that FGF1 is a neuronal survival factor and transgenic overexpression of FGF1 
protects neurons from apoptosis in ischemia and stroke models (Russell et al., 
2006, Ghazavi et al., 2017). FGF1 is detected at higher levels in the serum and 
CSF of Alzheimer’s patients and reactive astrocytes surrounding senile plaques 
express high levels. (Mashayekhi et al., 2010, Kimura et al., 1994). In diseases 
associated with neurocognitive impairment, lower levels of FGF1 in CSF 
correlated with poorer performance in five of seven cognitive tests (Bharti et al., 
2016). Taken together these studies suggest that the presence of FGF1 in MS is 
likely to perform several beneficial functions. FGF1 reduces inflammation and glial 
scar formation, promotes neuronal survival, and promotes OL differentiation and 
myelination. 
1.4.2.2 FGF2 
Studies of FGF2 highlight the complexity and wide ranging effects of FGF 
signaling as research in the areas of inflammation and neurodegeneration has 
produced varied and often contradictory findings. FGF2 can bind to all FGFRs 
except IIIb isoforms of FGFR2 and FGFR3 (Zhang et al., 2006). FGF2 performs a 
variety of functions in the CNS and likely mediates a host of effects in the course 
of many CNS pathologies. Some groups have shown that FGF2 activates 
astrocytes and induces Glial fibrillary acidic protein (GFAP) production (Goddard 
et al., 2002, Ballabriga et al., 1997); while other groups have found that FGF2 
suppresses astrocyte activation and inhibits GFAP messenger RNA (mRNA) 
expression (Kang et al., 2014, Reilly et al., 1998). A similar disparity was observed 
in the investigation of FGF2 on microglial activation: in vivo, injections of FGF2 into 
the lateral ventricle increased microglial ED1 expression (a marker of 
phagocytosis) and number of cytoplasmic granules (Goddard et al., 2002). 
However, in another study FGF2 inhibited microglia activation indirectly by 
enhancing CD200 expression on neurons and astrocytes (Cox et al., 2013); 
CD200 is an anti-inflammatory ligand and ligation maintains microglia in a 
quiescent state (Lyons et al., 2007).  
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FGF2 is upregulated in numerous CNS pathologies including brain/spinal cord 
injury, Parkinson’s, Alzheimer’s, stroke, and MS (Woodbury and Ikezu, 2014). In 
most of these conditions, research has shown FGF2 to be a potent 
neuroprotective agent, and several groups have investigated FGF2 as a 
therapeutic target for degenerative brain diseases and CNS injuries. In cortical 
lesions induced by aspiration or stereotactically localized knife wounds, FGF2 
mRNA levels were increased from four hours post-injury and remained elevated 
two weeks later (Frautschy et al., 1991, Logan et al., 1992). Microglia and reactive 
astrocytes were the main sources of FGF2, with some produced in vascular 
endothelial cells. FGF2 is expressed by neurons and reactive astrocytes in SCI in 
and around the lesioned area and is still upregulated three weeks post-injury 
(Madiai et al., 2003). 
Many studies have shown FGF2 is a potent survival factor for different neuronal 
populations: in the presence of FGF2, hippocampal and dopaminergic neurons are 
more resistant to glutamate-induced cell death and cholinergic/non-cholinergic 
neurons are more likely to survive axon transection (Mattson et al., 1993, Casper 
and Blum, 1995, Otto et al., 1989, Cummings et al., 1992). FGF2 promoted 
survival of grafted dopaminergic neurons in a rat Parkinson’s model which led to 
greater behavioural improvements over grafts without FGF2 (Takayama et al., 
1995). Degenerating neurons secrete FGF2 which attracts microglia and 
enhances phagocytosis of neuronal debris which helps to protect neurons from 
glutamate toxicity (Noda et al., 2014). In another study, FGF2 gene delivery to 
retinal ganglion cells promoted axon regrowth following acute optic nerve injury 
(Sapieha et al., 2003). FGF2 also indirectly promotes neuronal survival by 
inducing proliferation of glial cells that produce a range of trophic factors (Perkins 
and Cain, 1995). Ischemia as the result of stroke or CNS injury results in rapid 
neuronal loss, which several studies have shown, is prevented by FGF2 treatment 
(Martone et al., 2000, Nakata et al., 1993, Bethel et al., 1997, Wei et al., 2000). 
FGF2 is doubly beneficial for ischemic injuries as it is a potent angiogenic factor 
that stimulates VEGF expression in endothelial cells (Issa et al., 2005, Thau-
Zuchman et al., 2012, Seghezzi et al., 1998). In a Huntington’s disease transgenic 
mouse model, injection of FGF2 in neurogenic niches increased neural stem cell 
proliferation and differentiation into neurons. Newly formed neurons from the SVZ 
migrated to the basal ganglia and projected axons. FGF2 injection also increased 
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neuronal survival and improved the life span and motor functions of Huntington’s 
disease-transgenic mice (Jin et al., 2005, La Spada, 2005, Tao et al., 1996).  
FGF2 gene delivery in an Alzheimer’s disease model improved spatial learning, 
enhanced neurogenesis and amyloid-β clearance by microglia, and reduced 
amyloid-β production by neurons (Kiyota et al., 2011, Takami et al., 1998). 
Intrathecal injection of FGF2 and EGF in the injured rat spinal cord reduced size of 
the injury site and more white matter was preserved compared to untreated 
injuries (Jimenez Hamann et al., 2005). In a mouse SCI model, subcutaneous 
injection of FGF2 reduced TNFα expression, monocyte/macrophage infiltration, 
and reactive gliosis, while enhancing neurogenesis and axon regeneration in the 
lesion, which led to improved recovery of hind limb function (Goldshmit et al., 
2014). Blocking endogenous FGF2 with neutralising antibodies reduced functional 
recovery from motor cortex injury in rats which was associated with decreased 
neuronal survival (Rowntree and Kolb, 1997). A similar reduction in neuronal 
survival was observed in in FGF2-null mice in neurotoxin-induced lesions (Timmer 
et al., 2007). Together these studies show that FGF2 is neuroprotective in the face 
of a variety of insults and an important component of the brains endogenous 
recovery processes. 
(Butt and Dinsdale, 2005) showed that doses of FGF2 at or above 350 ng/mL 
injected into the CSF of healthy rats is sufficient to disrupt myelin and OL 
physiology. Mature OLs in these animals lost the ability to support myelin sheathes 
and began to express OPC markers, which led to pronounced demyelination. 
Armstrong et al have published a series of papers delineating the effects of FGF2 
signaling in demyelinating mouse models: they first showed that FGF2 was 
upregulated by astrocytes in focally demyelinated spinal cord lesions and FGFR 
expression was highest at the onset of remyelination (Messersmith et al., 2000). 
They then induced cuprizone-demyelination in FGF2 null mice and found  
remyelinating lesions in the null animal contained more OLs than the wildtype 
(Armstrong et al., 2002). Using these KO mice the group then induced chronic 
cuprizone-demyelination from which wildtype mice do not spontaneously recover, 
and found that lesions in the KOs underwent spontaneous remyelination 
(Armstrong et al., 2006). By downregulating FGFR expression in in vitro OPCs 
treated with FGF2 they showed FGFR1 signaling was responsible for the inhibition 
of OPC maturation (Zhou et al., 2006). More recently, they showed that deleting 
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FGFR1 in OL lineage cells in the cuprizone-demyelination model resulted in 
increased remyelination and OL maturation compared to wildtypes (Zhou et al., 
2012). Improved remyelination in FGF2 and FGFR1 null mice leads to functional 
recovery following acute or chronic demyelination (Mierzwa et al., 2013) 
suggesting that this signaling pathway contributes to the inhibition of remyelination 
observed in MS.  
In contradiction to findings from Armstrong et al, studies by groups using the 
inflammatory EAE model have shown that FGF2 improves lesion recovery and 
reduces inflammation (Rottlaender et al., 2011). Increasing FGF2 expression via 
viral gene transfer led to robust recovery in a chronic EAE mouse model. Inducing 
active EAE in FGF2 null mice resulted in more severe disease marked by 
enhanced microglia/macrophage and CD8+ T cell infiltration, and reduced 
remyelination. In a model of toxin-induced demyelination, animals treated with 
FGF2 had increased OPC and mature OL numbers in lesions and improved 
remyelination (Azin et al., 2015). Injections of FGF2 restored MBP expression and 
axonal function following lysolecithin-induced demyelination in the optic chiasm 
and hippocampus (Dehghan et al., 2012, Azin et al., 2015). Furusho et al. 
employed the toxin-induced acute and chronic cuprizone-demyelination models to 
investigate remyelination in mice that had FGFR1 and FGFR2 deleted in OL 
lineage cells (Furusho et al., 2015). They reported no difference in recovery 
following acute disease, but compromised remyelination after chronic disease. 
This was due to reduced expression of myelin proteins and myelin sheath 
thickness. OL numbers and maturation were unaffected in the KOs. Together, the 
studies of FGF2 in demyelinating animal models seem to suggest it has beneficial 
and detrimental properties. FGF2 appears to be anti-inflammatory and promote 
progenitor proliferation and migration, while at the same time inhibiting OPC 
maturation and myelination which prevents remyelination and functional recovery.  
1.4.2.3 FGF9 
FGF9 was identified as a target of interest when an in vitro screen of FGFs on a 
rat myelinating culture system revealed that FGF9 is a more potent inhibitor of 
myelination than FGF2. FGF9-treated myelinating cultures show a marked 
decrease in myelination at day in vitro 28 (DIV 28) without an obvious effect on 
underlying axons as shown in Figures 1.4 and 1.5.  
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FGF9 acts via a different mechanism than FGF2 but similarly promotes OPC 
proliferation and inhibits their differentiation to mature myelinating OLs. FGF2 
inhibits myelination directly by binding to FGFRs on OL lineage cells and so can 
inhibit differentiation of purified OPCs in vitro. Myelinating cultures treated with 
FGF9-conditioned astrocyte media displayed similar inhibition of myelination as 
FGF9-treated cultures (Lindner et al., 2015). This suggests that the mechanism of 
action of FGF9 is indirect and inhibits myelination by inducing the secretion of 
myelin inhibitory factors by astrocytes. FGF9 may be involved in promoting the 
recruitment of inflammatory cells via chemokine expression. Microarray and qPCR 
studies also showed that FGF9 induced the expression of proteases involved in 
tissue remodelling and pro-inflammatory cytokines, which could contribute to the 
impaired repair and inflammatory responses seen in MS (Lindner et al., 2015). A 
study in OL differentiation found that FGF9 had no significant effect in purified rat 
OPCs and induced little signaling, but activated MAPK in differentiated OLs 
(Cohen and Chandross, 2000). This led to a decrease in FGFR2 (OL maturation 
marker) expression and increase in FGFR1, with inhibition of myelin genes, Cnp, 
Mbp, and Plp. Similar changes were observed in differentiated OLs treated with 
FGF2. These findings suggest that FGF9 plays a pathogenic role in MS, by 
inhibiting myelination indirectly via astrocytes, and potentially by directly inhibiting 
OPC maturation. OPC proliferation was stimulated by FGF9 indicating that it may 
have some beneficial properties in MS where OLs have been depleted. Mice with 
cuprizone-induced EAE given dietary cholesterol display enhanced remyelination 
and axon-sparing which was associated with increased expression of FGF9 and 
FGF1 and a decrease in FGF2 (Berghoff et al., 2017). FGF9 is upregulated in 
Alzheimer’s plaques and amyotrophic lateral sclerosis (ALS) spinal cord, 
suggesting it is involved in the pathogenesis of neurodegenerative diseases 
(Nakamura et al., 1998). FGF9 is a potent neuronal survival factor and protects 
neurons from metabolic damage in Parkinson’s models (Kanda et al., 1999, Huang 
et al., 2009, Huang and Chuang, 2010). These findings suggest FGF9 may protect 
neurons and prevent axonal loss in MS, which is the main driver of disability.  
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Figure 1.4. FGF9 inhibits myelination in a dose dependant manner. Myelinating 
cultures were treated with different concentrations of recombinant human FGF9 from DIV 
18 - 28. DM- alone was used as a control to compare the effect on myelination. Cultures 
were fixed and stained with antibodies against MOG and SMI31 which label myelin and 
axons respectively. Myelination was quantified using CellProfiler as described in Section 
2.2.7. 50 ng/ mL and 100ng/ mL FGF9 significantly inhibited myelination (A) and 
treatment had no effect on axon density (B). Data presented are  the means ± SD relative 
to controls. This experiment was performed three times. *, p < 0.001 (one-way ANOVA 
with Dunnett's Multiple Comparison Test).  
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Figure 1.5. Representative images of myelinating cultures following FGF9 
treatment. Myelinating cultures were treated with different concentrations of 
recombinant human FGF9 from DIV 18 - 28. Cultures were fixed and stained with 
antibodies against MOG (green) and SMI31 (red). Myelin appears normal in DM- control 
cultures (A) and following treatment with 1ng FGF9 (B). A decrease in myelination is 
observed in cultures treated with 10ng FGF9, concomitant with the appearance of 
irregular, brightly staining MOG+ cells (C). Myelination is almost totally inhibited in 
cultures treated with 50ng (D) and 100ng FGF9 (E). 
Chapter 1 – General Introduction 39 
 
1.5 Thesis aims 
Following the recent discoveries made with regard to FGF9 in the pathogenesis of 
MS, the goals of this thesis were to further elucidate the mechanisms involved in 
FGF9 expression and signaling in MS. It was hypothesized that astrocytes and OL 
lineage cells would be the main target of FGF9-signaling in MS. To test this, 
studies of downstream FGF9 regulators were performed using post-mortem MS 
tissue, EAE samples, and in vitro cultures. Downstream regulators are expressed 
quickly in response to FGF-signaling making their presence a good indicator of 
where signaling is occurring. The trigger for FGF9 upregulation in MS is unknown 
and it was hypothesized that an aspect of the inflammatory process may be 
involved as higher FGF9 expression was seen in acute MS than in chronic stages.  
To test this hypothesis, several inflammatory mediators of MS and inducers of 
FGF9 in cancer were screened for their ability to induce FGF9 expression. As MS 
is a chronic disease characterised by bouts of inflammatory demyelination 
followed by remyelination it was hypothesized that downregulation of FGF9 
following high levels would promote remyelination. The long-term effects of 
increased levels of FGF9 were investigated using in vitro and in vivo models. The 
impact of FGF9 on mature myelin and FGF9 withdrawal were also investigated 
using the in vitro myelinating culture system. In addition, FGF9-gene containing 
vectors were administered to rat brains which were examined over a nine month 
period to examine the effects of chronic exposure of FGF9 in the CNS. These 
experiments were performed with the goal of increasing understanding of the 
mechanisms that drive pathogenesis in MS. 
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2 MATERIALS AND METHODS 
2.1 Animals 
Sprague Dawley (SD) and Dark Agouti (DA) rats were used in these studies. All 
animals were purchased from Harlan Laboratories (Blackthorn, UK) and were 
maintained at the University of Glasgow Central Research Facility. All animal care 
and procedures were in accordance with the Animals Scientific Procedures Act, 
1986, under project license no. 60/4314 and personal license no. 60/10857 issued 
by the UK Home Office and with approval from the University of Glasgow Ethical 
Review Process Applications Panel. 
2.2 Cell Culture 
All culture preparation and maintenance was performed in an aseptic fashion. 
Instruments and dissection tools were sterilized prior to use by autoclave or 70% 
ethanol. Tissue dissections were mostly performed at the bench, all in vitro work 
was done using laminar flow hoods. All tissue culture media used in these 
experiments contained the antibiotics penicillin and streptomycin and were filter 
sterilized before use. 
2.2.1 Generation of myelinating spinal cord cultures  
2.2.1.1 Generation of neurospheres 
The corpus striatum of P1 (post-natal day one) Sprague Dawley (SD) rats were 
dissected to generate neurospheres via the methods developed by (Reynolds and 
Weiss, 1996) with the modifications described by (Sorensen et al., 2008). P1 pups 
of both sexes were sacrificed by intraperitoneal injection of Euthanal. Once dead, 
the pups were decapitated and their brains excised and transferred to a petri dish 
containing cold Leibovitz’s L-15 media (Invitrogen). Using a scalpel, the cerebral 
hemispheres of the brain were separated and the portion of the cortex containing 
the striatum was isolated by making coronal slices through the cortex at the corpus 
callosum and just prior to the olfactory bulb. The striatum was then carefully 
dissected out of the cortex and placed into a bijou containing 1 mL of Leibovitz’s L-
15 media, on ice. 5 – 6 striata generated one flask of neurospheres. The striata 
were mechanically dissociated by trituration using a glass Pasteur pipette and 
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transferred into a 15 mL centrifuge tube. The suspension was centrifuged at room 
temperature for 5 minutes at 800rpm (~136g). The supernatant was discarded and 
the cell pellet resuspended in 2 mL neurosphere media (NSM) consisting of 
DMEM/F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12) (1:1, 
DMEM containing 4500 mg/L glucose), supplemented with 7.5% NaHCO3, 2 mM 
glutamine, 5000 U/mL penicillin, 5 µg/mL streptomycin, 5.0 mM HEPES, 0.0001% 
bovine serum albumin (BSA) (all from Invitrogen), 25 g/mL insulin, 100 g/mL 
apotransferrin, 60 M putrescine, 20 nM progesterone, and 30 nM sodium selenite 
(all from Sigma). To this mixture, 4 µL of EGF (20 ng/mL mouse submaxillary 
gland epidermal growth factor from R&D Systems) was added and the whole 
suspension was plated into a 75 cm3 uncoated tissue culture flask (Greiner), 
containing 18 mL of 37o C NSM. The cultures were incubated at 37o C in a 
humidified atmosphere of 7% CO2 /93% air. The cultures were fed twice a week by 
the addition of 5 mL NSM + 4 µL EGF. After 7-10 days, the neurospheres were 
visibly large enough to be plated down to form astrocytes. 
2.2.1.2 Generation of astrocyte monolayers from neurospheres  
Differentiation of astrocytes was performed as described by (Thomson et al., 
2006). Firstly, glass coverslips (13 mm diameter; VWR International) were coated 
with poly-L-lysine (PLL) (13 g/mL, Sigma Aldrich) by incubating them at 37o C for 
at least 1 hour. Twenty-four well plates (Corning Life Sciences) were prepared by 
placing PLL-coverslips individually into each well and letting them dry overnight in 
a laminar flow hood. Prepared 24 well plates were sealed in an autoclave bag and 
kept at 4o C until use. After 7 - 10 days in culture, flasks of neurospheres were 
scraped using a cell scraper (Grenier) and the suspension was transferred into a 
50 mL centrifuge tube 
. One flask of neurospheres would typically generate 5 – 6 plates of astrocyte 
monolayers. The neurospheres were centrifuged at 800rpm (~136g) for 5 minutes 
at room temperature and the pellet was triturated using a glass Pasteur pipette to 
produce a single cell suspension. The suspension was diluted to in 12 mL/ 24 well 
plate with low-glucose DMEM supplemented with 10% foetal bovine serum and 2 
mM L-glutamine (DMEM-FBS) (Sigma Aldrich). 0.5 mL of suspension was pipetted 
into each well followed by 0.5 ml of DMEM-FBS. The monolayers were incubated 
at 37o C in a humidified atmosphere of 7% CO2 /93% air and were maintained by 
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replacing half the media in each well with fresh DMEM-FBS twice a week until the 
cells formed a confluent monolayer, 7 - 10 days later. Astrocyte monolayers are 
produced without any cell-specific selection and as such are subject to 
contamination by other CNS cell types. Data of astrocyte monolayer purity is 
shown in Figure 8.3. OL lineage cells are the major contaminating cell type in 
astrocyte monolayers at DIV 7 however as this culture is mainly used as a base for 
myelinating cultures this is not considered to be a negative issue. 
2.2.1.3 Seeding of embryonic spinal cord cells on astrocyte monolayers  
The methods of generating myelinating cultures were developed by (Thomson et 
al., 2008) for mouse cultures and adapted by (Sorensen et al., 2008) for use in rat 
cultures with some modifications. Time-mated SD female rats were sacrificed by 
asphyxiation in a CO2 chamber on embryonic-day 15.5 (E15.5). The rats’ 
abdomen and dissection tools were sterilized with 70% ethanol. Using scissors the 
skin and abdominal wall were cut in a V shape to expose the embryos. The gravid 
uterus was removed and placed in a petri dish containing Hank’s balanced salt 
solution (HBSS) on ice. The embryos were removed from their embryonic sacs 
and transferred to 35 mm petri dish containing ice cold HBSS. Using forceps and 
pointed-tweezers the embryos were dissected under a microscope. First, the 
embryos were decapitated rostral to the cervical flexure to preserve the structure. 
The skin over the spinal cord was then carefully removed along its length and the 
cord was gently lifted out of the embryo. The meninges were peeled from the cord 
along with any attached dorsal root ganglia, and the cords placed in a bijou 
containing 1 mL HBSS without calcium or magnesium on ice. Up to five cords 
were collected in each bijou.  
The cords were dissociated by trituration with a glass Pasteur pipette and 
enzymatically digested with trypsin (2.5%, 100 µL, Sigma Aldrich) and collagenase 
I (1.33%, 100 µL, Invitrogen) in HBSS for 15 minutes at 37o C. To stop the 
enzymatic activity 2 mL of trypsin inhibitor containing 0.52 mg/mL soybean trypsin 
inhibitor, 3.0 mg/mL bovine serum albumin, and 0.04 mg/mL DNase (Sigma 
Aldrich) to prevent cell clumping, was added to the suspension. The spinal cord 
suspensions were shaken and incubated at room temperature for a few minutes to 
allow the DNase to work and the dissociated tissue to settle on the bottom of the 
bijou. 2 mL of media was carefully pipetted off and discarded from each bijou. The 
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dissociated cords were then triturated with a glass Pasteur pipette and pooled in a 
15 mL centrifuge tube and centrifuged at 1200rpm (200g) for 5 minutes. The 
supernatant was removed and the pellet was resuspended in 10 mL plating media 
(PM) consisting of 50% low-glucose DMEM (Gibco Life Sciences), 25% horse 
serum (Sigma Aldrich), 25% HBSS with calcium and magnesium, and 2 mM L-
Glutamine (Invitrogen). Cell numbers and viability were measured by diluting a 
sample of the suspension 1:1 with Trypan Blue and counting the living cells under 
a microscope using a Haemocytometer. The suspension was then diluted to 3 
x106 cells/mL with PM.  
Coverslips with neurosphere-derived astrocyte monolayers, described in section 
2.2.1.2 were removed from the 24 well plate using ethanol sterilized tweezers and 
placed into 35 mm petri dishes (3 per dish). 50 µL (150,000 cells) of the 
dissociated spinal cord suspension was pipetted onto each cover slip and the petri 
dishes were incubated at incubated at 37o C for 2 hours to allow the cord cells to 
adhere to the monolayer. After incubation 450 µL PM + 600 µL differentiation 
media + insulin (DM+) was added to each dish. DM+ consists of DMEM (4500 
mg/mL glucose) (Gibco Life Sciences), 10 ng/ml biotin (Sigma Aldrich), 50 nM 
hydrocortisone (Sigma Aldrich), 0.5X N1 supplement (Sigma Aldrich), and 0.5 
mg/mL insulin from bovine pancreas (Sigma Aldrich). These cultures were 
maintained in a humidified atmosphere of 7% CO2 /93% air and fed with DM+ 3 
times per week by swapping half the culture media with fresh DM+ until day-in 
vitro 12 (DIV 12). From DIV 12, the cultures were fed with DM- (DM+ without 
insulin) to allow OL lineage cells to differentiate and produce myelin. 
2.2.2 Generation of low-density astrocyte cultures 
Neurospheres were harvested and pelleted as described in Section 2.2.1.1. The 
supernatant was discarded and using a glass Pasteur pipette the pellet was 
triturated with 1 mL DMEM-FBS. This 1 mL cell suspension was divided between 2 
75 cm3 uncoated tissue culture flasks (Greiner) containing 11.5 mL DMEM-FBS. 
The cultures were maintained in a humidified atmosphere of 7% CO2 /93% air at 
37o C and were fed by removing 6 mL of media and adding 6 mL fresh DMEM-
FBS twice a week. After 1 week in culture the media was removed from the flask, 
the cells were gently aspirated with 10 mL cold sterile phosphate buffered saline 
(PBS) then trypsinised with 1 mL trypsin Ethylenediaminetetraacetic acid (EDTA) 
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0.05% (Invitrogen) and incubated at 37o C for 1 - 2 minutes. After incubation, 10 
mL DMEM-FBS was added to each flask to inhibit the trypsin. The adherent cells 
were separated from the flasks using cell scrapers (Greiner) and then pipetted into 
a 50 mL centrifuge tube before centrifugation at 1200rpm (200g) for 5 minutes. 
The supernatant was discarded and the cells were resuspended in 10 mL DMEM-
FBS and counted using Trypan Blue and a haemocytometer. The suspension was 
diluted to 25,000 cells/mL with DMEM-FBS. 1 mL of suspension was pipetted into 
each well of a 24 well plate containing PLL-coated glass coverslips as described in 
section 2.2.1.2. Cells were maintained in a humidified atmosphere of 7% CO2 
/93% air.  After 24 hours, the astrocytes had adhered to the coverslips and were 
transferred to 35 mm petri dishes, flooded with 1 mL DM-, and then fed twice 
weekly by removing and replacing half of the media in each dish.  
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Figure 2.1. Representative images of cells that constitute myelinating cultures at 
DIV 28. The projected axons of neurons are visualised by staining with SMI31 (A). 
Astrocytes that make up the supporting monolayer are stained with GFAP (B). Microglia 
are stained with IBA1 (C) and myelinating oligodendrocytes with PLP (D). 
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2.2.3 Generation of purified oligodendrocyte cultures.  
Purified oligodendrocyte cultures were generated from the cortices of P1 SD rat 
pups that were used to generate neurospheres. After the striatum was dissected 
out of the coronal section of the cortex, tweezers were used to peel away the 
meninges surrounding the cortex and within the ventricles. Four cortices were 
collected in a bijou containing 2ml HBSS without calcium or magnesium 
(ThermoFisher Scientific) on ice. Dissociation of the cortices was performed using 
a neural-tissue dissociation kit (Miltenyi Biotec) followed by A2B5 MACS 
microbead purification of oligodendrocyte lineage cells (Miltenyi Biotec). Cortices 
were minced in a 9 cm petri dish using a sterilized razor blade and collected in a 
15 mL centrifuge tube. The tissue was centrifuged at 300g for 2 minutes at room 
temperature and the supernatant discarded. 100 µL buffer X + 100 µL enzyme P 
were added to the centrifuge tube and the cortices were triturated slightly. The 
tube was incubated at 37o C for 10 minutes then 50 µL buffer Y and 25 µL enzyme 
A was added to the tube and the cortices were triturated again before another 10 
minute incubation at 37o C. Following one more trituration and 10 minute 
incubation at 37o C the cortices were spun down at 300g for 2 minutes, some of 
the enzyme solution was removed and the cells resuspended in the remaining 
solution and centrifuged again at 300g for 5 minutes. The remaining solution was 
removed and the cells were resuspended in 10ml HBSS with calcium and 
magnesium and counted using a haemocytometer. The cells were centrifuged at 
300g for 5 minutes at room temperature and resuspended in 1 mL MACS buffer 
(PBS + 0.5% BSA) then centrifuged again at 300g for 5 minutes at room 
temperature. The buffer was removed and the cells resuspended in 70 µL MACS 
buffer/ 10 million cells. 20 µL anti-A2B5 coated microbeads/ 10million cells was 
added and the cells were incubated on ice for 15 minutes. Anti-A2B5 monoclonal 
antibodies recognise a cell surface ganglioside epitope expressed by 
oligodendrocyte progenitor cells. During this incubation, an LS column (Miltenyi 
Biotec) was set up in a MACS separator magnet and washed with 500 µL MACS 
buffer. 2 mL MACS buffer was added to the cell suspension for washing and the 
tube was centrifuged at 300g for 5 minutes. The supernatant was removed and the 
magnetically labelled cells were resuspended in 500 µL MACS buffer and put onto 
the column through a 30 µm pre-separation filter (Miltenyi Biotec). The column was 
then washed with 3 x 3 mL MACS buffer and the negative cells collected in a 15 
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mL centrifuge tube. After washing the column was removed from the magnet and 
magnetically labelled cells were eluted by pressing 5 mL MACS buffer through the 
column into a 15 mL centrifuge tube. The eluted cells were centrifuged at 300g for 
5 minutes, the buffer was removed and the cells were resuspended in 0.5 mL 
oligodendrocyte differentiation media (BDM media) and counted with a 
haemocytometer. From this stage the cells were cultured under different 
conditions depending on the experiment as described below: 
For fluorescence microscopy studies the cells were resuspended in BDM media at 
20,000 cells/mL and 40,000 cells/mL for RNA extraction. 
In experiments involving mature oligodendrocytes PDGFα and FGF2 (both from 
Peprotech) were added to the cell suspensions at 50 ng/mL prior to plating. 1 mL 
of suspension was plated onto a PLL coated coverslip in a 24 well plate as 
described in Section 2.2.1.2. The cells were maintained in a humidified 
atmosphere of 7% CO2 /93% air. After two days the coverslips were transferred 
into 35 mm tissue culture dishes and 1mL Sato’s media was added to each dish 
without PDGFα and FGF2 to allow the cells to differentiate. OLs were checked 
daily by bright field microscopy to assess viability and differentiation state. Cells 
were fed by exchanging half of the media with fresh Sato’s 3 times per week. 
Treatments for these experiments began at DIV 6. 
In studies of immature OLs, cells were suspended and diluted in Sato’s media 
instead of BDM. These cells were cultured for 2 days before treatments were 
initiated. Experiments performed by previous members of the lab showed that OLs 
purified by these methods are over 90% pure throughout the first seven DIV. The 
only contaminating cell type is astrocytes which begin to proliferate and take over 
the cultures after DIV 7. 
2.2.4 Generation of bone marrow-derived macrophage cultures. 
SD female rats were sacrificed by asphyxiation as in Section 2.2.1.3. The animals’ 
hind legs and dissection instruments were sterilized with 70% ethanol. Using 
pointed scissors and forceps the skin was cut from the abdomen along the inside 
of the hind leg to the ankle. The skin around the ankle was cut and peeled back 
towards the abdomen to expose the musculature of the leg up to the hip. Most of 
the muscle surrounding the upper and lower legs was removed with scissors and 
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the leg was twisted to dislocate the hip joint. Any tissue still connecting the hind 
leg to the body was cut away and the leg transferred to a 50 mL centrifuge tube 
containing ice-cold PBS. Both legs from one animal were typically collected. In a 
laminar flow hood the legs were removed from the centrifuge tube and sterilized 
with 70% ethanol. Sterilized medium duty bone shears were used to remove the 
foot, fibula, and separate the knee joint of each leg. Using fine banded scissors the 
remaining muscle was removed from the femurs and tibias. The trabeculae of the 
bones were removed by one clean cut with the bone shears, being careful not split 
the bone along its length and expose the bone marrow. A 10 mL syringe was filled 
with ice cold complete Roswell Park Memorial Institute -1640 media (cRPMI), 
containing RPMI-1640 with 10% FBS, and connected to a 25G needle. Marrow 
was flushed from the bones into a 9 cm petri dish and then dissociated by drawing 
the suspension through the needle several times. The bone marrow was passed 
through a 70 μm cell strainer (Corning) into a 50 mL centrifuge tube and pelleted 
by centrifugation at 2000 rpm (~480g) for 5 minutes at room temperature. The 
supernatant was discarded and the pellet was agitated and incubated with 2 mL 
ACK lysis buffer (ThermoFisher Scientific) for 90 seconds to lyse erythrocytes. An 
excess of PBS was then added to the centrifuge tube to inhibit lysis followed by 
another centrifugation at 2000rpm. The pellet was resuspended in 10 mL cRPMI 
and the cells were counted using Trypan Blue and a Haemocytometer. The cells 
were diluted with cRPMI to a density of 1 million cells/mL and 50 ng/mL rat 
macrophage colony-stimulating factor (M-CSF, peprotech) was added to the 
suspension. M-CSF promotes differentiation of macrophages from bone marrow 
progenitor cells.  1 mL of cell suspension was plated into 35 mm petri dishes. The 
cultures were incubated at 37o C in a humidified atmosphere of 5%CO2/95% air. 
Every 2-3 days all media were removed from each dish and the cells were 
carefully washed with PBS before adding fresh cRPMI + 50 ng/mL M-CSF. 
Macrophage progenitors adhere to the dishes while other bone marrow cells 
remain in suspension and were removed by washing with PBS. Bone marrow-
derived macrophages (BMDMs) were fully differentiated after 7 days in culture. 
Purity of BMDM cultures was not analysed as part of these experiments however 
this is a well-established protocol for BMDM generation which is described to 
produce cultures that are 95 – 99% pure (Ying et al., 2013). 
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2.2.5 Generation of enriched neuronal cultures. 
E15.5 embryos from SD rats were harvested and dissected as described in 
section 2.2.1.3. Brains from the decapitated heads of the embryos were carefully 
dissected from the skulls using forceps. The meninges were removed and the 
brains transferred into a bijou containing 1 mL HBSS without calcium and 
magnesium, striata from two brains were placed in each bijou which were kept on 
ice. The brains were digested and pelleted identically to E15.5 spinal cords. The 
final pellet was resuspended in 10 mL neuron media: Neurobasal media (Gibco) 
containing 1 X B27 supplement (Gibco), 2 mM L-Glutamine (Invitrogen), and 5000 
U/mL penicillin, 5 µg/mL streptomycin. Cell numbers and viability were measured 
with Trypan Blue using a Haemocytometer and cells were diluted to a density of 
80,000/ mL. 0.5 mL cell suspension was pipetted onto PLL-coated coverslips in a 
24 well plate. Neurons were incubated in a humidified atmosphere of 7% CO2 
/93% air for 4 days. Coverslips were then transferred into 35 mm petri dishes and 
flooded with 300 µL conditioned neuron media and 800 µL fresh neuron media. 
After 6 DIV neurons were fully differentiated. Neuorbasal media supresses 
differentiation of cell types other than neurons however some contamination does 
occur as shown in Figure 8.4. In particular, astrocytes and OL lineage cells appear 
at DIV3 and continue to increase the longer the cultures are maintained. 
2.2.6 In vitro culture treatments 
2.2.6.1 Myelination experiments 
The myelinating cultures (one petri dish per condition) were treated with human 
FGF9 (R&D systems) at a concentration of 100 ng/mL from DIV 18 for 1 to 10 
days. The factor was added at the specified concentration to the DM- media for 
feeding (double the concentration was used on the first day of treatment). 
2.2.6.2 Astrocyte experiments 
For these experiments the low density astrocyte coverslips were placed in petri 
dishes and treated in the same way as the myelinating cultures with 100 ng/mL of 
each FGF. Low density astrocytes were used in imaging studies while astrocyte 
monolayers were used in qPCR experiments. 
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2.2.6.3 FGF9 experiments 
The myelinating cultures (one petri dish per condition) were treated with human 
FGF9 (R&D systems) at a concentration of 100 ng/ml from DIV 18 for 10 or 20 
days and from day 28 for 10 days. The factor was added at the specified 
concentration to the DM- media for feeding (double the concentration was used on 
the first day of treatment). 
2.2.6.4 Cytokine experiments 
Myelinating cultures were treated with a range of cytokines: tumour necrosis factor 
α (TNFα), interferon-γ (IFNγ), interleukin-6 (IL-6), IL-1β, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), IL-10, transforming growth factor-β1 (TGFβ1), 
(all from Peprotech), prostaglandin E2 (Santa Cruz), or benzo[a]pyrene (Sigma) at 
concentrations of 5, 50, or 100 ng/ml from day 18 for 24 hours or 10 days. 
2.2.6.5 Hypoxia experiments 
Myelinating cultures and astrocyte monolayers were incubated in a hypoxic 
chamber (Modular Incubator Chamber (MIC-101) and flooded with 1% O2 at a rate 
of 20 L/min for four minutes before being sealed and placed in a 37o C incubator 
for 6, 24, or 48 hours. Control cultures were maintained in a normal incubator at 
7% CO2. Some of the hypoxic cultures were then incubated at normal O2 levels for 
a further 24 or 48 hours. 
2.2.6.6 Macrophage experiments 
After 7 days in culture BMDMs were treated with 100 ng/mL recombinant rat IFNγ 
(Peprotech) or 100 ng/mL recombinant rat IL-13 (Peprotech) to drive macrophage 
polarization towards the M1 (inflammatory) or M2 (repair) phenotype respectively. 
Polarized macrophages were then treated for a further 24 hours with 100 ng/mL 
FGF1, 2, or 9 before they were lysed to collect mRNA for qPCR. 
2.2.6.7 Purified oligodendrocyte experiments 
Mature and immature oligodendrocytes were treated with 100 ng/mL FGF1, 2, or 9 
for 24 hours. The cultures were then fixed for immunofluorescence staining or 
lysed for RNA extraction. 
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2.2.6.8 Enriched neuron experiments 
Neurons were treated from DIV6 with 100 ng/mL FGF9 for 10 days then 
processed for immunofluorescence. Where 5-Fluoro-2'-deoxyuridine (FDU) was 
used in conjunction with FGF9, FDU treatment was started at DIV 4. 
2.2.7 Immunofluorescence staining of in vitro cultures 
After treatment, the cultures were fixed and stained with antibodies for 
immunofluorescence microscopy. All staining steps were performed at the bench 
with incubations taking place at room temperature. Media was removed from 
culture dishes and cells were fixed with 4% paraformaldehyde (PFA) for 20 
minutes followed by permeabilization with Triton X-100 0.5% (Sigma Aldrich) for 
10 minutes. Coverslips were then blocked for 30 minutes in blocking buffer (1% 
BSA (bovine serum albumin), 10% horse serum, in PBS). Primary and secondary 
antibodies used in imaging experiments are detailed in Table 2.2 below. Primary 
antibodies were diluted in blocking buffer and 40 µl was applied to each coverslip 
and incubated for 45 minutes. Coverslips were then washed in PBS and incubated 
with fluorescently-tagged secondary antibodies, prepared in blocking buffer, for 15 
minutes in the dark to avoid photo-bleaching. After incubation coverslips were 
washed 3 x in PBS followed by a final wash in distilled water and mounted on 
glass slides (ThermoFisher Scientific) with 10 µl Mowoil 4-88 + DAPI (4',6-
Diamidino-2-Phenylindole, Dihydrochloride) (Sigma Aldrich). 
2.2.8 Imaging and quantitative analysis 
For all culture experiments imaging was performed using an Olympus BX51 
fluorescent microscope and images were captured using Image-Pro software. For 
quantitative analysis of each culture system, 10 images from each coverslip were 
taken randomly at 20X magnification. Each condition was performed in triplicate (1 
petri dish = 1 condition = 3 coverslips); therefore, 30 images were taken per 
condition per experiment and used for quantification and analysis in in vitro culture 
experiments.  
Fluorescence intensity of staining of each antibody was quantified using 
CellProfiler software (http://www.cellprofiler.org/) with a pipeline developed to 
measure the pixel intensity from individual colour channels. Pipelines used in 
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these experiments can be downloaded from https://github.com/muecs/cp. 
Myelination percentage and axon densities were calculated using the myelin.cp 
pipleline. Total cell counts were measured using the dapi.cp pipeline to count cell 
nuclei. Total OL lineage cell numbers were counted using the olig2-aa3.cp pipeline 
to count green-labelled nuclei. Mean fluorescent intensities of FGF9 staining in 
hypoxia experiments was calculated using the pixel-int-g.cp pipeline. NG2+ OPCs 
were counted manually using the cell counter function of ImageJ. MAP2+ Neurons 
were also counted manually.  
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Table 2.1. Primary antibody list 
Antigen Host Target Isotype Dilution Source Clone 
PLP Rat M, R, H IgG 1-100 Hybridoma AA3 
DUSP 5 Rb H IgG 1-200 Abcam Poly 
DUSP 6 Rb M, R, H IgG 1-2000 Abcam EPR129Y 
CD68 Ms M, R, H IgG1 1-1000 Abcam ED1 
FGF9 Rb M, H IgG 1-400 Abcam Poly 
FGF9 Rb M, R, H IgG 1-200 Abnova Poly 
GFAP Rb M, R, H IgG 1-1000 DAKO Poly 
GFAP Ms M, R, H IgG1 1-1000 Abcam GF5 
IBA1 Rb M, R, H IgG 1-1000 Alpha Poly 
MAP2 Rb M, R, H IgG 1-100 Abcam Poly 
MOG Ms M, R, H IgG2a 1-500 Hybridoma Z2 
NeuN Ms M, R, H IgG1 1-100 Millipore A60 
NG2 Rb R, H IgG 1-200 Abcam Poly 
Olig-2 Rb M, R, H IgG 1-500 Chemicon Poly 
NF-H Ms M, R, H IgG1 1-1500 Affininty SMI31 
Sprouty 2 Ms H IgG1 1-200 Abcam ab60719 
Sprouty 4 Rb H IgG 1-200 Abcam ab103114 
Table 2.2. Fluorescent secondary antibody list. 
Antibody 
AlexaFluor
488 
AlexaFluor
568 
AlexaFluor
350 
goat-anti-mouse IgG + + 
 
goat-anti-mouse IgG1 + + 
 
goat-anti-mouse IgG2a + + 
 
goat-anti-mouse IgG2b + + 
 
goat-anti-rat IgG + + 
 
goat-anti-rabbit IgG + + + 
All secondary antibodies were purchased from Invitrogen and used at a working 
dilution of 1:400. 
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2.3 Immunohistochemical analysis of human tissues 
Immunohistochemical studies were performed on archived, formalin-fixed, 
paraffin-embedded brain material from 14 patients with MS and six controls 
without neurological disease or evidence of brain lesions. Samples were provided 
by the archive of the Centre for Brain Research at the Medical University of Vienna 
for immunopathological studies of human MS and control brain tissue under 
license from Ethik Kommission of the Medical University of Vienna (EK No. 
535/2004). 
Immunohistochemical studies were performed on consecutive deparaffinized 5 µm 
sections after endogenous peroxidase was blocked with H2O2/methanol. Antigen 
retrieval was performed using citrate buffer (pH 6.0) or EDTA buffer (pH 8.5) and 
non-specific antibody binding was blocked by incubating sections in 10% foetal 
calf serum. Primary antibodies to Sprouty2 (1:500) and Sprouty4 (phospho-Y75, 
1:250) (both rabbit polyclonal IgG (immunoglobulin G) from Abcam) were applied 
overnight at 4°C. After incubation and washing, antibody binding was routinely 
visualized using the horse radish peroxidase conjugated secondary antibody, 
biotin-donkey-anti-rabbit IgG, (1:2000), and 3,3’-diaminobenzidine (DAB). Cell 
nuclei were counterstained with haematoxylin prior to mounting. Photomicrographs 
were taken under a light microscope at 10X or 25X magnification.  
Confocal fluorescence immunohistochemistry was performed as described for light 
microscopy with some modifications. For fluorescent double labelling Sprouty2 
rabbit polyclonal IgG, 1:250, or Sprouty2 mouse monoclonal IgG, 1:150 (Abcam), 
were applied with glial fibrillary acidic protein (GFAP), goat polyclonal IgG, 1:100, 
or GFAP rabbit polyclonal IgG, 1:1500. Primary antibodies from different species 
were applied simultaneously at 4 °C overnight. After washing, appropriate 
secondary antibodies: Cy5-conjugated donkey-anti-goat (1:100), Cy3-conjugated 
donkey-anti-mouse (1:500), biotinylated donkey-anti-mouse (1:500), and 
biotinylated donkey-anti-rabbit (1:2000) (all from Jackson ImmunoResearch, West 
Grove, PA, USA) were applied simultaneously for 1 hour followed by application of 
Streptavidin-Cy2 (Jackson ImmunoResearch) for 1 hour at room temperature. 
Images were acquired using a confocal laser scanning microscope (Leica SP5, 
Leica Mannheim, Germany) equipped with lasers for 488, 543 and 633 nm 
excitation. 
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Table 2.3. List of patient samples used in human lesion studies 
Case Number LesionType Age Sex 
132-92-1 control 65 male 
421-92-5 control 80 female 
36989 control 36 female 
579-91-3 control 46 female 
37343 control 42 female 
68-93-4 control 83 male 
581-96-7A acute MS 35 male 
90-09-6 acute MS 69 female 
A01-144 acute MS 34 female 
S403-97 acute MS 45 male 
270-99-2 acute MS 45 male 
Spanien C2 RRMS 40 male 
70-93-6 acute MS 78 male 
146-01-8 active/ chronic active 41 male 
67-05-9 chronic active 34 male 
39-03-15 chronic active 67 male 
144-90-3 chronic active/ inactive 77 female 
244-94-7 chronic inactive 81 female 
285-81-1 chronic inactive 78 female 
72-83-6 chronic inactive 64 female 
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2.4 Molecular Biology 
2.4.1 RNA extraction  
2.4.1.1 RNA extraction from in vitro cultures 
RNA was extracted from myelinating cultures, astrocyte monolayers, purified 
oligodendrocytes, neuronal cultures, and BMDM cultures using the Qiagen 
RNeasy Micro kit (Qiagen, #74034). At the bench, media were completely 
removed from the tissue culture dishes. 350 µL RNeasy lysis buffer was then 
pipetted directly onto the coverslips. The coverslips were scraped with a cell 
scraper (Grenier) and the lysates were collected and homogenized by 
centrifugation through QIAshredder spin columns (Qiagen, #79654). Lysates were 
used immediately or stored at -80o C to aid homogenization. From this point, RNA 
extraction preceded according to manufacturer’s instructions; the lysates were 
centrifuged through a genomic DNA eliminator spin column, then mixed with an 
equal volume of 70% ethanol and transferred to RNeasy Mini Spin Columns. The 
columns were washed with provided buffers and RNA was eluted in 14 μL RNase-
free water and stored at -80o C. RNA quantity, quality, and integrity were 
measured using a Nanodrop ND-1000 Spectrophotometer (ThermoFisher 
Scientific). 
2.4.1.2 RNA extraction from tissues 
Tissue samples were added to RNase-free microcentrifuge tubes with 1 mL Trizol 
reagent (Ambion, #15596026) and a 5 mm stainless steel bead (Qiagen, #69989). 
Tubes were placed in a tissue homogeniser for 10 minutes at 50 
oscillations/second. 400 μL chloroform was added to the tubes which were shaken 
vigorously by hand for 15 seconds. The mixed homogenate was incubated on ice 
for 3 minutes and centrifuged at 12,000g for 15 minutes at 4o C. 700 μL of the 
resulting clear interface was pipetted into a fresh RNase-free microcentrifuge tube 
containing 700 μL 70% ethanol and mixed thoroughly. The mixture was pipetted 
onto a PureLink® RNA Mini Kit (Ambion, #12183030) and RNA was extracted 
according to manufacturer’s instructions. RNA was eluted in 30 μL RNase free 
water and stored at -80o C after measuring concentration and purity on a 
Nanodrop. 
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2.4.2 cDNA synthesis 
The volume of each RNA sample containing 500 ng RNA was transferred to a 
PCR (polymerase chain reaction) tube and made up to 12 µL with RNase free 
water. cDNA was synthesized using the Qiagen QuantiTect® Reverse 
Transcription Kit following the manufacturer’s instructions. 2 µl genomic DNA wipe-
out buffer was added prior to the first cycling step followed by 4 µL reaction buffer, 
1 µL reverse transcriptase and 1 µL random primer mix. Cycling parameters were 
as follows: first cycle (DNA wipe-out step) 42°C for 2 minutes, after adding reverse 
transcriptase, reaction buffer and primer mix second cycle: 42°C for 20 minutes, 
then 3 min for 95°C. 
2.4.3 Primer design 
Primers for use in qPCR experiments were designed from FASTA sequences in 
the NCBI nucleotide database, using the NCBI Pick Primers tool. Primer 
sequences were tested with NCBI Primer BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and were purchased from Integrated DNA 
Technologies. Before use, Primers were resuspended in RNase free water at a 
concentration of 100µM. A master mix of 1:1 forward and reverse primers were 
made in RNase free tubes and stored at -20o C. Primer sequences used in all 
experiments are detailed in Table 4 below. 
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Table 2.4. List of Primers used in qPCR experiments 
Gene Forward sequence Reverse sequence 
Arg1 CATATCTGCCAAGGACATCG GGTCTCTTCCATCACTTTGC 
Ccl2 TAGCATCCACGTGCTGTCTC TGCTGCTGGTGATTCTCTTG 
Ccl7 CCATCAGAAGTGGGTTGAGG CAGAAAGGACAAGGGTGAGG 
Dnah3 AACTGCCACCTGGCTACAAG CTGAGTCCTTTTGGGGGCTC 
Dnah6 TGCAGAACGAGTGCAGTCAA AGAGCCGGAAAGTGTCCTTG 
Dnah9 CAAAGGGATGCTGGAGCAGA TCACTTCGTTGTGGCTCTCC 
Dusp5 TTGAGGGGGTAGCAGGAAC CAGGGTAGGGAGGGAAACA 
Dusp6 AGTTTCTCTTGGGCAGCATC GCAAATCTCTCCCTCCGTAA 
Dync1i1 CCGTTCCAGATGACTCCGAT CAGCGGCTGCACTAGAGG 
Dynlrb2 TCCAATCCGAACAACCCTGG TCAGGTCATTCTGGGGGTCA 
Fgf1 TGTAGCATCTGGAGGGGTCT GGTAGGGGGAAGGGTAGTCA 
Fgf2 CTGTCTCCCGCACCCTATC CTTTCTCCCTTCCTGCCTTT 
Fgf9 GGAAAGACCACAGCCGATT TCTCTGAACACGCACTCCTG 
Fgfr1 AGAGACCAGCTGTGATGA CGCGTGACCAAAGTGGCC 
Fgfr2 GAGAGAAGGAGATCACAG CGCCACGGTGACTGCCTC 
Fgfr3 TGATGGAAACTGATGAGG GGCCACGGTGACAGGCTT 
Gapdh ATGACTCTACCCACGGCAAG TACTCAGCACCAGCATCACC 
Hk2 GGTTTCAAAGCGGTCGAACTG GAAATTGGTCAACCTTCTGCACT 
Ifny GCCCTCTCTGGCTGTTACTG CCAAGAGGAGGCTCTTTCCT 
Il10 CTCCCCTCGAGTGTCTTCAG CCATCAGCTGGGAATTTGTC 
Kif5a GGCCAGAGCAGAGATCACATT CTCCGACAGGTCAGCAAGAC 
Nefh AGGACACAGGGTTAGCAACG TCACTAGCAGGGTGGCTTTG 
Nos2 GAGACGCACAGGCAGAGG AGGCACACGCAATGATGG 
Rbfox3 TCTATGCAGTGACCAGTTTCCC CCACGGGACTGGCATTTTAAC 
Spry2 TGTCCCTCTTTCTGCCTTGT AACGCTATGTCGGCTTTTCA 
Spry4 TGAGGAAGAGGGAGGGTTTT AAGGGCAGGTGAGGTGTATG 
Sv2b CTCTACCGCTGAATCGCTCG TTTGACAAGGTCGGTCGGAG 
Tnf CCCCTTTATCGTCTACTCCTCA TTCAGCGTCTCGTGTGTTTC 
Tubb3 CAATGAGGCCTCCTCTCACA AATAGGTGTCCAAAGGCCCC 
 
Chapter 2 – Materials and Methods 60 
 
2.4.4 Quantitative real-time PCR 
Real-time PCR was performed using 7.5 µL 1X SYBR Green master mix (Applied 
Biosystems), 10 ng cDNA template (2 µL), 50 pmol/µL (0.3 µL) forward and 
reverse primers and 5.2 µL RNase free water per reaction. Amplifications for each 
sample were performed in triplicate on MicroAmp Fast 96-well Reaction Plates 
(Applied Biosystems). The reaction was amplified in an Applied Biosystems Fast 
Real-Time PCR System (ABI 7500) using the following cycle settings: 50°C for 5 
minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C 
for 1 minutes, and a final dissociation step at 95°C for 15 seconds. Melt curve 
analysis was then performed between 75 – 99°C in 1°C increments. The 
comparative CT method (or the 2-ΔCT (cycle threshold) method) (Livak and 
Schmittgen, 2001, Schmittgen and Livak, 2008) was used to determine differences 
in gene expression between conditions. 
2.5 Recombinant rat MOG1-125 production and purification 
2.5.1 Culture of rMOG-expressing E. coli 
E. coli expressing recombinant rat myelin oligodendrocyte glycoprotein1-125   
(rMOG) were cultured from frozen glycerol stocks generated previously. E. coli – 
strain DH5α F’Iq, were transformed using pQE12 vector (Qiagen) containing 
rMOG cDNA. This vector contained the inducible lac promotor which initiated gene 
expression when the bacteria were treated with Isopropyl β-D-1-
thiogalactopyranoside (IPTG). Included at the C-terminal end of rMOG cDNA in 
the plasmid were six histidine residues to allow for HisTrap purification. The 
pQE12 vector confers ampicillin resistance on transformed E. coli allowing them to 
be positively selected in ampicillin-containing media. 
10 L Lysogeny broth (L. broth) was prepared by combining 100g tryptone, 100g 
NaCl, and 50g Yeast in 10 L distilled H20. 2 L of L. broth was added to 4 x 4L 
flasks and 1 L in a 2 L bottle which were sealed with foil and autoclaved. 8 x 15 mL 
centrifuge tubes containing 5 mL L. broth, 5 µL kanamycin (25mg/mL), and 5 µL 
ampicillin (100mg/mL) were prepared and a glycerol stock of E. coli containing 
recombinant MOG expression vector was taken from a -80o C freezer. Once 
thawed slightly the pellet was scratched with a needle and E. coli was added to 7 
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of the prepared centrifuge tube, leaving the 8th as a control. The lids were loosely 
taped onto the tubes, which were secured in a shaking incubator at 37o C and 150 
rpm for 5 hours. After incubation, the tubes containing E. coli turned cloudy, 
indicating bacterial growth, and the control tube remains clear; the contents of 
centrifuge tubes were pooled in a bottle containing 1 L L. broth plus 1 mL 
kanamycin and 1 mL ampicillin, and the bottle was put in the shaking incubator 
overnight with the lid loosely taped on. After overnight incubation, the contents 
were evenly distributed between the 4 prepared 4L flasks and put in the shaking 
incubator with loosely taped on lids. Samples of broth were taken from one flask 
before and after the addition of the E. coli and then subsequently every 30 
minutes. The growth phase of E. coli was estimated by measuring the optical 
density (OD) of the samples at 600nm using the sample containing no E. coli as a 
blank. When exponential phase was reached (OD 600nm = 0.7-0.8, around 1 - 2 
hours) the E. coli were induced to begin expressing rMOG by adding 20 mL 0.1 M 
IPTG to each flask. The flasks were put back in the incubator for 5 hours and then 
the bacteria were collected in one pellet by repeated centrifugation at 15,000rpm 
for 20 minutes, 4o C (Beckman Coulter, F10BCI). The pellet was weighed and 
frozen at -20o C. 
2.5.2 Lysis of E. coli 
The pellet was thawed at room temperature and then resuspended in 5 mL/g PBS. 
The bacterial suspension was transferred to a glass homogeniser in batches and 
homogenised on ice before being collected in a sterile glass bottle on ice. Lysis 
was achieved with the addition of lysozyme (1mg/mL) (Sigma Aldrich) and DNAse 
(5ug/mL) (Sigma Aldrich) to the suspension which was shaken for 30 minutes on 
ice. N,N-Dimethyldodecylamine N-oxide (LDAO) was added to the bottle to make 
a 0.5% concentration and the whole suspension was transferred to a sterile 200 
mL glass beaker. The suspension was sonicated on ice (Soniprep 150) for 10 
minutes at 10 - 15 amplitude. The suspension was distributed between 4 x 35 mL 
centrifuge bottles which were topped up with PBS until full. The suspension was 
centrifuged at 15,000rpm for 20 minutes, then the supernatant was discarded and 
the pellets resuspended in 10 mL PBS and homogenized using a glass 
homogeniser. This step was repeated 3 times. After these washing steps the pellet 
was collected in one bottle, weighed, and frozen at -20o C. 
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2.5.3 Dissolving inclusion bodies 
The frozen pellet was thawed and resuspended in 10 mL/g 8 M Urea buffer in a 50 
mL centrifuge tube. To this, 8 µL/mL β-mercaptoethanol was added to reduce 
disulphide bonds and the suspension put on a shaker for 30 minutes with the lid 
sealed with parafilm. The suspension was distributed between 4 x 35 mL 
centrifuge bottles and 20 mL urea buffer was added to each bottle. The 
suspension was centrifuged at 15,000 rpm for 20 minutes at 4o C. The supernatant 
was collected and vacuum filtered (0.45µm, Nalgene) into a sterile glass bottle. 
2.5.4 Nickel-chelate affinity chromatography 
The supernatant containing rMOG was purified using an ÄKTAprime plus 
chromatography system (GE Healthcare). First, the ÄKTAprime loads a HisTrap 
column (GE Healthcare) with NiCl that binds to His-tagged rMOG. The bound 
protein is then eluted from the column by passing through excess imidazole 
(Sigma Aldrich) which displaces the His-tagged protein from the column. 10 µL 
samples from each eluted fraction were analysed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (15% SDS-PAGE). The gel was run at 200V for 
30 minutes with 5 µL SeeBlue Plus2 pre-stained protein standard (ThermoFisher 
Scientific) followed by a 2 hour stain with Coomassie Blue and 1 hour de-stain with 
50% methanol/ 10% acetic acid solution. 
2.5.5 Dialysis of protein 
Eluted fractions which left rMOG-positive bands on the Coomassie-stained gel 
were selected for dialysis. The samples were dialysed in 1000:1 20mM sodium 
acetate buffer (pH3.5) at 4o C. Strips of 12-14 kDA dialysis tubing (Spectra/ Por 
Biotech) were prepared by boiling in a 2% sodium bicarbonate + 1 mM EDTA 
solution for 10 minutes followed by 10 minute boil in 1 mM EDTA solution and then 
rinsed with distilled water. The tubing was sealed at one end using a clip and the 
protein-containing fractions were transferred into the tubing which was sealed with 
a buoyancy clip. The elution was dialysed 4 L at a time at 4o C with the buffer 
being changed every 24 hours until the elution had been dialysed in 1000 x its 
volume. 
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2.5.6 BCA protein concentration assay 
The concentration of rMOG in dialysed elution was determined using a Pierce 
bicinchoninic acid (BCA) assay (ThermoFisher Scientific) according to the 
microplate method in the manufacturer’s instructions. BCA working reagent, 
protein standards, and dilutions of rMOG solution were added to a flat-bottomed 
96 well plate (Corning Life Sciences) and incubated for 30 minutes at 37o C to 
allow the reaction to develop. The absorbance at 562 nm was measured using a 
Magellan Tecan Sunrise plate reader and a standard curve of known protein 
concentration vs light absorbance was used to determine the concentration of 
rMOG in the elution. rMOG was diluted to a concentration of 1 mg/mL using sterile 
water in a 50 mL centrifuge tube. 
2.5.7 X-ray sterilization of purified rMOG  
The rMOG sample was placed in an ARAD 225 X-ray generator and given a dose 
of 50,000 cGy. Following this, the sample was taken to a laminar flow hood and 
aliquoted in sterile cryotubes at 1 mL per tube. Aliquots were stored at -20o C. 
2.6 In vivo experiments 
2.6.1 MOG-induced EAE in DA rats 
rMOG (1mg/mL) was thawed and mixed 1:1 with complete Freund’s adjuvant 
(CFA) (Sigma Aldrich). An emulsion was formed by pumping the mixture through a 
24 gauge connector using two glass syringes. The emulsion was kept at 4o C and 
mixed every 2 hours until very viscous. Twelve, 12-week-old, female  DA rats were 
ear marked and weighed before 10 rats were given an injection of 100 µL 
emulsion (containing 50µg rMOG) subcutaneously at the base of the tail. 
2.6.1.1 Clinical scoring of EAE 
Following immunization with rMOG, rats were weighed and clinically assessed 
daily and twice daily after the first symptoms were detected. Rats were assigned a 
score from the following scale: 0 = no sign of disease; 0.5 = distal limp tail; 1 = 
limp tail; 2 = mild paraparesis, ataxia; 3 = moderate paraparesis, occasional 
tripping; 3.5 = one hind limb is paralysed; 4 = complete hind limb paralysis; 5 = 
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complete hind limb paralysis and incontinence; 6 = moribund, difficulty breathing, 
does not eat or drink, front limb paralysis; 7 = dead. A clinical score of 6 was 
considered the humane endpoint of the experiment and any animals that reached 
this score were immediately euthanized. Rats that did not develop a clinical score 
of 6 were euthanized at peak clinical severity during the first or second phase of 
EAE. Rats were scored consistently by the same person to minimize variation.  
2.6.1.2 Perfusion and harvesting of rat spinal cord 
Rats were sacrificed by asphyxiation in a CO2 chamber. Once determined to be 
dead by assessing pain and blink reflexes were absent the rats were quickly 
perfused with PBS followed by 4% PFA. First the rat was decapitated then, using a 
scalpel to open the skin and cut away surrounding tissue, the vertebral column 
was exposed. Using fine pointed scissors, a laminectomy was performed and the 
spinal cord was carefully lifted out of the spinal column and submerged in a 15 mL 
centrifuge tube containing 4% PFA. The cords were kept at 4o C for 24 hours to 
ensure the tissue was well fixed. For qPCR experiments, the cords were removed 
after perfusion with PBS and the lumbar portion was placed in a sterile bijou and 
frozen at -80o C. RNA extraction was then performed as described in section 
2.4.1.2. 
2.6.1.3 Preparing rat spinal cord for immunohistochemistry 
The lumbar portions of fixed spinal cords were cut into 2 mm coronal sections 
using a rat brain matrix and microtome blade. Sections were collected in cassettes 
and dehydrated using a Leica TP 1020 Tissue Processor. Paraffin embedding of 
the sections was then performed using a Leica EG1160 Embedding Center. 
Consecutive 6 µm coronal sections were made from paraffin embedded spinal 
cords and mounted on Superfrost™ Plus microscope slides (Thermo  Fisher 
Scientific). 
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2.6.2 Cortical injection of AAV6 viral vectors in Lewis rats 
2.6.2.1 Stereotactic injections 
These procedures were performed by Dr Claudia Wrsoz in collaboration with Prof 
Christine Stadelmann from the Neuropathology department at the University of 
Göttingen. Adult female Lewis rats (n=60) were anaesthetised by intraperitoneal 
injection with Xylazine and Ketamine (100 mg/kg and 5 mg/kg respectively). The 
scalp was shaved and, using a scalpel, the skin was opened with a sagittal cut 
from the eyes to ears to reveal the bregma. Rats were fixed in a stereotactic 
frame, holes were drilled through the skull (Dremel 300-1/5 driller) 2 mm posterior, 
and 2 mm lateral of each side of the bregma. Using a fine glass capillary (Ø = 
0.05–0.1 mm) 1 µL adeno-associated virus (AAV) vector solution (containing 108 
vectors) (shown in Figure 2.2) was injected 2.5 mm into the cortex of each 
hemisphere. Monastral Blue (Sigma-Aldrich) was added as a marker dye to trace 
the injection site. 6 rats were injected with AAV6-egfp vectors and 6 with AAV6-
Fgf9 vector per time point. Time points were 10 days, 30 days, 3 months, and 9 
months. After surgery the wound was closed with sutures and the animals were 
allowed to recover until they were euthanized at each given time point. 
2.6.2.2 Harvesting and preparing rat brain for immunohistochemistry 
Animals were euthanized by lethal intraperitoneal injection of 200 µL 14% chloral 
hydrate. When dead, animals were quickly perfused with PBS followed by 4% 
PFA. The rats were then decapitated and the heads were perfused for a further 48 
hours in 4% PFA at 4o C. After perfusion, the brains were dissected from the skull 
a coronal section was made using a razor blade to cut several mm anterior and 
posterior of the injection as identified by Monastral Blue. These sections were 
dehydrated and processed for paraffin embedding. Using a Microtome (Leica 
Biosystems) 6 µm sections were made and mounted on Superfrost™ Plus 
microscope slides (Thermo  Fisher Scientific). 
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B 
A 
Figure 2.2. Adeno-associated viral vectors used in in vivo experiments. Infections 
were performed using (AAV-6)-based vectors containing the Egfp (pAAV-eGFP) (A) and 
Fgf9 (pAAV-FGF9) (B) genes driven by the astrocyte GFAP promoter. These vectors also 
contain Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) to 
enhance target gene expression. 
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2.6.3 Staining and imaging of rat brain and spinal cords 
Immunohistochemical and immunofluorescence studies were performed on 
consecutive deparaffinized 5 μm sections after endogenous peroxidase was 
blocked with H2O2/methanol. Antigen retrieval was performed using citrate buffer 
(pH 6.0) or EDTA buffer (pH 8.5) and non-specific antibody binding was blocked 
by incubating sections in 10% fetal calf serum. Primary antibodies against MOG, 
MBP, CNPase (2',3'-cyclic-nucleotide 3'-phosphodiesterase), MAG (myelin-
associated glycoprotein), PLP (proteolipid protein), β-APP (beta-amyloid precursor 
protein), FGF9, and Sprouty2 were applied overnight at 4° C. After washing, 
appropriate horseradish peroxidase (HRP)-conjugated or fluorescently labelled 
secondary antibodies were applied simultaneously for 1 hour. Sections were 
incubated with DAB until staining was detected and cell nuclei were 
counterstained with haematoxylin. For myelin quantification, in AAV6-Fgf9 lesions, 
FIJI image processing software was used to delineate lesions. Colour 
deconvolution software in FIJI was then used to select only the DAB staining and 
then the image was converted to binary to generate an image in which DAB 
staining appeared as black particles which could be measured with particle 
analysis. These data were then used to calculate the area of each lesion that was 
positive for myelin proteins. β-APP counts were obtained by counting β-APP+ 
axonal swellings in a grid from 6 different areas of each lesion at 40x 
magnification. Counts were performed twice. 
2.7 Statistical analysis 
Experimental data were analyzed using GraphPadPrism 5.0 (GraphPad Software, 
San Diego, CA, USA). Data were expressed as the means ± standard deviation 
(SD). Two tailed T-tests and one-way analysis of variance (ANOVA) statistical 
analysis were performed with post hoc tests used where appropriate. Significance 
was set at P < 0.05. 
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3  FEEDBACK INHIBITORS OF FGF9 IN MS AND 
MYELINATING CULTURES 
3.1 Introduction 
FGFs play a role in every stage of embryonic development and accomplish their 
varied functions through the establishment of ligand gradients, activation of 
several signaling pathways, and an array of regulatory mechanisms (Ornitz and 
Itoh, 2015). The major positive and negative regulators of FGF signaling are 
discussed in section 1.2.4. Sproutys and DUSPs comprise two families of MAPK 
inhibitors that are induced by FGF signaling (Branney et al., 2009, Minowada et 
al., 1999). While DUSP1 and DUSP5 upregulation is a general response to ERK-
MAPK signaling, Sprouty2 and Sprouty4 are only induced by ligation of IIIc 
isoforms of FGFRs, for which FGF9 is specific (Branney et al., 2009, Sylvestersen 
et al., 2011). DUSP6 expression requires FGF signaling through FGFR1 or 
FGFR2 (Li et al., 2007). Using the Sproutys and DUSPs as surrogate markers for 
FGF signaling could reveal which cell types are targets of FGF9 in MS and 
increase our understanding of its mechanisms of action.  
Microarray analysis of FGF-treated myelinating cultures found Sprouty2, Sprouty4, 
DUSP5, and DUSP6, were significantly upregulated by FGF9 24 hours and 10 
days after commencement of treatment (Table 3.1). FGF1 induced no significant 
changes in expression of these genes at 24 hours or 10 days. FGF2 induced 
upregulation at 24 hours but at 10 days, this effect had largely diminished. These 
findings suggest FGF9 signaling maintains higher levels of feedback inhibitor 
expression over a protracted period while signaling via other FGFs tails off. If the 
same is true in MS, this may mean that over time Sprouty/DUSP expression in 
lesions is a direct result of FGF9 signaling alone.   
The aims of the experiments in this chapter were to analyse expression of FGF 
feedback inhibitors in MS lesions, and investigate the effects of FGF9 on feedback 
inhibitor expression in vitro. Human brain sections from patients with acute or 
chronic MS lesions, as well as healthy controls (Table 2.3), were stained with 
antibodies against Sprouty2 and Sprouty4 to assess in which condition feedback 
inhibitor expression was highest and how this related to FGF9 expression. 
Astrocytes, OLs, neurons, and macrophages were identified based on their 
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nuclear and cytoplasmic morphology. Some sections were double stained with 
cell-type specific antibodies to confirm which cells in the lesions were responding 
to FGF signaling. In vitro myelinating, OL, and astrocyte cultures were generated 
and treated with FGFs to assess negative-feedback inhibitor expression by qPCR 
and immunofluorescence. 
 
Gene 
FGF1 FGF2 FGF9 
24 hours 10 Days 24 hours 10 Days 24 hours 10 Days 
Spry1 1.66429 -1.13181 2.62865 1.15258 2.82015 3.20257 
Spry2 1.39665 -1.34698 2.58598 1.16276 2.63593 3.76283 
Spry3 -1.02506 -1.10525 1.01039 -1.13094 1.02613 1.03482 
Spry4 1.59551 -1.10347 8.51173 1.28566 7.3989 5.58061 
       
Dusp1 1.00992 1.0935 1.32224 1.19059 1.03682 1.63413 
Dusp2 1.00202 -1.06506 1.18446 -1.01644 1.10998 -1.22667 
Dusp4 2.27261 -1.1606 4.53533 -1.08873 4.8481 1.79124 
Dusp5 1.38495 1.07075 8.21072 2.04495 6.81049 2.70486 
Dusp6 1.57391 1.37269 5.51279 1.99727 5.01733 6.50911 
Dusp7 1.07361 1.04134 1.54146 1.12073 1.52373 1.31843 
Dusp8 -1.12153 -1.06968 -1.35298 -1.61927 -1.30864 -2.46719 
Dusp9 1.01812 -1.03094 1.10596 1.00125 1.03068 1.02193 
Dusp10 1.19886 -1.13546 1.69085 -1.27421 1.29386 1.03969 
Dusp16 1.05861 -1.12203 1.27194 -1.03076 1.25538 1.02237 
       
Fgfr1 -1.03445 -1.02274 -1.17369 1.10437 -1.12936 1.18193 
Fgfr2 -1.34399 1.02231 -1.39775 -1.04508 -1.31047 -1.03827 
Fgfr3 -1.08078 -1.00257 -1.35427 1.10586 -1.33396 2.39353 
Fgfr4 -1.18494 1.0023 -1.25267 1.00702 -1.28403 -1.07927 
 
 
3.2 Results 
Table 3.1. Differentially expressed genes in rat myelinating cultures treated with 
FGF1, 2, or 9, for 24 hours and 10 days. Microarray analysis  of FGF-associated gene 
expression shows that negative feedback inhibitors, Sproutys and Dusps (fold changes 
marked in red), are similarly upregulated by FGF2 and FGF9 after 24 hours but only FGF9 
maintains negative feedback regulator expression after 10 days. Data derived from 
Microarray performed by Lindner et al., 2015. 
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3.2 Results 
3.2.1 FGF-feedback inhibitor expression was increased in acute 
and chronic MS 
3.2.1.1 There was constitutive expression of FGF-feedback inhibitors in 
healthy human brain 
FGF9 is present in the adult CNS of humans and rats (Lindner et al., 2015, 
Nakamura et al., 1999, Nakamura et al., 1997).  To determine levels of constitutive 
feedback inhibitor expression in healthy brains, sections were stained with 
antibodies against Sprouty2 and Sprouty4. Expression was categorised by region 
and cell type and results are shown in Table 3.2 and representative images in 
Figure 3.1. FGF9 staining was mainly associated with neurons in grey matter and 
occasionally astrocytes of the grey and white matter. OL expression of FGF9 was 
rare in control brains. Sprouty2 and Sprouty4 staining deposition overlapped with 
areas of FGF9 expression and the same cell types expressing FGF9 were usually 
immunoreactive for Sprouty2 and Sprouty4. Sprouty2 staining was more 
pronounced and appeared in more cells than Sprouty4. 
 
 
 
 
 
 
 
 
 
 
Chapter 3 – Feedback inhibitors of FGF9 in MS and Myelinating Cultures 72 
 
 
 
Control 
Cases 
Region FGF9 Sprouty2 Sprouty4 
132-92-11 
Grey Matter Neurons Neurons Neurons 
White Matter Astrocytes Astrocytes 0 
421-92-5 
Grey Matter Neurons Neurons Neurons 
White Matter 0 Astrocytes 0 
8-04-1 Grey Matter Neurons Neurons Neurons 
 
White Matter 0 Astrocytes 0 
579-91-3 
Grey Matter Neurons Neurons Neurons 
White Matter Astrocytes, OLs Astrocytes, OLs Astrocytes, OLs 
28-03-2 
Grey Matter Neurons 
Astrocytes, 
Neurons 
0 
White Matter OLs Astrocytes 0 
68-93-4 
Grey Matter Neurons 
Astrocytes, 
Neurons 
Neurons 
White Matter Astrocytes Astrocytes 0 
 
 
 
 
 
 
 
 
Table 3.2. Characterisation of FGF9, Sprouty2, and Sprouty4 staining in human 
control brain sections. Sections from archived, formalin-fixed, paraffin embedded 
tissues processed for immunohistochemistry and stained with antibodies against FGF9, 
Sprouty2, and Sprouty4. Constitutive FGF9 expression is common to neurons in grey 
matter and less frequently, astrocytes and OLs in white matter. Sprouty2 and Sprouty4 
expression profiles largely matched that of FGF9, but Sprouty4 staining was present in 
fewer cases than Sprouty2. 0 denotes areas where no staining was detected. 
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Figure 3.1 FGF9 and Sproutys were associated with neurons in healthy adult 
brains. Representative images of healthy brain stainings from case 132-92-11. Sections 
from archived, formalin-fixed, paraffin embedded tissues processed for 
immunohistochemistry.  Antibodies against FGF9 (A, B), Sprouty2 (C, D), and Sprouty4 
(E, F) stained serial sections from grey (A, C, E) and white (B, D, F) matter regions in 
healthy control brains. Cells that were positive for each protein were identified 
morphologically by DAB deposition under light microscopy. All three proteins are 
expressed by neurons in GM and in a small number of astrocytes and OLs in WM. 
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3.2.1.2 FGF-feedback inhibitor expression was highest in acute MS lesions  
The previous study showed a correlation between the cell types expressing FGF9 
and those expressing feedback inhibitors in healthy brains, suggesting autocrine 
FGF signaling. Lindner et al., 2015 showed astrocytes and OLs are the main 
source of FGF9 in acute MS lesions, and FGF9 signaling in astrocytes was 
responsible for inhibition of myelination seen in myelinating cultures. This indicated 
that astrocytes in MS lesions will upregulate feedback-inhibitor expression in 
response to FGF9. 
The next step was to examine a variety of MS lesions and characterise feedback 
inhibitor expression in different regions of each. Astrocytes were the main cells 
associated with Sprouty2 and Sprouty4 staining (Table 3.3). Where macrophages 
were present they were strongly FGF9+, Sprouty2+, and Sprouty4+ to a lesser 
extent. Examination of NAWM in acute cases showed FGF9 and Sprouty 
expression profiles similar to those seen in healthy controls (Figure 3.2 A - D). 
FGF9 staining was diffuse and punctate throughout the NAWM, and weak 
Sprouty2 and Sprouty4 staining was observed mostly in OLs and infrequently in 
astrocytes. FGF9, Sprouty2, and Sprouty4 staining was common in hypertrophic 
astrocytes in acute lesion cores (Figure 3.2 F - H). Where they were present, OLs, 
stained for FGF9 and the Sproutys to a variable degree. Overall, acute lesion rims 
and cores displayed similar feedback inhibitor expression. 
FGF9 staining appeared mostly in astrocytes in the core of a balo lesion, and 
astrocytes and macrophages around the active rim (Figure 3.3 F, J). Sprouty2 
staining was strong in astrocytes and macrophages in both the lesion core and rim 
(Figure 3.3 G, K). Sprouty4 was also in astrocytes and macrophages but the 
staining was much weaker than Sprouty2 (Figure 3.3 H, L). In case 70-93-6, 
astrocytes and OLs were FGF9+ in the early active lesion whereas astrocytes and 
macrophages were FGF9+ in the late active lesion (Table 3.3). This was 
somewhat mirrored in Sprouty expression: astrocytes and OLs were Sprouty2+ in 
the early active lesion while weaker Sprouty4 staining was only observed in 
astrocytes (Figure 3.4). Astrocytes and macrophages were Sprouty2+ and 
Sprouty4+ in the late active lesion respectively. In normal-appearing grey matter 
(NAGM) neurons stained positive for FGF9, Sprouty2, and Sprouty4. Large 
distended neurons with irregular shapes were found in grey matter adjacent to the 
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lesion. These cells, thought to be a result of axonal transection with the lesion, 
stained intensely for FGF9, Sprouty2, and Sprouty4 (Figure 3.4). 
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Acute 
Cases 
Region FGF9 Sprouty2 Sprouty4 
581-96-7A 
NAWM - 0 OLs 
Early active lesion core - 0 0 
Early active lesion rim - 0 0 
Late active lesion - Astrocytes, OLs Astrocytes 
90-09-6 
NAWM Astrocytes, OLs Astrocytes, OLs Astrocytes 
Inactive lesion core Astrocytes Astrocytes Astrocytes 
Active lesion rim Astrocytes Astrocytes Astrocytes 
A01-144 
NAWM Diffuse extracellular 0 0 
Balo lesion core Astrocytes, OLs 
Astrocytes, 
Macrophages 
Astrocytes, OLs 
Balo lesion rim Macrophages 
Astrocytes, 
Macrophages 
Astrocytes, 
Macrophages 
S403-97 
NAWM 0 0 0 
Early active lesion - 
Astrocytes, 
Macrophages 0 
Late active lesion - 
Astrocytes, 
Macrophages Astrocytes 
270-99-2 
NAWM - Astrocytes Astrocytes 
Early active lesion - Astrocytes Astrocytes 
Late active lesion - Astrocytes Astrocytes 
Spanien C2 
NAWM - 0 0 
Inactive lesion Astrocytes Astrocytes Astrocytes 
70-93-6 
NAWM Astrocytes Astrocytes, OLs Astrocytes 
Early active lesion core Astrocytes, OLs Astrocytes, OLs Astrocytes 
Early active lesion rim Astrocytes Astrocytes Astrocytes 
Late active lesion 
Astrocytes, 
Macrophages 
Astrocytes, 
Macrophages Astrocytes 
NAGM Neurons 
Astrocytes, 
Neurons 
Neurons 
GM at subcortical 
lesion 
Neurons Neurons Neurons 
 
 
 
Table 3.3. Characterisation of FGF9, Sprouty2 and Sprouty4 staining in acute MS 
lesions.  Sections from archived, formalin-fixed, paraffin embedded tissues processed for 
immunohistochemistry. Sprouty2 stained intensely in astrocytes in active lesion cores and 
lesion rims while very little staining was seen in NAWM. In both cases where they were 
present, infiltrating macrophages stained for FGF9 and Sproutys. Sprouty4 had a similar 
staining pattern to Sprouty2 but was consistently weaker. 0 denotes areas where no 
staining was detected, - denotes cases not imaged.  
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Figure 3.4 Swollen neurons in a grey matter lesion from case 70-93-6 displayed 
intense granular staining for FGF9 and the Sproutys. Sections from archived, formalin-
fixed, paraffin embedded tissues processed for immunohistochemistry. Antibodies against 
FGF9, Sprouty2, and Sprouty4 were used to stain serial sections from different regions 
within and around lesion sites. Dense, granular FGF9, Sprouty2, and Sprouty4 staining 
was observed in swollen neurons in a grey matter lesion. 
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3.2.1.3 FGF-feedback inhibitor expression is a feature of chronic MS but is 
less pronounced compared to acute disease 
FGF9 expression is more common in acute MS lesions than chronic lesions 
(Lindner et al., 2015). This suggests that feedback inhibitor expression would be 
less common in chronic lesions than acute. Imaging of chronic lesions showed this 
to be the case. FGF9 stained mainly astrocytes in white matter lesions and 
neurons in cortical lesions (Table 3.4). As in acute lesions, Sprouty2 expression 
closely mirrored that of FGF9 and staining was generally less intense for FGF9 
and Sprouty2 versus acute lesions. Sprouty4 staining was detected in astrocytes 
in only a few of the chronic cases. FGF9 and Sprouty2 staining was more common 
in NAWM than in acute MS or healthy controls (Table 3.4). Representative images 
of staining in a chronic white matter lesion from case 146-01-8 are shown in Figure 
3.5 
The next step in these experiments was to perform double stainings and examine 
sections using confocal microscopy. Case 67-05-9 was stained with MAP2 
(neuronal marker), GFAP (astrocytic marker), FGF9, and Sprouty2 antibodies. 
Imaging revealed prominent FGF9 staining in neurons of NAGM (Figure 3.6 A) 
and swollen neurons in a cortical lesion (Figure 3.6 B). NAWM astrocytes lacked 
FGF9 staining (Figure 3.6 C). Astrocytes in a white matter lesion contained 
variable amounts of granular FGF9 staining over a diffuse background of 
extracellular punctate FGF9 (Figure 3.6 D). Sprouty2 was also absent from NAWM 
(Figure 3.6 E) but stained intensely in astrocyte cell bodies as well as diffusely in 
the extracellular background of the white matter lesion (Figure 3.6 F).  
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Chronic 
Cases 
Region FGF9 Sprouty2 Sprouty4 
146-01-8 
NAWM Astrocytes Astrocytes 0 
Lesion core 0 Astrocytes Astrocytes 
Lesion rim Astrocytes Astrocytes Astrocytes 
NAGM Neurons Neurons 0 
Cortical lesion Neurons Neurons 0 
67-05-9 
NAWM Astrocytes 0 0 
Lesion core Astrocytes Astrocytes Astrocytes 
Lesion rim Astrocytes Astrocytes 0 
NAGM Neurons Neurons Neurons  
Cortical lesion Neurons Neurons Neurons 
39-03-15 
NAWM Astrocytes Astrocytes 0 
Lesion core Astrocytes Astrocytes 0 
Lesion rim Astrocytes Astrocytes Astrocytes 
144-90-3 
NAWM Astrocytes, OLs  0 0 
Lesion core 0 Astrocytes 0 
Lesion rim Astrocytes Astrocytes 0 
244-94-7 
NAWM Astrocytes, OLs Astrocytes 0 
Lesion core 0 Astrocytes 0 
Lesion rim Astrocytes Astrocytes 0 
285-81-1 
NAWM 0 0 Astrocytes 
Lesion core 0 0 Astrocytes 
Lesion rim 0 0 Astrocytes 
72-83-6 
NAWM 0 0 0 
Lesion core 0 Astrocytes 0 
Lesion rim 0 0 0 
 
 
Table 3.4. Characterisation of FGF9, Sprouty2 and Sprouty4 staining in chronic MS 
lesions. Sections from archived, formalin-fixed, paraffin embedded tissues processed for 
immunohistochemistry. FGF9 and Sprouty2 stained astrocytes in lesion rims and was 
more common in NAWM of chronic cases than acute cases. Staining was with all three 
antibodies was generally less intense than that seen in the acute lesions. Again, Sprouty4 
had a similar staining pattern to Sprouty2 but was weaker in most cases. 0 denotes areas 
where no staining was detected.   
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Figure 3.6 FGF9 and Sprouty2 colocalized in astrocytes in white matter lesions. 
Images from chronic case 67-05-9. Sections from archived, formalin-fixed, paraffin 
embedded tissues processed for immunofluorescence. Antibodies against FGF9, 
Sprouty2, MAP2, and GFAP were used to stain neurons and astrocytes. Neurons in 
NAGM and damaged-appearing neurons in GM lesion stain with FGF9 (A, B) Astrocytes in 
NAWM are negative for FGF9 (C) and Sprouty2 (E) but in WM lesions these cells stain 
strongly for FGF9 (D) and Sprouty 2 (F). Diffuse extracellular staining with FGF9 and 
Sprouty2 occurs within lesions. 
10 μm 
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3.2.2 Assessing feedback-inhibitor expression in myelinating 
cultures 
3.2.2.1 FGF9 induced feedback-inhibitor expression in myelinating cultures 
while FGF1 and FGF2 did not  
The previous sections showed that FGF-feedback inhibitor expression was 
increased in MS and correlated with cells and regions of FGF9 expression. To 
investigate the effects of FGF9 on cells of the CNS directly, feedback inhibitor and 
FGFR expression in myelinating cultures was assessed. Primers for rat Spry2, 
Spry4, Dusp5, Dusp6, Fgfr1, Fgfr2, and Fgfr3 were designed. Myelinating cultures 
were generated as descried in section 2.2, followed by treatment with 100 ng/ mL 
FGF1, 2, or 9 for 24 hours from DIV 18, then processed for qPCR as described in 
section 2.4. According to results from the microarray (Table 3.1), FGF1 and FGF2 
should act as negative and positive controls for feedback inhibitor expression 
respectively. 
Results from qPCR analysis showed that all four feedback inhibitors were 
upregulated after 24 hours by FGF9 but not FGF1 or FGF2 (Figure 3.7 A - D). 
Spry2 expression was increased 5.1 ± 1.7 fold vs control, Spry4 was increased 
11.2 ± 5.9 fold, Dusp5 was increased 10.5 ± 4.1 fold, and Dusp6 was increased 
6.2 ± 1 fold. Feedback inhibitor expression following treatment with FGF1 and 
FGF2 never varied far from baseline. Looking at Fgfr expression in these same 
samples revealed no changes in cultures treated with FGF1 or FGF2. However, 
there was downregulation of Fgfr2 and Fgfr3 following FGF9 treatment (Figure 3.7 
E – F). These changes were significant but minor as Fgfr2 expression only fell -2.1 
± 1 fold and Fgfr3, -2 ± 0.4 fold. 
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Figure 3.7. Feedback inhibitor expression was increased and FGFR expression 
decreased in myelinating cultures treated with FGF9. Myelinating cultures were treated 
with 100 ng/mL recombinant human FGF1, 2, or 9 for 24 hours on DIV 18. Cells were 
lysed and processed for RNA extraction and cDNA synthesis. qPCR was performed using 
primers for Spry2, Spry4, Dusp5, Dusp6, Fgfr1, Fgfr2, Fgfr3 with Gapdh as the 
housekeeping standard.. Treatment with FGF9 induced variable but significant 
upregulation of Sprys and Dusps (A – D) versus control cultures while FGF1 and FGF2 
had no effect. Fgfr2 and three were downregulated by FGF9 but not FGF1 or FGF2 and 
Fgfr1 expression was unaffected by any of the FGFs tested (E – G). Fold changes in gene 
expression are shown relative to untreated control values, data presented are the means ± 
SD. This experiment was performed four times. *, p < 0.05, **, p < 0.01 ***, p <0.001 (one-
way ANOVA with Dunnett's Multiple Comparison Test performed on delta CT values).  
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3.2.2.2 Mature OLs, OPCs, and neurons responded to FGF2 and FGF9 
Purified cultures containing single cell types were produced to elucidate cell-type 
specific responses to FGF9. These cultures were treated with FGFs for 24 hours 
as in the previous section. Firstly, OLs were cultured from P1 rat cortices as 
described in section 2.2.3 then after 6 days in culture, OLs fully differentiated and 
were treated with FGF1, 2, and 9. Similar upregulation of feedback inhibitors was 
observed following treatment with FGF2 and FGF9, while FGF1 had no significant 
effect (Figure 3.8 A – D). Spry2 expression increased 2.9 ± 0.5 fold after FGF2 
and 2.4 ± 0.7 fold after FGF9. Spry4 expression increased 16.1 ± 5.4 fold after 
FGF2 and 12.9 ± 3.7 fold after FGF9. Dusp5 expression increased 13.6 ± 8.3 fold 
after FGF2 and 4.9 ± 2.5 fold after FGF9. Dusp6 expression increased 11.7 ± 2.5 
fold after FGF2 and 8.33 ± 0.8 fold after FGF9. Fgfr2 and Fgfr3 expression were 
downregulated following treatment with FGF2 and FGF9 but not FGF1 (Figure 3.8 
E – G). Fgfr2 was downregulated 6.6 ± 1.3 fold after FGF2 and 4.6 ± 0.7 fold after 
FGF9. Fgfr3 was downregulated 7.3 ± 5.5 fold after FGF2 and 1.9 ± 1.3 fold after 
FGF9. 
OPCs treated with FGFs from DIV 2, as described in section 2.2.5.7, displayed a 
similar but less pronounced effect on feedback inhibitor expression than fully 
differentiated OLs. (Figure 3.9 A – D). Spry2 was upregulated 2.6 ± 0.1 fold by 
FGF2 and 4.6 ± 1.9 fold by FGF9. Spry4 was upregulated 7.5 ± 3.5 fold by FGF2 
and 8.7 ± 5.8 fold by FGF9. Dusp5 was upregulated 38 ± 42.6 fold by FGF2, and 
Dusp6 was upregulated 9.1 ± 2.3 fold by FGF2 and 5.7 ± 2.1 fold by FGF9. Fgfr2 
expression was downregulated -4 ± 3.5 fold by FGF2 and -3.9 ± 2.7 fold by FGF9, 
Fgfr1 and 3 expression were unchanged following treatment (Figure 3.9 E – G). 
Enriched neuronal cultures were generated as described in section 2.2.6 and 
treated with FGFs for 24 hours. Feedback inhibitor expression was similar 
following FGF2 and FGF9 treatment (Figure 3.10). Spry2 was upregulated 1.9 ± 
0.2 fold by FGF2 and 1.9 ± 0.3 fold by FGF9. Spry4 was upregulated 10.3 ± 1.5 
fold by FGF2 and 12.6 ± 5.9 fold by FGF9. Dusp5 was upregulated 2.6 ± 1 fold by 
FGF2, and Dusp6 was upregulated 4.2 ± 0.7 fold by FGF2 and 3.7 ± 1.7 fold by 
FGF9. Dusp5 was not upregulated by FGF9 and Spry4 was the only feedback-
inhibitor upregulated by FGF1, 3.68 ± 1.7 fold. 
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Figure 3.8. Mature OLs upregulated feedback inhibitors and downregulated Fgfr2 
when treated with FGF2, and 9. Oligodendrocytes were cultured as described in section 
2.2.3 and maintained in Sato’s media for four days without growth factors to allow them to 
differentiate. OLs were treated for 24 hours with 100 ng/mL FGF1, 2, or 9. Cells were 
lysed and processed for RNA extraction and cDNA synthesis. qPCR was performed using 
primers for Spry2, Spry4, Dusp5, Dusp6, Fgfr1, Fgfr2, Fgfr3 with Gapdh as the 
housekeeping standard. All feedback inhibitors of FGF signaling were induced by FGF2 
and FGF9 (A – D). Fgfr1 expression was unaffected by FGF treatment (E). FGF2 and 
FGF9 downregulated Fgfr2 while FGF1 had no effect (F) and only FGF2 downregulated 
Fgfr3 (G). Fold changes in gene expression are shown relative to untreated control 
values, data presented are the means ± SD. This experiment was performed five times. **, 
p < 0.01 ***, p <0.001 (one way ANOVA with Dunnett's Multiple Comparison Test 
performed on delta CT values).  
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Figure 3.9. OPCs were less responsive to FGFs than mature OLs. Oligodendrocytes 
were cultured as described in section 2.2.3 and maintained in Sato’s media for 2 days 
before treatment. OPC cultures were treated for 24 hours with 100 ng/mL FGF1, 2, or 9. 
Cells were lysed and processed for RNA extraction and cDNA synthesis. qPCR was 
performed using primers for Spry2, Spry4, Dusp5, Dusp6, Fgfr1, Fgfr2, Fgfr3 with Gapdh 
as the housekeeping standard. OPCs similarly upregulated feedback inhibitors in response 
to FGF2 and FGF9 (A – D). FGF2 and FGF9 downregulated Fgfr2 while FGF1 had no 
effect (F) Fgfr1  and Fgfr3 were unaffected by FGF treatment (E - G). Fold changes in 
gene expression are shown relative to untreated control values, data presented are the 
means ± SD. This experiment was performed three times. *, p < 0.05, **, p < 0.01 (one 
way-ANOVA with Dunnett's Multiple Comparison Test performed on delta CT values).  
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Figure 3.10. Neurons similarly upregulated feedback inhibitors when treated with 
FGF2 and FGF9. Neurons were purified as described in section 2.2.5 and cultured in 
neuro-basal medium for 6 days to allow them to differentiate. Neuronal cultures were 
treated for 24 hours with 100 ng/mL FGF1, 2, or 9. Cells were lysed and processed for 
RNA extraction and cDNA synthesis. qPCR was performed using primers for Spry2, 
Spry4, Dusp5, Dusp6, with Gapdh as the housekeeping standard. FGF2 and FGF9 
induced negative feedback inhibitor expression to a similar degree in neurons. Fold 
changes in gene expression are shown relative to untreated control values, data 
presented are the means ± SD. This experiment was performed three times. **, p < 0.01 
***, p <0.001 (one-way ANOVA with Dunnett's Multiple Comparison Test performed on 
delta CT values).  
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3.2.2.3 Feedback inhibitor expression in astrocytes was induced only by 
FGF9.  
The next cell type assessed for feedback-inhibitor and FGFR gene expression 
were astrocytes. Astrocyte monolayers were generated as described in section 
2.2.1.2 and treated with FGFs from DIV 7. qPCR analysis revealed that Spry4  and 
Dusp6 were upregulated by FGF9 treatment but other feedback inhibitors and 
FGFR gene expression were unaffected (Figure 3.10). FGF1 and FGF2 induced 
no change in any of the genes examined in this study. FGF9 upregulated Spry2 
17.5 ± 4 fold and Dusp6 8.3 ± 2.7 fold. Fgfr expression was highly variable 
following FGF treatment but no clear trends towards up or downregulation 
emerged (Figure 3.10 E – G). 
To determine if similar effects were seen at the protein level, low-density astrocyte 
cultures were prepared as described in section 2.2.2 and treated for three days 
with FGF1, 2, and 9. After treatment, cultures were fixed and stained with 
antibodies against Sprouty2, Sprouty4, DUSP5, and DUSP6. The mean 
fluorescent intensity of staining for each feedback inhibitor was calculated using 
CellProfiler as detailed in section 2.2.7. Following treatment, Sprouty4, DUSP5, 
and DUSP6 were upregulated by FGF9 but not by FGF1 or FGF2 (Figure 3.11). 
Sprouty4, C = 8.2 ± 2.7, FGF9 = 21.9 ± 1.2. DUSP5, C = 11.3 ± 4.6, FGF9 = 26.9 
± 3.4. DUSP6, C = 6.1 ± 2.4, FGF9 = 12.4 ± 2.9. There was a slight trend for 
Sprouty2 to stain more strongly after treatment with all three FGFs but the 
changes were variable and not significant (Figure 3.11 A). Examining the cells 
using fluorescence microscopy revealed Sprouty2 stains in astrocyte nuclei and 
weakly in cell bodies (Figure 3.12 A, B). Sprouty4 is found in cell bodies in control 
astrocytes (Figure 3.12 C) and in cell bodies and nuclei after FGF9 treatment 
(Figure 3.12 D). DUSP5 stains in a few cell nuclei in controls (Figure 3.12 E) and 
is seen in cell bodies and nuclei following treatment (Figure 3.12 F). DUSP6 is 
present at low levels in nuclei and cell bodies in controls (Figure 3.12 G) and is 
upregulated mainly in cell bodies after FGF9 treatment (Figure 3.12 H). 
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Figure 3.11. Only FGF9 upregulated feedback inhibitor expression in astrocytes. 
Astrocyte monolayers were generated as described in section 2.2.1.2 and cultured for 7 
days before treatment. Cells were treated with 100 ng/mL recombinant human FGF1, 2, or 
9 for 24 hours. Cells were lysed and processed for RNA extraction and cDNA synthesis. 
qPCR was performed using primers for Spry2, Spry4, Dusp5, Dusp6, Fgfr1, Fgfr2, Fgfr3 
with Gapdh as the housekeeping standard. FGF9 induced upregulation of Spry4 and 
Dusp6 (B, D) whereas FGF1 and FGF2 had no effect on any feedback inhibitors (A – D). 
Fgfr was highly variable following FGF treatment, but no trends emerged and mean 
expression was near control levels. Fold changes in gene expression are shown relative to 
untreated control values, data presented are the means ± SD. This experiment was 
performed five times. ***, p <0.001 (one-way ANOVA with Dunnett's Multiple Comparison 
Test performed on delta CT values).  
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Figure 3.12. FGF feedback inhibitor expression was increased by FGF9, but not other 
FGFs in astrocytes. Low-density astrocyte cultures were generated as described in 
section 2.2.2 and treated for 72 hours with 100 ng/mL FGF1, 2, or 9. Cells were fixed and 
stained with antibodies against Sprouty2, Sprouty4, DUSP5, and DUSP6. Feedback-
inhibitor expression was quantified as mean fluorescent intensities using CellProfiler as 
described in section 2.2.7. FGF9 significantly upregulated Sprouty4, DUSP5, and DUSP6 
at the protein level. FGF1 and FGF2 did appear to have small effects on Sprouty2 and 
Sprouty4 but these were not significant. This experiment was performed three times. *, p < 
0.05, **, p < 0.001 (one-way ANOVA with Dunnett's Multiple Comparison Test).  
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Figure 3.13. Representative images of FGF feedback inhibitors in cultured 
astrocytes following treatment with FGF9. Low-density astrocyte cultures were 
generated as described in section 2.2.2 and treated for 72 hours with 100 ng/mL FGF1, 2, 
or 9. Cells were fixed and stained with antibodies against Sprouty2, Sprouty4, DUSP5, and 
DUSP6. Treatment induced increases in Sprouty and DUSP staining increases in astrocyte 
cytoplasm. Sprouty4 is present in cell nuclei following treatment. 
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3.3 Discussion 
FGF signaling is enormously complex and facilitates activation of several signaling 
pathways depending on ligand-receptor specificity and a host of regulatory 
mechanisms discussed in section 1.2.4. Expression of the appropriate FGFR does 
not ensure signaling by its cognate FGF ligand as heparan sulphates regulate 
FGF-FGFR interactions (Chang et al., 2000). This makes determining the target of 
FGF-signaling in tissues comprising multiple cell types difficult. Activation of 
downstream markers in cells can be used as an indicator that FGF signaling is 
occurring. Feedback inhibitors are rapidly induced in response to FGF signalling 
(Minowada et al., 1999, Branney et al., 2009). To determine if feedback inhibitors 
can be used as surrogate markers of FGF9 signaling in MS, feedback inhibitor 
expression was investigated in MS lesions and FGF-treated myelinating cultures.  
Most of the sections used in this study were used to characterise FGF9 expression 
in MS lesions (Lindner et al., 2015), therefore direct comparisons between FGF9 
and feedback inhibitor staining could be made. Sprouty2 and Sprouty4 staining 
was characterised on cell-type specific expression. Cell-type was determined by 
morphological examination of nuclei size and cell body shape which are unique in 
cells of the CNS. Sprouty2 and Sprouty4 staining was observed in grey matter 
neurons and occasional white matter astrocytes and OLs in healthy brains (Table 
3.2, Figure 3.1). Sprouty2 staining closely mirrored FGF9 staining while Sprouty4 
staining was generally much weaker. This suggested autocrine or paracrine FGF 
signaling is occurring in the healthy CNS.  
FGF9 and Sprouty2 stained most intensely in acute MS lesions (Table 3.3, Figure 
3.2, 3.3) and staining patterns in lesion rims and cores were very similar for both 
antibodies. Sprouty4 staining was also similar but consistently less intense and 
less common than Sprouty2. Astrocytes were immunoreactive for FGF9 and the 
Sproutys in most of the lesions examined. In three out of seven cases, OLs were 
immunoreactive for FGF9 and Sproutys. Infiltrating macrophages were also 
immunoreactive for FGF9 in the two acute cases in which they were present. This 
was surprising as macrophage FGF9 immunoreactivity was not detected in 
previous studies with these MS cases (Lindner et al., 2015). Macrophages are 
mostly associated with acute MS and populate the lesion rim where demyelination 
is taking place (Brück et al., 1995). FGF9 staining in macrophages was less 
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pronounced than in astrocytes, but Sprouty2 stained strongly. FGF2 has been 
shown to recruit and activate macrophages, and stimulate production of 
inflammatory cytokines and chemokines (Ribatti et al., 2006). Macrophages can 
also be a source of FGF2 under the right conditions (Vacca et al., 1999, Presta et 
al., 2009, Jetten et al., 2014). These findings suggest macrophages could be a 
source of FGF9 in acute MS and might be responding to FGF signaling. This 
prompted further investigation of FGF9 in the context of macrophages, which is 
discussed in the next chapter.  
Of the cases examined, two displayed different lesions from those normally 
associated with acute MS. FGF9+ macrophages were associated with these 
lesions due to their high degree of lesion activity. Case A01-144 came from a 
patient with Balo’s concentric sclerosis, in which demyelinated areas appear as 
concentric rings alternating with areas of undamaged myelin (Li et al., 2009). This 
disease is considered a rare variant of MS and, despite the bizarre lesion 
structure, possesses most of the same symptoms and pathological features as 
classical MS. At the rims of expanding MS lesions inflammation and demyelination 
are most active and phagocytosis of myelin breakdown products by macrophages 
can be observed (Figure 3.3 I). The second interesting lesion was in case 70-93-6, 
which contained examples of an early active lesion, and an acute subcortical 
lesion that appeared to be affecting neurons in the adjacent grey matter (Figure 
3.4). Swollen neurons with intense FGF9, Sprouty2 and Sprouty4 staining were 
observed. Neuronal swelling is often associated with CNS injury and precedes 
neuronal death (Staub et al., 1993, Rungta et al., 2015). The presence of swollen 
neurons in this MS case was believed to be the result of axonal transection but the 
reason for accumulation of FGF9 and Sprouty+ cytoplasmic granules is unknown. 
In chronic lesions astrocytes stained for FGF9 and Sprouty2 in lesion rims, and 
less frequently in inactive lesion cores (Table 3.4, Figure 3.5). Sprouty4 staining 
was of lower intensity and observed less frequently than in acute MS. 
Immunoreactivity for FGF9 and Sprouty2 was detected in all chronic-active cases 
but only in one of three chronic-inactive cases (case 244-94-7). Sections from 
chronic case 67-05-9 were double stained with the neuronal marker MAP2 and 
astrocytic marker GFAP (Figure 3.6). Confocal microscopy showed colocalization 
of FGF9 and MAP2 in NAGM and swollen neurons of a grey matter lesion (Figure 
3.6 A, B). FGF9 and Sprouty2 were not detected in NAWM (Figure 3.6 C, E), but 
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colocalized with GFAP in the white matter lesion. There was also diffuse 
immunoreactivity of FGF9 and Sprouty2 throughout the lesion. FGF9 is normally 
localized on cell surfaces and the ECM as it is a secreted factor, but why Sprouty2 
was detected outside of cells is unclear. In summary, FGF9 and Sprouty2 were 
detected in the same cell types in MS lesions, which suggests autocrine FGF9 
signaling is occurring. 
The next step in these experiments was to determine if the feedback inhibitor 
response in FGF9-treated myelinating cultures reflected the findings in MS lesions. 
qPCR experiments were performed to validate the microarray data, shown in 
Table 3.1. Unexpectedly, only FGF9 induced significant upregulation of Spry2, 
Spry4, Dusp5, and Dusp6 after 24 hour treatment (Figure 3.7 A – D). Fgfr2 and 
Fgfr3 were downregulated (Figure 3.7 F, G), which suggests inhibition of OPC 
maturation or changes in astrocytic FGFR expression. As discussed in section 
1.3.2.1, astrocytes express FGFR2 and FGFR3, and OLs express FGFR3 
transiently during maturation, and FGFR2 on myelin membranes. These findings 
suggested that only FGF9 is capable of driving changes in feedback inhibitor and 
FGFR expression in myelinating cultures in contrast to the microarray data. FGF1 
can interact with all seven FGFR variants and FGF2 interacts with all IIIc variants 
(Zhang et al., 2006) which suggests some signaling should occur in myelinating 
cultures. To try and understand these findings, the experiment was repeated on 
purified cultures of OPCs, mature OLs, and astrocytes. 
Expression of all feedback inhibitors was increased by FGF2 and FGF9 in mature 
OLs (Figure 3.8 A – D) but no effect was seen with FGF1. Fgfr2 expression was 
reduced by FGF2 and FGF9, which was expected as both of these factors are 
known to inhibit OL maturation and myelination (Figure 3.8 F). Fgfr3 is expressed 
by OPCs transiently during maturation and while some downregulation was seen 
with FGF9, only FGF2 significantly reduced expression of this receptor (Figure 3.8 
G). These results are in line with previous research showing FGF2 and FGF9 can 
signal in mature OLs (Fortin et al., 2005). OPCs were less responsive to FGF 
treatment but similarly upregulated feedback inhibitors in response to FGF2 and 
FGF9 (Figure 3.9 A – D). This was surprising, as OPCs are believed to be 
insensitive to FGF9 (Fortin et al., 2005, Lindner et al., 2015), but these results 
suggest FGF9 is initiating MAPK signaling. Fgfr2 expression was reduced in OPCs 
after FGF2 and FGF9 treatment, which is in line with the finding that FGF9 inhibits 
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OPC maturation (Lindner et al., 2015). Neurons upregulated feedback inhibitor 
expression in a similar fashion after exposure to FGF2 and FGF9 (Figure 3.10). 
FGF9 was not predicted to stimulate signaling in neurons as their major FGF 
receptor, FGFR1 does not interact strongly with FGF9 (Choubey et al., 2017, 
Zhang et al., 2006). Neurons were the only cell type studied to respond to FGF1: 
Spry4 expression was elevated but to a much lesser extent than in FGF2 or FGF9 
treated neurons (Figure 3.10 B).   
Astrocytes were only responsive to FGF9 treatment, despite expressing FGFR1, 
2, and 3 (Miyake et al., 1996, Choubey et al., 2017). Spry4 and Dusp6 expression 
was elevated by FGF9, and FGFR expression was unaffected by any factor. There 
was a trend towards increased Spry2 expression in FGF9-treated astrocytes but 
the change was not statistically significant. FGF1 has been shown to activate 
FGFR1 on astrocytes (Cassina et al., 2005) and FGF2 affects astrocytes in 
several ways: it regulates proliferation, differentiation, gap junction coupling, and 
reactivity (Gómez-Pinilla et al., 1995, Gómez-Pinilla et al., 1997, Reuss et al., 
2000, Eclancher et al., 1996). This suggests feedback inhibitors would be 
upregulated in astrocytes exposed to FGF1 and FGF2 but this was not the case. 
There are two possibilities as to why astrocytes do not appear to respond to FGF1 
and FGF2 in these experiments: either FGF1 and FGF2 are inducing signaling, but 
not feedback inhibitor expression, or astrocytic FGFRs are not being activated. 
Both of these reasons seem unlikely as FGF signaling is intrinsically linked to 
feedback inhibitor expression and FGF9 preferentially binds FGFR2 and FGFR3. 
FGF1 and FGF2 are promiscuous and should be able to bind FGFRs on 
astrocytes. Sulphation level of heparan sulphate has been shown to regulate 
FGFR activation by FGF1 and FGF9 in astrocytes (Higginson et al., 2012) so 
perhaps heparan sulphate expression in in vitro neurosphere-derived astrocytes is 
impermissible to signaling activation by FGF1 and FGF2. Either way, these results 
show expression of FGFRs does not guarantee signaling when cognate ligands 
are available and supports the idea that feedback inhibitor expression in MS 
lesions is a result of FGF9 signaling. 
One important point to note is that while DUSP6 expression is a specific response 
to FGF signaling, this is not the case for other feedback inhibitors. Sprouty2, 
Sprouty4, DUSP5 antagonise ERK-MAPK, and have been shown to regulate FGF, 
EGF, VEGF, and PDGF signaling (Gross et al., 2001, Lee et al., 2001, Kramer et 
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al., 1999, Casci et al., 1999, Kucharska et al., 2009). VEGF is upregulated in 
RRMS and Progressive MS while EGF is mainly produced by immune cells in 
RRMS. VEGF is found at higher levels in progressive MS than RRMS (Tejera-
Alhambra et al., 2015, Levy et al., 2013, Proescholdt et al., 2002). PDGF levels 
vary in RRMS but are decreased in progressive MS (Mori et al., 2013, Harirchian 
et al., 2012). In order to say for certain that the presence of feedback inhibitors in 
MS is a result of FGF9 signaling, these growth factors must be tested for their 
ability to induce Sproutys and DUSP5 in cells of the myelinating cultures. 
Astrocytes were the only cell type studied to increase feedback inhibitor 
expression in response to FGF9 but not FGF2. This suggests the feedback 
inhibitor response to FGF9 in myelinating cultures is due to astrocytes as they are 
the most numerous cell-type present. OL and neuronal responses to FGF2 are 
potentially diluted  beyond detection by qPCR. In conclusion, Sproutys and DUSPs 
can be upregulated in astrocytes in vitro by FGF9 treatment. Sprouty upregulation 
is also seen in astrocytes in human MS lesions and there was a strong correlation 
between cells expressing FGF9 and the Sproutys. This suggests 
autocrine/paracrine FGF9 signalling is occurring in MS lesions and astrocytes are 
the main target. These findings provide some further evidence to support the 
hypothesis that astrocytic responses to FGF9 are involved in the development of 
MS lesions.  
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4 INDUCTION OF FGF9 IN CELLS INVOLVED IN 
PATHOGENESIS OF MS 
4.1 Introduction 
FGF9 availability is increased in the MS brain and the effects of this pleiotropic 
growth factor likely contribute to the failure of remyelination (Lindner et al., 2015). 
In order to manipulate FGF9 expression for therapeutic benefit in MS, it is 
important to understand the triggers for its upregulation.  Despite its prominent 
roles in development and certain cancers, the mechanisms involved in regulation 
of FGF9 expression are mostly unknown. Aberrant inflammation is the main driver 
of lesion development in acute MS where FGF9 expression is greatest. 
Astrocytes, OLs, and macrophages appear to be the primary sources of FGF9 in 
acute MS. Inflammation is a critical component of the healing process, and not 
only precedes progenitor proliferation and tissue remodelling, but actively induces 
these processes (Eming et al., 2007, Donnelly and Popovich, 2008). Numerous 
studies have demonstrated the ability of astrocytes to respond local inflammation 
via the expression of multiple cytokine and chemokine receptors (Liberto et al., 
2004, Barnett, 2012). Astrocytes respond to these stimuli by secreting cytokines, 
chemokines, and growth factors (Deng et al., 2010, Liberto et al., 2004), including 
FGF2 (Proia et al., 2008, Albrecht et al., 2002). These findings suggest 
inflammatory mediators might also induce astrocytic expression of FGF9 in MS 
lesions. If this hypothesis is correct it could explain why chronic MS lesions are 
associated with lower expression of FGF9 as there is less inflammation. 
Cancer models have shed some light on mechanisms of FGF9 induction. 
Prostaglandin E2 (PGE2) was shown to induce FGF9 in an endometriosis model 
(Chuang et al., 2006). Briefly, PGE2 activates PGE2 receptor 3, which leads to 
protein kinase C and ERK1/2 signaling. This then leads to phosphorylation of the 
TF, Elk1, which binds to the promoter region of the FGF9 gene and induces 
expression. Elevated PGE2 levels have been found in the CSF of MS patients 
(Mattsson et al., 2009), therefore this pathway may be involved in FGF9 
expression. 
FGF9 over-expression has been implicated in pathogenesis of lung 
adenocarcinomas where it has been linked to aryl hydrocarbon receptor (AhR) 
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activation (Wang et al., 2009). Ligation of AhR increased FGF9 mRNA levels via 
enhanced transcriptional activity at the FGF9 promoter. AhR activation leads to 
ligand-dependant promotion of Th17 or Treg cells (Quintana et al., 2008) and 
deletion of the AhR gene protected mice from EAE (Veldhoen et al., 2008). These 
findings suggest AhR might play a role in MS and could be involved in the 
regulation of FGF9 expression.  
Another potential trigger for FGF9 induction in MS is hypoxia: breakdown of the 
vasculature around MS lesions, as a result of inflammatory damage of small blood 
vessels, limits oxygenation (Lassmann, 2003). An increase in overall metabolic 
processes and production of toxic metabolites by immune cells also reduces 
oxygen availability in lesions. A normal response to hypoxic injury is angiogenesis, 
which produces new blood vessels. FGFs have been shown to enhance 
angiogenesis in response to hypoxia and ischemia (Issa et al., 2005, Yang et al., 
2015). Chen et al. described a mechanism whereby FGF9 upregulation is induced 
by hypoxia in colon cancer (Chen et al., 2014). They found an increase in FGF9 
protein expression was due to increased translational efficiency. Translation of 
FGF9 is normally maintained at low levels by upstream open reading frame 
dependant repression. Hypoxia induces a conformational change in the internal 
ribosome entry site on FGF9 mRNA that overcomes this repression and promotes 
translation. Hypoxia-inducible factor 1-alpha (HIF1α) and other stress response 
proteins are regulated in this way to facilitate rapid protein expression (Pagé et al., 
2002, Lang et al., 2002). MS lesions display profound similarities to tissue 
alterations in acute white matter stroke and both involve induction of HIF1α (Zeis 
et al., 2008, Aboul-Enein et al., 2003). This all suggests hypoxia may drive 
expression of FGF9 in MS. 
Macrophages are highly plastic and can exhibit a range of phenotypes in response 
to their environment (Mosser and Edwards, 2008, Martinez and Gordon, 2014). 
The classification of macrophages into distinct subsets has become controversial 
but for simplicity, inflammatory and anti-inflammatory macrophages will be termed 
M1 and M2 respectively throughout this chapter. M1 macrophages are activated 
by IFNγ released by T cells in MS lesions and produce pro-inflammatory cytokines 
such as TNFα (Bsibsi et al., 2014). During remyelination, macrophages express 
anti-inflammatory cytokines including TGFβ1 and IL-10, and growth factors such 
as EGF, PDGF, and FGFs, which promote angiogenesis and proliferation (Lloyd 
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and Miron, 2016, Boven et al., 2006, Jetten et al., 2014).  Macrophages display a 
spectrum of phenotypes in MS and up to 70% express markers of both M1 and M2 
activation (Bogie et al., 2014, Vogel et al., 2013). Macrophages polarized towards 
the M2 phenotype can produce FGF2 (Jetten et al., 2014) and are a source of 
FGF2 in EAE (Liu et al., 1998). These data suggest FGF9 produced by 
macrophages in MS might be a result of anti-inflammatory M2 macrophages. 
Taken together, this research provides several avenues to explore in the search 
for the trigger of FGF9 expression in MS. The aims of experiments in this chapter 
were to assess the ability of a range of factors associated with MS to induce FGF9 
up regulation in CNS and macrophage cultures. 
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4.2 Results 
4.2.1 Inflammatory mediators had little effect on myelination in 
vitro 
To address the possibility of cytokines inducing FGF9 expression in MS, 
myelinating cultures were treated with a range of inflammatory and anti-
inflammatory cytokines involved in MS (Durán et al., 2001, Romme Christensen et 
al., 2012, Maimone et al., 1991, Tsukada et al., 1991) as described in section 
2.2.6.4. PGE2 and the AhR agonist, benzo[a]pyrene (BaP) (Machala et al., 2001) 
were tested in conjunction with inflammatory mediators. PGE2 and BaP were 
reconstituted in DMSO (dimethyl sulfoxide) so DMSO alone was also tested as a 
control. The first step was to assess myelination and axon densities following 
treatment with each factor. Myelinating cultures were treated with 100 ng/mL of 
each factor from DIV 18 - 28 and stained with antibodies against MOG and 
neurofilament (SMI31). Cultures were imaged using immunofluorescence 
microscopy. Myelination and axon density were calculated in CellProfiler as 
described in section 2.2.8. Of all the factors tested, only IFNγ inhibited myelination 
(10d C = 14.9 ± 0.2%, 10d IFNγ = 6.9 ± 3.3%) (Figure 4.1 A). Axon densities were 
unaffected by any treatment at DIV 28 (Figure 4.1 B). 
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Figure 4.1. A selection of inflammatory mediators had little effect on myelination or 
axon density. Myelinating cultures were treated with a range of inflammatory cytokines 
previously shown to be expressed in MS lesions. Cultures were treated with factors at 100 
ng/mL from DIV 18 – 28. Cultures were fixed and stained with antibodies against MOG 
(Z2) and axons (SMI31). Myelination rates and axon densities were calculated in 
CellProfiler. Data presented are  the means ± SD. This experiment was performed three 
times. *, p < 0.05, (one-way ANOVA with Dunnett's Multiple Comparison Test). 
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4.2.2 Treatment with inducers of FGF9 in cancer or inflammatory 
mediators did not induce expression of FGFs  
DIV 18 myelinating cultures were treated with each factor for 24 hours then 
processed for qPCR as described in section 2.4. No significant changes in 
expression of Fgf1 (Figure 4.2), Fgf2 (Figure 4.3), or Fgf9 (Figure 4.4) were 
detected following treatment with any of the factors at each of three concentrations 
tested. 
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Figure 4.2. Inflammatory mediators did not upregulate Fgf1 expression in 
myelinating cultures. Myelinating cultures were treated with a range of inflammatory 
cytokines previously shown to be expressed in MS lesions. Cultures were treated with 5, 
50, or 100 ng/mL of each factor for 24 hours on DIV 18. The cells were lysed and 
processed for RNA extraction and cDNA synthesis. qPCR was performed using primers 
for Fgf1 and Gapdh as the housekeeping standard. Expression of Fgf1 was unaffected by 
treatment with any factor tested. Fold changes in gene expression are shown relative to 
untreated control values, data presented are the means ± SD. This experiment was 
performed three times.(one-way ANOVA with Dunnett's Multiple Comparison Test was 
performed on the delta CT values).  
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Figure 4.3. Inflammatory mediators did not upregulate Fgf2 expression in 
myelinating cultures. Myelinating cultures were treated with a range of inflammatory 
cytokines previously shown to be expressed in MS lesions. Cultures were treated with 5, 
50, or 100 ng/mL of each factor for 24 hours on DIV 18. The cells were lysed and 
processed for RNA extraction and cDNA synthesis. qPCR was performed using primers 
for Fgf2 and Gapdh as the housekeeping standard. Expression of Fgf2 was unaffected 
by treatment with any factor tested. Fold changes in gene expression are shown relative 
to untreated control values, data presented are the means ± SD. This experiment was 
performed three times. (one-way ANOVA with Dunnett's Multiple Comparison Test was 
performed on the delta CT values).  
TNFa
5ng 50ng 100ng
-2
-1
0
1
2
3
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
IFNy
5ng 50ng 100ng-4
-2
0
2
4
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
IL-6
5ng 50ng 100ng
0
1
2
3
4
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
IL-1B
5ng 50ng 100ng
0
1
2
3
4
5
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
IL-10
5ng 50ng 100ng
-2
0
2
4
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
GM-CSF
5ng 50ng 100ng
-2
0
2
4
6
8
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
TGFB1
5ng 50ng 100ng
0
2
4
6
8
10
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
BaP
DMSO 5ng 50ng 100ng-6
-4
-2
0
2
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
PGE2
DMSO 5ng 50ng 100ng-3
-2
-1
0
1
2
F
o
ld
 C
h
a
n
g
e
 v
s
 C
o
n
tr
o
l
Chapter 4 – Induction of FGF9 in Cells Involved in Pathogenesis of MS 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Inflammatory mediators did not upregulate Fgf9 expression in 
myelinating cultures. Myelinating cultures were treated with a range of inflammatory 
cytokines previously shown to be expressed in MS lesions. Cultures were treated with 5, 
50, or 100 ng/mL of each factor for 24 hours on DIV 18. The cells were lysed and 
processed for RNA extraction and cDNA synthesis. qPCR was performed using primers 
for Fgf9 and Gapdh as the housekeeping standard. Expression of Fgf9 was unaffected 
by treatment with any factor tested. Fold changes in gene expression are shown relative 
to untreated control values, data presented are the means ± SD. This experiment was 
performed three times (one-way ANOVA with Dunnett's Multiple Comparison Test was 
performed on the delta CT values).  
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4.2.3 Inflammatory mediators did not induce FGF9 expression at 
the protein level 
Myelinating cultures were treated as in the previous sections in this chapter from 
DIV 18 – 21.  Cultures were stained with an anti-FGF9 antibody and imaged using 
fluorescence microscopy. FGF9 expression was determined by calculating the 
mean fluorescent intensity (MFI) of staining in each image using CellProfiler. In 
DIV 28 control myelinating cultures, FGF9 staining was observed mostly in 
astrocytes (Figure 4.5 A, B) and axons (Figure 4.5 B). In treated cultures, levels of 
FGF9 expression did not significantly differ from control values for any factor 
tested (Figure 4.6).  
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Figure 4.5. Representative images FGF9 and GFAP staining in control myelinating 
cultures on DIV 28. Cultures were fixed and stained with antibodies against FGF9 and 
GFAP. FGF9 mainly stains in astrocytes and axons, denoted with blue arrows. FGF9 
staining is observed throughout some, but not all, astrocyte cell bodies at high 
magnification. 
A 
B 
DIV 28 Myelinating Culture FGF9 GFAP 
100 μm 
10 μm 
DIV 28 Myelinating Culture FGF9 GFAP DAPI 
GFAP 
FGF9 
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Figure 4.6. FGF9 was not induced at the protein level by inflammatory mediators. 
Myelinating cultures were treated with a range of inflammatory cytokines previously shown 
to be expressed in MS lesions. Cultures were treated with factors at 100 ng/mL from DIV 
18 – 21. Cultures were fixed and stained with an anti-FGF9 antibody. FGF9 expression was 
quantified as the mean fluorescent intensity of FGF9 staining using CellProfiler as 
described in section 2.2.7. Data presented are  the means ± SD. This experiment was 
performed three times. *, p < 0.05, (one-way ANOVA with Dunnett's Multiple Comparison 
Test). 
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4.2.4 Hypoxia upregulated FGF9 in myelinating cultures 
The first experiments in this set were to test the viability of myelinating cultures 
exposed to hypoxia. DIV 18 myelinating cultures and astrocyte monolayers were 
incubated in a hypoxic chamber according to the schematic on page 111.  From 
the two biological replicates performed, after 24 hours in a hypoxic chamber with 
1% O2, cultures appeared to have less myelin than controls and there was a slight 
reduction in axonal density. (Figure 4.7, 4.8B). After 24 hours in hypoxia and 24 
hours reperfusion, myelin and axons were completely wiped out (Figure 4.7, 4.8 
D). Cultures in Figure 4.8 D displayed a random scattering of MOG and SMI31 
positive cellular debris. 
Cultures from these same conditions were stained with an antibody against FGF9 
and the MFI of staining was measured as described previously in this chapter. 
Baseline FGF9 fluorescent intensity in DIV 19 and DIV 20 control cultures was 
around 7% (Figure 4.9.). Following 24-hour hypoxia, FGF9 levels increased 
slightly and after 24-hour reperfusion more than doubled (Figure 4.9) however as 
only two repeats of this experiment were performed, additional repeats will be 
necessary to confirm this finding. Despite the complete loss of axons and myelin, 
underlying astrocyte monolayers remained intact after hypoxia and reperfusion 
(Figure 4.10 B, D) and more intense FGF9 staining is visible after reperfusion.   
The expression of FGF genes and a surrogate marker for hypoxia, Hexokinase 2 
(HK2) (Menendez et al., 2015), were then measured in myelinating cultures. Hk2 
expression was increased around 20 fold after 24 hours in hypoxia and returned to 
baseline after reperfusion (Figure 4.11 A). Fgf1 expression did not appear to be 
affected by hypoxia or subsequent reperfusion (Figure 4.11 B). Fgf2 expression 
was upregulated around seven fold after hypoxia and equally after reperfusion 
(Figure 4.11 C). Fgf9 expression was downregulated around two fold after both 
hypoxia and reperfusion. Additionally these experiments will require repetition 
before statistical analysis can be performed. 
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Figure 4.7. Myelinating cultures lost axons and myelin following hypoxia and 
reperfusion. Myelinating cultures at DIV 18 were incubated in a hypoxic chamber at 1% 
0
2
 for 24 hours. The cultures were then fixed or transferred into a 7% CO2 /93% air 
incubator for a further 24 hours to simulate reperfusion. Cultures were fixed and stained 
with antibodies against MOG (Z2) and axons (SMI31). Myelination percentages and axon 
densities were calculated in CellProfiler. Myelination was reduced in hypoxic cultures at 
both time points (A). Axonal density was slightly reduced after 24 hours hypoxia and 
severely reduced following reperfusion (B). Data presented are the means ± SD, this 
experiment was performed twice. 
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Figure 4.8. Representative images of myelin and axons in hypoxia experiment. 
Myelinating cultures at DIV 18 were incubated in a hypoxic chamber at 1% 0
2
 for 24 
hours. The cultures were then fixed or transferred into a 7% CO2 /93% air incubator for a 
further 24 hours to simulate reperfusion. Cultures were fixed and stained with antibodies 
against MOG (Z2) and axons (SMI31). Myelination is reduced after 24 hours hypoxia and 
SMI31 staining appears more punctate (B). Following reperfusion myelin and axons are 
totally eliminated from the cultures (D). 
24h                           48h 
24h                           48h 
Hypoxia Chamber 
Normal O
2
 Incubator 
Half of 
Cultures 
Transferred 
Myelinating 
Cultures + 
Astrocyte 
Monolayers 
Cultures 
lysed and 
fixed for 
qPCR and 
staining 
Experimental design of hypoxia experiments. 
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Figure 4.9. Astrocytes increased FGF9 expression in response to hypoxia. 
Myelinating cultures at DIV 18 were incubated in a hypoxic chamber at 1% 0
2
 for 24 
hours. The cultures were then fixed or transferred into a 7% CO2 /93% air incubator for a 
further 24 hours to simulate reperfusion. Cultures were fixed and stained with an anti-
FGF9 antibody and expression was quantified as the MFI of staining using CellProfiler as 
described in section 2.2.7. Data presented are the means ± SD. This experiment was 
performed twice. 
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Figure 4.10. Representative images of astrocytes and FGF9 in hypoxia experiment. 
Myelinating cultures at DIV 18 were incubated in a hypoxic chamber at 1% 0
2
 for 24 
hours. The cultures were then fixed or transferred into a 7% CO2 /93% air incubator for a 
further 24 hours to simulate reperfusion. Cultures were fixed and stained with an anti-
FGF9 antibody. FGF9 staining appears in a subset of astrocytes in controls with diffuse 
staining in the background (A, C). FGF9 stained much more intensely in astrocytes 
following hypoxia and reperfusion.  
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Figure 4.11. FGF9 expression was reduced at the mRNA level following hypoxia 
while FGF2 expression was elevated. Myelinating cultures at DIV 18 were incubated in 
a hypoxic chamber at 1% 0
2
 for 24 hours. cells were lysed and processed for RNA 
extraction and cDNA synthesis. qPCR was performed using primers for Fgf1, Fgf2, Fgf9, 
and Gapdh as the housekeeping standard. Hk2 expression was increased after 24 hours 
in hypoxia and returned to baseline following reperfusion (A). Fgf1 expression did not 
appear to vary far from control values in either condition (B). FGF2 levels were similarly 
elevated following each treatment (C) and Fgf9 was downregulated after hypoxia and 
reperfusion (D). Data presented are the means ± SD, this experiment was performed 
twice. 
A 
D C 
B 
Chapter 4 – Induction of FGF9 in Cells Involved in Pathogenesis of MS 118 
 
4.2.5 Macrophages polarised towards an anti-inflammatory 
phenotype upregulate FGF9 gene expression 
Experiments detailed in the previous chapter showed that macrophages in acute 
CNS lesions are immunoreactive for FGF9. Macrophages in a lesion setting 
display a range of phenotypes geared towards promoting or reducing 
inflammation, healing, and fibrosis. To study the expression of FGFs by 
macrophage lineage cells, BMDMs were cultured for one week then treated with 
the M1 and M2 polarizing cytokines, IFNγ and IL-13 as detailed in Section 2.2.6.6.  
In the first experiments, cultured BMDMs were treated with polarizing cytokines for 
24 hours then processed for qPCR. Nos2 expression is robustly increased 
following 24 or 48-hour treatment with IFNγ (Figure 4.12 A). 24h IFNγ = 4838.2 ± 
1863.7 fold, 48h IFNγ – 6652 ± 52.9 fold. Arg1 expression is induced with IL-13 
treatment (Figure 4.12 B) but this change only became statistically significant after 
48 hours. 48h IL-13 = 79.3 ± 66.1 fold). FGF expression in polarized BMDMs was 
then assessed. Fgf1 levels fluctuated around baseline in BMDMs polarized to M1 
or M2 and were never significantly elevated or decreased (Figure 4.13 A). FGF2 
expression was increased 24 hours after polarization with IL-13, 15.1 ± 5.4 fold, 
(Figure 4.13 B). FGF9 expression appeared slightly elevated after 24 hours of M2 
polarization but was not significantly increased until 48 hours after treatment, 82.2 
± 66.2 fold, (Figure 4.13 C).  
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Figure 4.12. Polarization of bone marrow-derived macrophages with IFNγ and IL-13. 
BMDMs were cultured with M-CSF for 7 days followed by treatment with 100 ng/mL IFNγ 
or IL-13. Cells were lysed and processed for RNA extraction and cDNA synthesis. qPCR 
was performed using primers for Nos2, Arg1, and Gapdh as the housekeeping standard. 
Nos2 expression was robustly upregulated after 24 and 48 hour treatment with IFNy (A). 
Arg1 upregulation reached significance after 48 hours of IL-13 treatment. Fold changes in 
gene expression are shown relative to untreated control values, data presented are the 
means ± SD. This experiment was performed seven times. *, p < 0.05, *** p < 0.001 (one-
way ANOVA with Bonferroni’s Multiple Comparison Test). 
 
A 
B 
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Figure 4.13. FGF 2 and FGF9 were induced by IL-13 in BMDMs. BMDMs were 
cultured with M-CSF for 7 days followed by treatment with 100 ng/mL IFNγ or IL-13. Cells 
were lysed and processed for RNA extraction and cDNA synthesis. qPCR was performed 
using primers for Fgf1, Fgf2, Fgf9, and Gapdh as the housekeeping standard. IL-13 had 
no effect on FGF1 expression (A) but significantly upregulated FGF2 (B) after 24 hours 
and FGF9 (C) after 48 hours. Fold changes in gene expression are shown relative to 
untreated control values. Data presented are the means ± SD. This experiment was 
performed seven times. *, p < 0.05, ** p < 0.01 (one-way ANOVA with Bonferroni’s 
Multiple Comparison Test). 
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4.2.6 FGF-treatment does not induce feedback inhibitor 
expression or alter cytokine production in polarised 
macrophages 
Following the finding that macrophages polarised towards an anti-inflammatory 
phenotype express FGF9, the next step was to determine what effects, if any, 
FGFs have on macrophages. Using Sprouty and DUSP expression as readouts, 
macrophages were treated with polarizing cytokines in combination with FGF1, 2, 
or 9, for 24 hours. Macrophages were then processed for qPCR as in the previous 
section. IFNγ and IL-13 induced no upregulation of Spry2, Spry4, Dusp5, or Dusp6 
(Figure 4.14). Combination treatment with polarising cytokines and FGFs also led 
to no increase in feedback inhibitor expression. M1 polarization with IFNγ led to a 
marked but variable downregulation of each of the four feedback inhibitors which 
again, was not affected by the presence of FGFs. Relative expression of M1 and 
M2-associated genes Nos2, Arg1, Tnf and il10 were also unaffected by FGFs 
(Figure 4.15). Results in these graphs were normalised to the effects of polarizing 
cytokines alone. 
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Figure 4.14. FGF treatment did not induce feedback inhibitor expression in 
macrophages. BMDMs were cultured with M-CSF for 7 days followed by 24-hour treatment 
with 100 ng/mL IFNγ or IL-13 in combination with FGF1, 2, or 9. Cells were then lysed and 
processed for RNA extraction and cDNA synthesis. qPCR was performed using primers for 
Spry2, Spry4, Dusp5, Dusp6, and Gapdh as the housekeeping standard. IFNγ reduced 
expression of all inhibitors, which was not affected by the presence of FGFs compared to 
unpolarised controls. IL-13 alone or in combination with FGFs did not induce upregulation of 
feedback inhibitors. Fold changes in gene expression are shown relative to untreated control 
values, data presented are the means ± SD. This experiment was performed 7 times. *, p < 
0.05, ** p < 0.01, ***, p < 0.001 (one-way ANOVA with Bonferroni’s Multiple Comparison 
Test). 
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Figure 4.15. FGF9 did not influence macrophage polarization or cytokine expression. 
BMDMs were cultured with M-CSF for 7 days followed by 24-hour treatment with 10, 50, or 100 
ng/mL IFNγ or IL-13 in combination with 100 ng/mL FGF9. Nos2 expression increases in a 
dose-dependent manner with IFNγ treatment (A) and FGF treatment alone does not induce 
Nos2 expression. Similarly Arg1 is induced by treatment with IL-13, and FGF treatment alone 
had no effect (B). Normalising fold change between FGF9-treated and untreated macrophages 
revealed that FGF9 had no effect on M1 (C) or M2 (D) polarization. Inflammatory cytokine Tnf-α 
(E) and anti-inflammatory cytokine il10 (F) expression were also unaffected by the presence of 
FGF9 in polarizing conditions. Fold changes in gene expression are shown relative to untreated 
control values, this experiment was performed once. 
Chapter 4 – Induction of FGF9 in Cells Involved in Pathogenesis of MS 124 
 
4.3 Discussion 
Acute inflammatory exacerbations are considered to be the main driver of lesion 
development in RRMS and acute lesions were found to have higher levels of 
FGF9 compared to chronic lesions (Lindner et al., 2015). This was correlated with 
higher FGF9 expression and suggests aspects of the inflammatory response might 
drive expression of FGF9 in MS. Studies investigating cytokine profiles of MS 
lesions and the CSF of MS patients have found that TNFa, IFNy, IL-6, IL-1β, IL-10, 
GM-CSF, and TGFβ1 are the most prominent cytokines produced in acute MS 
(Romme Christensen et al., 2012, Durán et al., 2001, Tsukada et al., 1991, 
Maimone et al., 1991). PGE2 has been shown to play a role in the regulation of 
FGF9 and might be involved in the pathogenesis of MS (Chuang et al., 2006, 
Mattsson et al., 2009). AhR activation has been linked to upregulation of FGF9 in 
adenocarcinoma and inflammation in MS (Wang et al., 2009, Quintana et al., 
2008). These factors were tested for their ability to induce FGF9 expression at the 
mRNA and protein level in myelinating cultures as they are a good representation 
of the CNS, can be used for protein and RNA detection, and contain astrocyte and 
OLs which express FGF9 in acute MS lesions (Lindner et al., 2015). 
Each factor was tested for its ability to inhibit myelination in the same manner as 
FGF9 treatment: 100 ng/mL from DIV 18 – 28. Most of the factors, with exception 
to TNFα (Cammer and Zhang, 1999) IFNy (Agresti et al., 1996), and IL-6 (Zhang 
et al., 2006) have not been studied with regards to myelination in vitro. IFNy was 
the only factor tested that had any significant effect on myelination (Figure 4.1 A). 
TNFα inhibited myelination in the study referenced above, however it had no effect 
in this myelinating culture system. IL-6 has been demonstrated to increase myelin 
production by cultured OLs (Zhang et al., 2006) but no effect was observed in the 
myelinating cultures (Figure 4.1A)  The difference in effects on myelination seen in 
these experiments and the others mentioned may be due to the differences in the 
culture systems used. Treatment doses and durations also varied between studies 
making direct comparisons difficult. Axonal density was not reduced by treatment 
with any factor, which indicates that axonal integrity is not affected by long-term 
exposure to these inflammatory mediators alone (Figure 4.1 B). 
FGF9 in myelinating cultures was measured at the messenger and protein level 
due to the different ways PGE2, Ahr activation, and hypoxia have been shown to 
Chapter 4 – Induction of FGF9 in Cells Involved in Pathogenesis of MS 125 
 
regulate FGF9 expression (Wang et al., 2009, Chuang et al., 2006, Chen et al., 
2014). qPCR for Fgf1, Fgf2, and Fgf9 following 24-hour treatments showed no 
significant differences between any of the treatments and control cultures (Figure 
4.2 – 4.4). These findings indicate that none of the inflammatory mediators tested 
are involved in FGF gene transcription in cells of the CNS in this culture system. 
BaP and PGE2 have both been shown in other experimental models to up 
regulate FGF9 mRNA expression (Wang et al., 2009, Chuang et al., 2006) and 
that they did not here may be due to the different cell types that make up each 
model system. Myelinating cultures lack the immune cells that populate MS 
lesions and these may be necessary to facilitate a downstream effect on FGF9 
expression. Lack of inflammation and damage in the cultures may also be 
inhibiting any effect of the factors as the multiple regulatory mechanisms of FGF9 
expression may need to be disrupted for these factors to have an effect. BaP and 
PGE2 were shown to upregulate FGF9 in cancer models. FGF signalling 
dysregulation is a hallmark of many cancers so these models may be associated 
with underlying FGF dysregulation that is not present in the myelinating cultures.  
FGF9 protein expression in cells of myelinating cultures was assessed by 
immunofluorescence. Immunohistochemical studies of human and rat CNS tissues 
have shown that FGF9 is expressed by neurons, with the highest levels being in 
motor neurons in the spinal cord (Garcès et al., 2000, Nakamura et al., 1999, 
Nakamura et al., 1997). Myelinating rat cultures are composed of spinal cord-
derived neurons and oligodendrocytes, and an underlying monolayer of striatum-
derived astrocytes. Staining for FGF9 in the cultures shows that some axons are 
clearly immunoreactive for FGF9 (Figure 4.5 A). Astrocytes also stained for FGF9 
against a background of diffuse FGF9 reactivity (Figure 4.5 A, B). Diffuse staining 
is likely due to FGF9 bound to cell surfaces and ECM components. The 
intermittent expression of FGF9 conserved in axons is likely due to some portions 
of the axons lying out of focus in another layer of the culture. These findings are 
similar to those observed in rat and human CNS, particularly the spinal cord. 
Cultures were treated from DIV 18 with each factor for three days and then stained 
for FGF9. Images were taken and analysed to calculate the MFI of FGF9 staining 
in each condition. None of the factors affected the levels of FGF9 protein 
expression in the cultures at 100 ng/mL. These results suggest inflammatory 
mediators, PGE2, and AhR activation do not induce in FGF9 upregulation in 
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healthy CNS cells in myelinating and astrocyte cultures and may be relevant to 
elucidating the triggers for FGF9 upregulation in MS. Baseline levels of FGF9 in 
myelinating cultures appeared surprisingly high, which is not the case in the adult 
CNS. This may be due to the age of the cells being examined as myelinating 
cultures are derived from rat pup and embryonic cells. FGF9 is most highly 
expressed during development and levels in the brain are lower in adults 
(Nakamura et al., 1999).  
Following the lack of induction observed by the panel of inflammatory mediators, 
other mechanisms of FGF9 upregulation in MS were investigated. Hypoxia was 
chosen for study due to its well documented roles in FGF regulation and evidence 
showing MS lesions can become hypoxic (Ganat et al., 2002, Yang et al., 2015, 
Aboul-Enein et al., 2003). Reduced oxygen concentration in cells activates HIF1α, 
the master regulator of the cellular response to hypoxia (Pagé et al., 2002), which 
enters the nucleus and induces gene transcription. HIF1α has also been detected 
in the nuclei of cells in MS CNS tissue.  
(Chen et al., 2014) established a link between hypoxia and FGF9 expression in 
colon cancer and HEK293 cells. FGF9 protein expression was increased in 
cancerous sections compared to control colon and correlated with HIF1α 
activation. HEK293 cells cultured under hypoxic conditions also upregulated FGF9 
protein but had a reduced number of FGF9 mRNA transcripts. This suggested 
FGF9 expression was mediated by translational regulation hypoxia. These findings 
suggested hypoxia  might be involved in FGF9 regulation in MS. 
To determine whether hypoxia could induce FGF9 in vitro, myelinating cultures 
were incubated in a sealed chamber flooded with 1% O2 for 24 hours. To test the 
effects of reperfusion, some cultures were transferred into a standard incubator for 
24 hours following hypoxia. Myelination increased slightly between DIV 19 and 20 
in control cultures (Figure 4.7 A; 4.8 A, C), whereas virtually no myelin was 
present in cultures exposed to hypoxia (Figure 4.7 A; 4.8 B, D). Axonal density 
was slightly reduced by 24 hours hypoxia but following reperfusion axons were 
completely absent from the cultures (Figure 4.7 B; 4.8 B, D). This would seem to 
suggest that the duration of treatment was too long and hypoxia lead to total cell 
death in myelinating cultures. However, this was not the case as astrocytes 
survived hypoxia and reperfusion (Figure 4.10). Staining for FGF9 in the surviving 
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astrocytes at 24 hours revealed a slight increase in MFI (Figure 4.9). Following 
reperfusion, astrocytic FGF9 expression was more than double control levels. 
These results are only representative of two experiments that will need to be 
repeated, however these findings suggest hypoxia leads to upregulation of FGF9 
in astrocytes. Astrocytes have been shown to increase their use of glycolysis in 
hypoxia which might explain why they survived treatment (Marrif and Juurlink, 
1999). 
The next step in these experiments was to investigate gene expression in 
myelinating cultures following hypoxia. qPCR studies showed that Hk2 expression 
is increased in myelinating cultures around 20 fold following 24 hours of hypoxia 
and returns to baseline after reperfusion (Figure 4.11A). HIF1α expression is 
regulated translationally (Pagé et al., 2002), so Hif1α mRNA levels are not a useful 
marker for hypoxia. Hk2 encodes an enzyme involved in glycolysis that is 
upregulated by HIF1α as part of the cellular response to hypoxia (Menendez et al., 
2015). HIF1α is constitutively expressed by all cells and is activated, but not 
upregulated, by hypoxia. Therefore HK2 is often used as a surrogate marker for 
HIF1α activation. FGF1 mRNA levels were not affected by hypoxia or reperfusion 
(Figure 4.11B). Fgf2 expression on the other hand was upregulated around seven 
fold following hypoxia and reperfusion (Figure 4.11C). FGF2 upregulation has 
been well documented in response to hypoxia, so this result was expected. It also 
suggests that astrocytes produce FGF2 and FGF9 in hypoxia. Fgf9 expression 
was decreased two to three fold after hypoxia and reperfusion (Figure 4.11 D). 
This finding combined with the effects observed on FGF9 protein levels indicates 
that FGF9 levels in myelinating cultures exposed to hypoxia is regulated by 
hypoxia-induced translational activation as described by Chen et al.  (Chen et al., 
2014).  
In the previous chapter, macrophages in acute MS were shown to be 
immunoreactive for FGF9. In these experiments, BMDMs were treated with 
polarizing cytokines and their FGF mRNA expression was analysed. IFNγ robustly 
induced Nos2 expression in BMDMs after 24 and 48 hours, and this effect had 
mostly dissipated 24 hours after IFNγ withdrawal (Figure 4.12 A).  Arg1 expression 
was significantly increased only after 48 hours treatment with IL-13 (Figure 4.12 
B). FGF1 expression was unaffected in IFNy and IL-13-polarised macrophages 
(Figure 4.13 A). FGF2 levels were unchanged by IFNy but were significantly 
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elevated after 24-hour treatment with IL-13 but these levels decreased slightly 
after a further 24 hours and the change was no longer significant (Figure 4.13 B). 
Macrophages polarised towards a repair phenotype have been shown to produce 
FGF2 in previous studies (Jetten et al., 2014) and this result is in line with those 
findings. Fgf9 mRNA was increased in IL-13-polarised BMDMs to a variable extent 
after 24 hours but only became significantly upregulated after 48 hours (Figure 
4.13 C). Fgf9 was only increased after Arg1 was also significantly elevated and the 
levels were variable but overall higher than those seen for Fgf2 upregulation. M1 
polarization of BMDMs had no effect on the expression of any FGFs tested which 
suggests FGF production is a feature of anti-inflammatory macrophages.  
The next question to be answered concerning macrophages was whether FGFs 
influence macrophage phenotype and function. BMDMs were treated with 
polarising cytokines in the presence or absence of FGF1, 2, or 9, and screened for 
expression of FGF-feedback inhibitors, polarisation markers, and associated 
cytokines. None of the FGFs tested induced feedback inhibitor upregulation in 
macrophages polarized with IFNγ or IL-13, suggesting that macrophages are not a 
target for FGF signaling (Figure 4.15). In addition to these results, no differences 
in Nos2, Arg1, Tnf, or Il10 expression were seen in macrophages polarised in the 
presence or absence of FGFs (Figure 4.16). This experiment has only been 
performed once and will have to be repeated but the results are in line with the 
results in Figure 4.14. 
Interestingly, expression of all four feedback inhibitors was reduced in IFNγ treated 
macrophages, indicating that downregulation of MAPK signaling inhibitors is a 
component of M1 polarisation. Sprouty2 downregulation in IFNγ treated 
macrophages has been described before (Atomura et al., 2016) and in this study 
small‐interfering RNA knockdown of Sprouty2 expression drove macrophages 
towards the M2 phenotype. This would suggest that reduced expression of MAPK 
inhibitors promotes an anti-inflammatory phenotype in macrophages and may be a 
component of intrinsic regulation of inflammation in macrophages. Together these 
data support the finding that macrophages are a source of FGF9 in MS and predict 
that FGF9+ macrophages in MS lesions will exhibit a repair phenotype and 
express Arg1. Additionally, macrophage polarisation and cytokine expression 
profile is not influenced by the presence of FGFs associated with MS lesions. 
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In this chapter, potential mechanisms involved in the induction of FGF9 in MS 
were investigated in in vitro CNS cultures. Inflammatory and anti-inflammatory 
mediators produced in MS lesions did not induce FGF9 mRNA or protein 
expression in myelinating cultures. Hypoxia was lethal for most CNS cell types but 
astrocytes persisted and up regulated FGF9 protein expression while mRNA levels 
fell. This suggests FGF9 in myelinating and astrocyte cultures is subject to the 
same regulatory pathways triggered by hypoxia as those described for colon 
cancer (Chen et al., 2014).  Macrophages were also shown to up regulate FGF9 
when polarized towards an anti-inflammatory phenotype. Together these findings 
suggest FGF9 up regulation in myelinating cultures is a consequence of normal 
repair mechanisms, and the failure of the lesion to resolve results in chronically 
increased production of FGF9. These findings suggest that hypoxia may play a 
role in FGF9 up regulation in MS and future studies should examine the 
expression of FGF9 and markers of hypoxia in MS brains to determine whether 
there is a correlation. 
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5  FGF9 DISRUPTED MYELINATION AND INDUCED 
AXONAL PATHOLOGY 
5.1 Introduction 
The main drivers of symptoms and disability in MS are loss of myelin sheathes 
required for saltatory conduction, and loss of axons at which point, damage 
becomes irreparable. Targeting both of these pathogenic mechanisms 
therapeutically would restore functional nerve transmission, and preserve and 
protect axons (Chandran et al., 2008). This is especially true in progressive MS 
where inflammation is less prevalent and a range of neurodegenerative 
mechanisms drive disease progression. 
In earlier stages of MS, OPCs efficiently repopulate demyelinated lesions and do 
not lose proliferative capacity after several bouts of demyelination (Penderis et al., 
2003). Despite robust replacement of progenitors, complete remyelination only 
occurs in a small subset of MS patients and becomes less efficient with age and 
increasing disease duration (Patrikios et al., 2006, Sim et al., 2002). The proposed 
reasons for remyelination failure in MS are myriad which in itself suggests many 
contributing factors create a lesion environment that is impermissible to 
remyelination. As the problem does not appear to lie with replacement of 
progenitors, the point of remyelination failure likely occurs as OPCs try to 
differentiate and produce myelin. Complex growth factor and intracellular signaling 
pathways regulate the processes of OPC differentiation and myelination, which are 
perturbed by the complex inflammatory cytokine and growth factor signaling 
environment of the MS lesion (Franklin, 2002). FGF9 is one such contributing 
factor to remyelination failure as it promotes OPC proliferation but inhibits their 
differentiation via astrocyte-secreted factors (Lindner et al., 2015). A feature of 
FGF9-treated myelinating cultures is the appearance of round MOG+ cells, which 
may represent a failed attempt at OPC differentiation (unpublished observation). 
The pathogenic mechanisms underlying axonal loss in progressive MS are 
discussed in section 1.1.2.2. Loss of myelin sheathes leave axons more 
vulnerable to damage and increases metabolic stress. Similar processes underpin 
neuronal damage in other neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s disease. Dystrophic neurites and astrocytes are immunoreactive for 
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FGF9 in Alzheimer’s plaques, suggesting it plays a role in disease pathology 
(Nakamura et al., 1998). Several studies demonstrated a neuroprotective role for 
FGF9 in different toxin-induced neurodegeneration models (Huang et al., 2009, 
Huang and Chuang, 2010, Kanda et al., 1999). In myelination experiments, FGF9 
inhibited myelination without affecting the density of underlying axons (Figure 1.3). 
Immunohistochemical analysis of post-mortem MS brains (Lindner et al., 2015) 
showed FGF9 is expressed in acute lesions, and to a lesser degree, in chronic-
active lesions.  So far, investigation of FGF9 using the myelinating culture system 
has mainly focused on its effects on primary myelination. While this provides 
insight into the roles of FGF9 in remyelination, it does not address the impact of 
FGF9 expression during other stages of MS. The myelinating culture system can 
be used to address these questions: 
1. Does longer-term treatment with FGF9 have additional pathological effects 
that are not apparent at DIV 28? 
 
2. In addition to inhibition of myelination, can FGF9 cause demyelination? 
 
3. Can myelination recover in cultures that have been treated with FGF9? 
To answer these questions the following experiments were performed: 10 and 20-
day FGF9 treatments were performed in myelinating cultures between DIV 18 and 
38. 10-day FGF9 treatments were started on DIV 18 (onset of myelination) or DIV 
28 (when the majority of myelination has occurred). FGF9 was withdrawn from DIV 
18 – 28 treated cultures that were then maintained in control media until DIV 38. 
Control cultures were maintained in control media throughout, or treated with 
FGF9 from DIV 18 – 38. 
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5.2 Results 
5.2.1 FGF9 had different effects depending on the duration of 
treatment and age of cultures when treatment was initiated 
5.2.1.1 FGF9 did not cause demyelination after 10-day treatment 
Myelinating cultures produce the majority of their myelin sheathes between DIV 18 
and 28. Treating cultures with FGF9 between these time points results in near total 
inhibition of myelination (Figure 1.3, 1.4). To determine if FGF9 is a demyelinating 
factor, as well as a myelin-inhibitory factor, myelinating cultures were treated with 
FGF9 from DIV 28 – 38. At DIV 38, cultures were fixed and stained as described in 
section 2.2.7. The percentage of myelinated axons and axon densities were 
calculated using CellProfiler as described in section 2.2.8. Cultures treated in this 
fashion had comparable levels of myelination to control cultures at DIV 38, 
indicating FGF9 does not directly cause demyelination (Figure 5.1 A, 5.2 C). 
Although FGF9 did not appear to affect mature OLs, brightly staining MOG+ round 
cells were numerous in these cultures (Figure 5.2). These cells are a common 
feature of myelinating cultures treated with FGF9 at any time point and suggest 
that FGF9 has a detrimental effect on the OPC population in myelinating cultures 
and leads to aberrant maturation and production of myelin proteins.  
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A 
B 
Figure 5.1. FGF9 was not a demyelinating factor and pre-treatment increased myelin 
production. Myelinating cultures were alternately treated with FGF9 for 10 days from DIV 
18 followed by 10 days in control media or vice versa. Control cultures were treated with 
FGF9 or DM- for 20 days to compare the effects of alternating treatment. Cultures were 
fixed and stained with antibodies against MOG (Z2) and axons (SMI31). Myelination rates 
and axon densities were calculated in CellProfiler. Adding FGF9 at DIV 28 did not 
demyelinate cultures after 10-day treatment. Removing FGF9 at DIV 28 after 10-day 
treatment caused a significant increase in myelination by DIV 38. 20-day treatment with 
FGF9 led to a small but significant decrease in axon density. Data presented are  the 
means ± SD. This experiment was performed three times. *, p < 0.05, **, p < 0.01 (one-
way ANOVA with Dunnett's Multiple Comparison Test).  
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Figure 5.2. Representative images of myelinating cultures after alternating FGF9 
treatment. Myelinating cultures were alternately treated with FGF9 for 10 days from DIV 
18 followed by 10 days in control media or vice versa. Control cultures were treated with 
FGF9 or DM- for 20 days to compare the effects of alternating treatment. Cultures were 
fixed and stained with antibodies against MOG (Z2) and axons (SMI31). Representative 
images show myelination in 20 DIV (A) control cultures, and 20 DIV (B) FGF9-treated 
cultures, and cultures were FGF9 was added at DIV 28 (C) or removed at DIV 28 (D). 
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5.2.1.2 Removing FGF9 from cultures treated from DIV 18 - 28 led to 
increased but aberrant myelination 
FGF9 treatment form DIV 18 and 28 inhibits myelination in myelinating cultures. 
This is associated with a massive increase in OPC numbers (Lindner et al., 2015) 
and the appearance of round MOG+ cells, thought to be the product of disrupted 
OPC maturation. This raised the question of whether OPCs generated from FGF9 
treatment can facilitate normal myelination, or are they already on the path to 
defective maturation like the round MOG+ cells? To address this, FGF9 was 
withdrawn from cultures treated from DIV 18 – 28. These cultures were treated 
with control DM- for a further 10 days before fixation and processing for 
immunofluorescence. 
Assessing myelination using CellProfiler revealed that levels were greater in 
FGF9-withdrawal cultures than DIV 38 control cultures (10d F9 10d C: 27.5% ± 
6.4%; 20d C 16.6% ± 4.4%, p < 0.01) (Figure 5.1 A). MOG+ round cells were 
observed in these cultures 10 days after FGF9 treatment was stopped (Figure 5.2 
D). Under confocal microscopy the myelin produced in 10d F9 10d C cultures 
appears starkly different to myelin in untreated controls (Figure 5.3). Myelin 
sheathes in 20d C cultures present as long, continuous strands of an even 
thickness that envelop long portions of axons (Figure 5.3 A). Some normal-
appearing myelin sheathes are visible in 10d F9 10d C cultures (Figure 5.3 B), 
however, the majority of myelin sheathes appear irregular with significant 
membrane blebbing and separation from underlying axons (Figure 5.3 B, C).  
MOG+PLP+ cells appear after FGF9 treatment (Lindner et al., 2015) and resemble 
pre-myelinating OLs described in chronic MS lesions (Chang et al., 2002). These 
same cells persisted 10 days after FGF9 treatment. Cultures were stained with 
antibodies against MOG and PLP, and imaged by confocal microscopy. Examples 
of double-labelled cells are shown in Figure 5.4. Cell bodies and processes are 
filled with a mixture of MOG and PLP staining. The cell shown in Figure 5.4 A has 
produced a network of processes filled with punctate granules of MOG and PLP. 
The cell in Figure 5.4 B stains strongly for each myelin protein in the cell body, 
surrounded by a fine web of processes, which contain little of each protein. The 
appearance of these cells is highly variable and irregular and does not reflect the 
appearance of any stage of normal OL maturation. 
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Membrane blebbing and the punctate appearance of myelin proteins in these 
cultures somewhat resembles myelin breakdown products in MS and EAE. In 
these conditions, degrading myelin is rapidly phagocytosed by macrophages and 
microglia, and myelin proteins can be detected in phagocytic vacuoles (Boven et 
al., 2006). To determine if the irregular myelin seen in 10d F9 10d C myelinating 
cultures is also undergoing phagocytosis, cultures were double-labelled with IBA1 
and MOG. Searching under confocal microscopy, no colocalization of myelin in 
microglia membranes was detected suggesting the irregular myelin is not the 
result of myelin destruction and phagocytosis (Figure 5.5). 
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Figure 5.3 Pre-treatment with FGF9 disrupted myelination and causes an axonal 
pathology. Myelinating cultures were alternately treated with FGF9 for 10 days from DIV 
18 followed by 10 days in control media or vice versa. Cultures were fixed and stained 
with antibodies against MOG (Z2) (green) and axons (SMI31) (red), which label myelin 
and axons respectively. Myelin sheathes in controls (A) appear uniform and continuous 
whereas myelin produced 10 days after FGF9 withdrawal appears highly irregular with 
intermittent thick and thin portions, and extensive membrane blebbing (B, C). The 
underlying axons in image C are shown in D and display several axonal swellings 
(arrows), which are shown in C to be unmyelinated. 
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Figure 5.4 Confocal imaging of MOG+PLP+ cells reveals stark morphological 
differences from normal OLs. MOG positive cells observed in FGF9-treated 
myelinating cultures were stained together with an anti-PLP antibody, and imaged using 
confocal microscopy. High magnification revealed overlapping and distinct areas of PLP 
and MOG expression within the same cells. MOG+PLP+ cells were frequently observed 
to produce extensive processes which also contain myelin proteins. 
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Figure 5.5 Microglia did not phagocytose irregular myelin produced as a result 
of FGF9-treatment. Myelinating cultures were alternately treated with FGF9 for 10 
days from DIV 18 followed by 10 days in control media or vice versa. Control cultures 
were treated with FGF9 or DM- for 20 days to compare the effects of alternating 
treatment. Cultures were fixed and stained with anti-MOG (green) and anti-IBA1 (red) 
which label myelin and microglial respectively. Using confocal microscopy myelin was 
not observed within microglial membranes. 
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5.2.1.3 Long term treatment with FGF9 was detrimental to axons in 
myelinating cultures 
Myelinating cultures treated with FGF9 for 10 days (DIV 18 - 28) have comparable 
levels of axonal density to control cultures (Figure 1.3, 1.4). Doubling the length of 
treatment (DIV 18 – 38) led to a small but significant reduction in axonal density 
compared to control cultures (20d C = 43% ± 4%; 20 F9 = 36% ± 4.1%, p < 0.05) 
(Figure 5.1 B). This effect was not observed in cultures treated for just 10 days 
from DIV 18 or DIV 28, and 10 days after FGF9 withdrawal (Figure 5.1 B). This 
finding suggests that axons can remain intact through a short course of FGF9 
treatment but begin to suffer damage after chronic exposure. 
When examining axons in 10d F9 10d C-treated myelinating cultures under high 
power magnification, abnormalities in neurofilament (SMI31) staining and axon 
structure were observed (Figure 5.3 C, D). Axons in control cultures appear 
continuous with an even distribution of SMI31 staining along individual axons 
(Figure 5.3 A).  Intermittent bright and dark regions of neurofilament are apparent 
along the length of axons treated with FGF9, 10 days after its withdrawal. Axonal 
swellings are also apparent in FGF9-treated cultures, and are seen in areas of the 
axons that lack myelin (Figure 5.3 C, D). This suggests they have become 
damaged as a result of not being myelinated, or the areas of swelling are not able 
to undergo normal myelination. Re-examining the cultures used for Figure 5.1, 
under higher magnification, revealed axonal pathology is present after 10-day 
FGF9 treatment. Control axons at DIV 28 (Figure 5.6 A) and 38 (Figure 5.6 B) 
appear similarly healthy and uniform. Cultures treated with FGF9 for 10 days 
(Figure 5.6 C, E), 20 days (Figure 5.6 D), or 10d FGF9 10d C (Figure 5.6 F) all 
display a similar axonal pathology characterised by swellings and more punctate 
neurofilament staining. Although 10-day FGF9 treatment is not associated with a 
reduction in axon density, this observation shows that physical changes precede 
loss of axons seen after 20-day FGF9 treatment. 
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Figure 5.6. Axonal pathology preceded reduction in density in FGF9-treated 
myelinating cultures. Representative images show control axons at DIV 28 (A) and DIV 38 
(B). Axons in FGF9-treated cultures have more punctate neurofilament staining and the 
presence of swellings along the length of axons after 10 (C) or 20 (D) day treatment. Axons 
still have an irregular appearance when treatment is started late (E) and 10 days after FGF9 
withdrawal (F). 
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5.2.1.4 Oligodendrocyte numbers increased by FGF9 treatment return to 
control levels after the factor is withdrawn  
OPCs proliferate rapidly in myelinating cultures in response to FGF9 and remain in 
a progenitor state (Lindner et al., 2015), however the fate of these cells has not 
been investigated. Results from the previous section suggest that many of these 
OPCs attempt to differentiate and produce myelin sheathes with limited success. 
Using the FGF9-treatement regime used in the previous sections of this chapter, 
myelinating cultures were fixed and stained with antibodies against NG2 (a 
chondroitin sulphate proteoglycan expressed on OPC cell membranes) and Olig2 
(transcription factor specific to OL lineage cells). OPC numbers were counted 
manually in ImageJ and total OL lineage cell numbers were calculated by 
CellProfiler. Cells were counted from 30 fields of view per condition and results 
were expressed as cells/ field of view (FOV). 
NG2+ cell numbers more than doubled in 20d F9 and 10d C 10d F9 treated 
cultures compared to controls (20d C = 30.2 ± 6.4 cells/FOV; 20d F9 = 81.6 ± 9.2 
cells/FOV, 10d C 10d F9 = 73.3 ± 12.5 cells/FOV, p < 0.001) (Figure 5.7 A). NG2+ 
cell numbers reached a similar level despite one course of treatment being twice 
the length of the other. In 10d F9 10d C treated cultures NG2+ cells numbers were 
almost the same as in the 20d C (10d F9 10d C = 32.7 ± 4.9 cells/FOV). A similar 
trend was observed when total OL lineage cell numbers were quantified: 20d F9 
and 10d C 10d F9 treatment increased Olig2+ cell numbers by 4 fold (20d C = 66.3 
± 37.1 cells/FOV; 20d F9 = 251.4 ± 60.5 cells/FOV, 10d C 10d F9 = 265.4 ± 78.8 
cells/FOV, p < 0.05) (Figure 5.7 B). Total OL numbers remained elevated in 10d 
F9 10d C treated cultures, 132.9 ± 34.3 cells/FOV, however this was not 
significantly different from 20d C OL numbers. Representative images of NG2 and 
Olig2 stainings in FGF9-treated myelinating cultures are shown in Figure 5.8 and 
Figure 5.9 respectively.  
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Figure 5.7. OPC  and OL lineage cell numbers increased after FGF9 treatment and 
returned to baseline levels after it is withdrawn. Alternately treated myelinating 
cultures were fixed and stained with NG2 (OPCs) and Olig2 (OL lineage marker), and cell 
numbers were quantified. FGF9 treatment doubled NG2+ cell populations after 10 or 20-
day treatment (A) but these numbers returned to control levels 10 days after the 
withdrawal of FGF9. Total OL numbers, observed as Olig2+ cells similarly increased and 
contracted following FGF9 treatment. Data presented are the means ± SD. This 
experiment was performed three times. *, p < 0.05, ***, p <0.001 (one-way ANOVA with 
Dunnett's Multiple Comparison Test).  
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Figure 5.8. Representative images of NG2 staining after alternating FGF9 treatment. 
NG2+ cell numbers were similar in controls (A) and FGF9 treated cultures 10 days after it 
had been withdrawn (D) whereas cultures treated with FGF9 to the experiment endpoint 
(B, C) appeared to have much greater numbers of OPCs. 
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Figure 5.9. Representative images of Olig2 staining after alternating FGF9 treatment. 
Total OL numbers were increased following all 3 variants of FGF9 treatment compared to 
control cultures, but were decreased 10 days after FGF9 withdrawal. 
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5.2.2 FGF9 treatment reduced neuronal numbers, axonal density, 
and axonal transport-gene expression in enriched neuronal 
cultures 
5.2.2.1 Expression of genes involved in axonal transport were reduced in 
myelinating cultures treated with FGF9 
Screening of the microarray performed by Lindner et al., 2015 revealed FGF9 
treatment led to a reduction in expression of genes associated with axonal 
transport (Table 5.1). Neurofilament light, medium, and heavy chains comprise 
components of the neuronal cytoskeleton (Nefl, Nefm, NefH). Dnah3, Dnah6, 
Dnah9, Dync1i1, and Dynlrb2 encode members of the dynein motor protein family.  
Kif5α encodes a member of the kinesin motor protein family, and SV2B encodes 
Synaptic Vesicle Glycoprotein 2B, which is involved in vesicle trafficking and 
exocytosis. Rbfox3 and Tubb3 encode NeuN and β-tubulin III respectively, both of 
which are neuron-specific markers. After 24-hour or 10-day treatment with FGF1 
or FGF2, some of these genes were variably downregulated, however after 10-day 
treatment with FGF9, all genes shown were downregulated more than 1.4 fold. 
Some of the genes were downregulated at 24 hours with FGF9, but the effect was 
more pronounced after 10 days suggesting this is an effect of chronic exposure to 
FGF9. 
Validation of the microarray results by qPCR showed a similar pattern of 
downregulation of axonal transport genes after 10-day FGF9 treatment (Figure 
5.10). Nefh (-2.6 ± 1.2 fold), Dnah6 (-4.7 ± 2.9 fold), Dnah9 (-3.3 ± 1.8 fold), 
Dync1i1 (-2.9 ± 1.5 fold), Kif5α (-3.1 ± 2 fold), Sv2b (3.8 ± 1.4 fold), Rbfox3 (-3 ± 1 
fold), and Tubb3 (-5 ± 3.1 fold) were all significantly downregulated in FGF9 
treated myelinating cultures (Figure 5.10 A). Dnah3, Dynlrb2, and Tubb3 
expression trended towards downregulation but the changes were not statistically 
significant. Ccl2 (11.7 ± 9.5 fold) , and Ccl7 (20.7 ± 18.4)  fold changes were used 
as positive controls as they are upregulated by FGF9 in myelinating cultures 
(Figure 5.10 B) (Lindner et al., 2015). 
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Gene 
FGF1 FGF2 FGF9 
24 hours 10 Days 24 hours 10 Days 24 hours 10 Days 
Nefl -1.14265 -1.0903 -1.14096 -1.54368 -1.14265 -2.36118 
Nefm -1.22304 -1.31223 -1.30605 -2.25285 -1.22304 -4.331 
Nefh -1.2605 -1.30119 -1.43455 -2.50954 -1.2605 -6.09924 
Dnah3 -5.52951 -1.05453 -3.20084 -2.18922 -5.52951 -8.77238 
Dnah6 -4.25718 1.0832 -3.37902 -1.63581 -4.25718 -10.5408 
Dnah9 -3.32719 1.19712 -2.86807 -1.49013 -3.32719 -6.99545 
Dync1i1 -1.31006 -1.02431 -1.35517 -1.89736 -1.31006 -3.52551 
Dynlrb2 -4.46907 -1.07507 -3.62441 -1.40705 -4.46907 -5.40226 
Kif5a -1.25404 -1.03218 -1.28978 -1.42876 -1.25404 -2.80844 
Sv2b -1.24524 -1.03132 -1.53362 -1.54508 -1.24524 -4.73995 
Rbfox3 -1.28059 -1.08793 -1.35543 -1.59024 -1.28059 -2.78494 
Tubb3 -1.14227 1.05834 -1.11176 -1.24627 -1.14227 -2.55708 
 
 
 
 
 
 
Table 5.1 Differentially expressed neuronal genes in myelinating cultures treated 
with FGF1, 2, or 9, for 24 hours and 10 days. Microarray analysis of FGF-associated 
gene expression shows that axonal transport genes, neurofilament genes, and neuronal 
differentiation genes are reduced in myelinating cultures following 10-day treatment with 
FGF9. 24-hour treatment with FGF9 or the other FGFs had little or no effect on gene 
expression. Data derived from Microarray performed by Lindner et al., 2015 
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Figure 5.10 Axonal transport gene expression was reduced by FGF9 treatment. 
Myelinating cultures were treated with 100 ng/mL recombinant human FGF9 for 10 days 
from DIV 18. The cells were lysed and processed for RNA extraction and cDNA synthesis. 
qPCR was performed using primers for neuronal genes and GAPDH as the housekeeping 
standard. Expression of all genes analysed showed reduced expression in FGF9-treated 
cultures compared to controls similar to downregulation seen in the microarray (A). Ccl2 
and Ccl7 were used as positive controls (B). Fold changes in gene expression are shown 
relative to untreated control values, data presented are the means ± SD. This experiment 
was performed 6 times. *, p < 0.05, **, p < 0.01 (Wilcoxon matched pairs tests were 
performed on delta CT values).  
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5.2.2.2 Neuronal cell numbers and axon density were reduced by FGF9 
treatment 
Data from previous sections in this chapter provide evidence that FGF9, a 
neuroprotective survival factor, can actually damage axons and contribute to 
neurodegeneration. The next step in this vein of research was to determine if 
FGF9 mediated its effects on neurons directly or acted via other cell types as is 
the case with its effect on myelination. To address this question, enriched neuronal 
cultures were generated as described in section 2.2.5. Neurons were cultured for 6 
days to allow them to fully differentiate, then treated with 100 ng/mL FGF9 for a 
further 10 days. At DIV 16, neurons were fixed and stained with SMI31 and MAP2 
antibodies to visualise axons and neuronal cell bodies respectively. MAP2+ cells 
numbers were counted manually in ImageJ and axon densities were calculated 
using CellProfiler. 
FGF9 treatment significantly reduced axonal density in neuronal cultures (10d C = 
19.5 ± 4% MFI; 10d F9 = 12 ± 0.4% MFI, p < 0.05) (Figure 5.11 A). This was 
associated with a marked reduction in number of MAP2+ neurons compared to 
controls, however due to high variation in cell numbers between different 
experiments this result was not significant (10d C = 32.8 ± 12.2 cells/FOV; 10d F9 
= 13.2 ± 5.8 cells/FOV, p = 0.0546) (Figure 5.11 B). FGF9 treatment also led to an 
increase in proliferation of non-neuronal cells in culture as DAPI staining shows in 
Figure 5.12 B. To prevent the proliferation of contaminating glial cells in neuronal 
cultures treated with FGF9, FdU, a potent cytotoxic agent that drives apoptosis in 
proliferating cells, was added from DIV 4. FdU alone decreases axon density and 
neuron cell numbers compared to untreated neurons (Figure 5.11 C, D). FdU also 
prevented the explosion in DAPI+ nuclei numbers observed after FGF9 treatment 
(Figure 5.11 B, D). Axonal density and neuronal cell counts were virtually the 
same as controls in FGF9-treated cultures that were co-treated with FdU (Figure 
5.11 C, D).  
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Figure 5.11. Axon density and neuronal cell counts were reduced in neuronal 
cultures following 10-day FGF9 treatment. Neurons were purified as described in 
section 2.2.5 and cultured in neuro-basal medium for 6 days. Cultures were treated with 
FGF9 for 10 days from DIV6 before being fixed and processed for immunofluorescence. 
Cells were stained with MAP2 and SMI31 to visualise neuronal cell bodies and axons 
respectively. MAP2+ cells were counted manually and MFI of SMI31 staining was 
quantified using CellProfiler. 10-day FGF9 treatment reduced MFI of SMI31 staining (A). 
Neuron numbers in FGF9-treated cultures were also reduced but not significantly (B). 
Treating neurons with FdU reduced neuron numbers and axon density but completely 
abrogated the effect of FGF9 (C, D). Data presented are the means ± SD. These 
experiments were performed three times. *, p < 0.05, (Wilcoxon matched pairs test A, B) 
(one-way ANOVA with Tukey’s Multiple Comparison Test C, D). 
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Figure 5.12. Representative images of neurons and axons in FGF9-treated neuronal 
cultures. Neurons were purified as described in section 2.2.5 and cultured in neuro-basal 
medium for 6 days. Cultures were treated with FGF9 for 10 days from DIV6 before being fixed 
and processed for immunofluorescence. Cells were stained with MAP2 (red) and SMI31 
(green) to visualise neuronal cell bodies and axons respectively. MAP2+ cells were counted 
manually and MFI of SMI31 staining was quantified using CellProfiler. 10-day FGF9 treatment 
reduced SMI31 staining and neuron cell counts, and dramatically increased numbers of DAPI+ 
nuclei (B) versus control (A). FdU treatment alone reduced neuron number and axon density 
versus untreated neurons (C) but cancelled out the effects of FGF9 (D). 
10d C 10d F9 SMI31 MAP2 DAPI SMI31 MAP2 DAPI 
100 μm 
10d FDU 10d FDU + F9 SMI31 MAP2 DAPI SMI31 MAP2 DAPI 
C D 100 μm 
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5.3 Discussion 
MS is a complex disease with several pathogenic mechanisms contributing to 
demyelination and damage to axons. Inflammatory and neurodegenerative 
pathways drive progression at different stages of disease, however the majority of 
treatments currently available (Table 1.1) target the immune system in RRMS. 
Neurodegenerative pathways, described in section 1.1.2.2, are the primary cause 
of axonal pathology in PPMS. Loss of axons represents the point of no return, 
after which repair is no longer possible. Understanding the mechanisms 
responsible for remyelination failure and axonal degeneration is critically important 
if therapeutics targeting later stages of MS are to be developed.  
FGF9 was shown previously to inhibit primary myelination in vitro and 
remyelination in cerebellar slice cultures (Lindner et al., 2015). These studies did 
not address whether FGF9 has any effects on established myelin and mature OLs. 
FGF9-treatment also greatly increases OPC numbers, but these new cells had not 
been tested for their capability to produce functional myelin. The primary receptor 
for FGF9 is FGFR3c, but like most other FGFs, FGF9 is promiscuous and can 
signal through FGFR2c and 1c (Zhang et al., 2006). FGFR3c expression on OL 
lineage cells is lost by the time they have fully matured, FGFR2c is expressed on 
myelin membranes, and FGFR1c is expressed on OL cell bodies (Miyake et al., 
1996). In maturing OLs (A2B5-, O4+, O1+ cells that have extended membrane 
processes but have not yet produced myelin sheathes) FGF9 treatment reduces 
expression of FGFR2 (Figure 3.8) as well as MBP and PLP (Cohen and 
Chandross, 2000). This suggests FGF9 can cause de-differentiation in OL lineage 
cells. It was not known if the same is true for mature OLs that have produced 
myelin sheathes as this had not been investigated. 
To answer the question of whether FGF9 is a demyelinating factor, myelinating 
cultures were treated for 10 days from DIV 28, when most myelination has 
occurred. Other cultures were treated with FGF9 from DIV 18 – 28. FGF9-media 
was then removed and the cultures were maintained in control media for a further 
10 days. This was to show if cultures in which myelination had been inhibited 
could myelinate when FGF9 treatment was stopped. As these experiments were 
performed over 20 days, control cultures were treated with FGF9 or maintained in 
control media for the full 20-day duration. As expected, myelin and axons in DIV 
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38 control cultures were virtually identical to DIV 28 control cultures used in 
previous experiments (Figure 5.2 A). Cultures treated with FGF9 for 20 days 
mostly lacked myelin and contained numerous MOG+ round cells (Figure 5.2 B).  
Myelination rate was the same in DIV 38 control cultures as DIV 28 - 38 FGF9-
treated cultures (Figure 5.1 A). This result shows FGF9 did not induce 
demyelination in mature myelinating cultures.  
Cultures treated with FGF9 from DIV 18 - 28 produced almost double the myelin 
seen in control cultures at DIV 38 (Figure 5.1 A, 5.2 D). This suggested cultures 
treated with FGF9 for 10 days might have an increased myelination capacity due 
to the increase in OPC numbers in associated with treatment (Lindner et al., 
2015). It also suggests a subpopulation of OPCs are responsible for the 
appearance of MOG+PLP+ cells observed in FGF9 treated myelinating cultures, 
and that other OPCs can mature following FGF9 withdrawal. Examination of 
myelin generated after FGF9 treatment using confocal microscopy revealed this 
was not the case. Myelin in these cultures had a highly irregular structure 
compared with control myelin (Figure 5.3 C, D). Normal myelin sheathes are 
continuous, evenly thick, and always associated with underlying axons (Figure 5.3 
A). In contrast, myelin membranes in FGF9-treated cultures are loosely associated 
with axons and appear to balloon at different points along their length. Some MOG 
staining also appears in small dense granules adjacent to these irregular myelin 
membranes. Overall, it appears as though OLs have attempted to myelinate axons 
but the process has been disrupted. 
In normal OLs PLP stains in the cell body and myelin sheathes whereas MOG is 
localized only to the myelin sheath. The detection of MOG+PLP+ cells 10 days 
after FGF9 withdrawal suggests they are the product of disrupted OL maturation 
(Figure 5.4). Under high power magnification, these cells have a highly variable 
appearance. The cell shown in Figure 5.4 A has an extensive network of 
processes that are laden with MOG and PLP at random intervals. None of the 
processes appear to be forming myelin sheathes and the cell body almost 
exclusively contain PLP with a few surrounding specks of MOG. The cell in Figure 
5.4 B contains densely packed granules of MOG and PLP in the cell body with a 
surrounding network of processes containing little of each protein. These are two 
examples of a wide array of phenotypes displayed by MOG+PLP+ cells in FGF9-
treated myelinating cultures. 
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FGF signaling is involved in every aspect of OL development and myelination 
(Fortin et al., 2005). FGF2 and FGF9 induce process elongation in mature OLs 
and OL signaling regulates myelin sheath thickness (Fortin et al., 2005, Furusho et 
al., 2012). Several groups have also shown the ability of FGF2 to induce de-
differentiation of mature OLs (Bansal and Pfeiffer, 1997, Fressinaud et al., 1995, 
Butt and Dinsdale, 2005). This is associated with downregulation of myelin genes, 
re-expression of OPC markers, and uncompacting of myelin membranes. It is 
likely that similar events in FGF9-treated myelinating cultures are causing aberrant 
OL maturation and producing the strange, myelin-protein filled cell bodies and 
membranes described here. Further characterisation of these cells is required 
however, and co-staining with A2B5, NG2, O4, and MBP will help to characterise 
this variant of OL lineage cell. It would also be interesting to find out how long 
MOG+PLP+ cells can persist after treatment, which could be determined by 
maintaining the cultures for a longer period after FGF9-withdrawal. 
If the aberrant myelin produced in FGF9-treated cultures is undergoing 
degradation, it may undergo phagocytosis by microglia. To find out if this was the 
case, cultures were stained for MOG and the microglia marker, IBA1. The cultures 
were searched for the presence of myelin in microglial membranes using confocal 
microscopy. Producing 3D reconstructions showed microglia surrounding frilly 
myelin membranes but myelin was never detected within a microglial cell. A 
representative image of myelin and microglia in FGF9-treated myelinating cultures 
is shown in Figure 5.5. 
Myelinating cultures treated with FGF9 for 20 days showed a decrease in axon 
density (Figure 5.1 B). This was surprising as previous experiments with FGF9 
administered for 10 days found no change in the axons (Figure 1.3). In the 
experiments shown in this chapter, 10-day FGF9 treatments initiated at DIV 18 or 
28 produced no change in axon density compared to control cultures. This 
suggested that FGF9 has a detrimental effect on axons, but only after chronic 
exposure. When examining myelin at high magnification, axonal abnormalities 
were observed in FGF9-treated cultures (Figure 5.2 C, D). These can be 
characterised as swellings or beading along axons with bright and dim regions of 
neurofilament staining. Interestingly, regions of axons that were swollen also 
lacked myelin (yellow arrows in Figure 5.3 C, D) even though the axon at either 
side of the swelling was myelinated. This raises two possibilities: either aberrant 
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myelination leaves regions of axons nude and these become swollen, or axon 
swelling occurs first and these portions lose their myelin sheathes. A similar 
axonal phenotype was observed in FGF9-treated cultures regardless of the 
duration or initiation point of treatment (Figure 5.6). 10 and 20-day FGF9-treated 
cultures display swellings and variable brightness of neurofilament staining 
indicating that even though axon density is not reduced by short treatments, an 
underlying axonal pathology is taking place. 10 days after FGF9 withdrawal this 
pathology is still present (Figure 5.6 F), which suggests even short exposure to 
high levels of FGF9 can induce a prolonged axonal pathology. To continue this 
research a system of quantification of axonal swellings will need to be developed 
in order to compare pathology following different lengths of FGF9 treatment.  
The next experiments performed in this chapter looked at OL lineage cell numbers 
in myelinating cultures following alternating FGF9 treatment. It was hypothesised 
that the increase in myelination observed in 10d FGF9 10d C cultures would be 
associated with a decrease in OPC numbers, but an overall increase in OL cell 
number. To assess this, myelinating cultures were treated with FGF9 and stained 
with antibodies against NG2 and Olig2. NG2+ cell numbers were greatly elevated 
immediately following FGF9 treatment for 10 or 20 days (Figure 5.7 A, 5.8 B, C). 
NG2+ cell numbers were almost the same following 10 and 20-day FGF9 
treatment suggesting that there is a ceiling to the number of OL progenitors that 
can be generated in this culture system. 10 days after FGF9 withdrawal (Figure 
5.7 A, 5.8 D), NG2+ numbers had returned to control levels, suggesting that 
progenitors in these cultures had differentiated. This finding fits with the idea that 
OPCs in the CNS are maintained as a constant reservoir during homeostasis and 
that, absent any interference, this pool will be regulated at a constant level 
(Hughes et al., 2013). Total OL numbers closely matched OPC numbers in FGF9-
treated cultures (Figure 5.7 B, 5.9). Olig2+ cell numbers were similarly elevated 
following 10 and 20-day FGF9 treatments, and were still elevated, albeit to a 
lesser degree 10 days after FGF9 withdrawal. Olig2+ numbers in these cultures 
were roughly twice that of the controls; however, the difference was not significant 
due to a large amount of variation between cultures. Lower OL numbers observed 
10 days after withdrawal of FGF9 suggests a degree of OL death following 
withdrawal of FGF9, however further experiments would be required to confirm 
this.  
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Axonal swellings and reduced axonal density are features of progressive MS and 
chronic inactive lesions in particular (Fisher et al., 2007). Axonal swellings are also 
a hallmark of defective axonal transport (Van Den Berg et al., 2017) which is a 
contributing factor to neurodegeneration in progressive MS. The presence of 
axonal swellings and reduction in axonal density in FGF9-treated myelinating 
cultures suggests there may be a deficit in axonal transport. Axonal trafficking of 
proteins, lipids, and mitochondria is essential for neuronal and synaptic function 
(Millecamps and Julien, 2013). Due to the extreme length of some axons, 
transport deficits in any region can lead to axonal degeneration and neuronal cell 
death. Defects in the cytoskeleton, microtubule organisation and motor protein 
expression can lead to breakdown of transport between the cell body and axon tip. 
Axonal transport deficits have been shown to play a role in the pathology of 
numerous neurodegenerative diseases.  
Following the finding that FGF9 is detrimental to axons in myelinating cultures, the 
microarray performed by Lindner et al., 2015 was screened for differences in 
axonal transport genes. Results from the microarray are shown in Table 5.1. 
Genes involved in axonal transport, structure, and neuronal differentiation and are 
significantly downregulated following 10-day FGF9 treatment. Some of the genes 
are downregulated at 24 hours however, the effect is more pronounced at 10 days. 
FGF2 also downregulated these genes following 10-day treatment but to a lesser 
degree than with FGF9. Validation of these results by qPCR found that all the 
genes in Table 5.1 were downregulated by FGF9 except Dnac3, Tubb3, and 
Dynlrb2 (Figure 5.10). This suggests FGF9 might interfere with axonal transport by 
directly or indirectly downregulating gene expression which may be the reason for 
the axonal pathology shown in Figure 5.1, 5.3, and 5.6. As discussed in Chapter 1, 
FGFs are differentiation and survival factors for neurons and function mostly 
during embryonic development. Their potential roles in axon transport have not yet 
been investigated.  
The next step in the investigation of the effect of FGF9 on neurons and axons was 
to produce enriched neuronal cultures. This was performed as described in section 
2.2.6.8. Neurons in these cultures are fully differentiated by DIV 6, therefore this 
time point was chosen to begin treatment. Neurons were treated with FGF9 for 10 
days, then fixed and stained with antibodies against neuronal cell bodies (MAP2) 
and axons (SMI31). The cells were imaged and neuronal cell counts and axon 
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densities were quantified. 10-day FGF9 treatment reduced axon density at DIV 16 
by almost 50% (Figure 5.11 A). Neuron numbers were also reduced by around 
50% however, due to variation in the cultures this result was not significant and will 
have to be repeated (Figure 5.11 B). As neuronal differentiation peaks by DIV 6, 
reduction in axon density and neuron number most likely represents a loss of 
neurons as a result of FGF9 treatment.  
As this is an enriched culture system, generated from whole cortex, some 
contaminating CNS cells are present. These include astrocytes, microglia, OLs, 
and undifferentiated neuroprogenitor cells. B27 supplement in neuron 
differentiation media inhibits glial cell development but does not prevent 100% of 
glial cell generation. Contaminating OLs and astrocytes are believed to cause the 
massive increase in DAPI+ nuclei seen after FGF9 treatment (Figure 5.12 B). As 
inhibition of myelination by FGF9 is an indirect effect facilitated by astrocytes, it is 
possible that the effects of FGF9 on neurons also results from FGF9 signaling via 
another cell type. It is also possible that the massive proliferation induced by FGF9 
indirectly damages neurons, perhaps through increased metabolic stress. To 
address these issues, the experiment was repeated with the addition of FdU from 
DIV 4. FdU kills dividing cells so will eliminate contaminating glia that proliferate in 
the presence of FGF9 while leaving neurons intact. This ensures any indirect 
effects of FGF9 via contaminating cells are prevented.  
Addition of FdU alone reduced axon density and neuron numbers (Figure 5.11 C, 
D; 5.12 C, D). This may be due to a loss of trophic support provided by 
contaminating astrocytes and OLs being lost to FdU treated neurons, or a loss of 
neurons that were still undergoing differentiation. Ultimately, co-treatment with 
FdU completely abrogated the effects of FGF9 on neurons and axon density 
(Figure 5.11 C) and cell counts (Figure 5.11 D) were unchanged versus controls. 
This result does not resolve whether the effect of FGF9 on neurons is due to 
downstream signaling via other cell types or due to metabolic stress as a result of 
massive proliferation; however, it shows that FGF9 is not detrimental to neurons 
directly.   
Further experiments will be required to resolve the precise mechanism or 
mechanisms responsible for FGF9’s detrimental effect on axons. The findings that 
axonal pathology in myelinating cultures resembles axonal transport deficit, and 
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axonal transport genes are downregulated by FGF9 strongly suggests that this is 
at least a contributing factor. Axons observed in FGF9-treated cultures share 
characteristics with degenerating axons in progressive MS suggesting FGF9 might 
be contributing to disease pathogenesis. In addition to the effects on axons, pre-
treatment with FGF9 also interferes with OL differentiation and myelination and 
therefore likely contributes to failure of remyelination even when the factor is 
downregulated. These findings have wider implications in the investigation of FGF 
signaling as a therapeutic target in MS.   
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CHRONIC OVER-EXPRESSION OF FGF9 
INDUCED DEMYELINATION AND AXONAL 
PATHOLOGY 
6. CHRONIC OVER-EXPRESSION OF FGF9 
INDUCED DEMYELINATION AND AXONAL 
PATHOLOGY 
6.1 INTRODUCTION 
Results from the previous chapter show pre-treatment with FGF9 can perturb 
myelination, and therefore, increased OPC proliferation due to FGF9 may yield no 
therapeutic benefit in MS. Surprisingly, prolonged FGF9 treatment also led to 
axonal pathology and reduced neuron numbers in vitro. Several studies have 
shown FGF9 to be a neuroprotective factor: spinal and basal forebrain neurons 
survive longer in vitro with FGF9 treatment (Kanda et al., 1999, Garcès et al., 
2000, Kanda et al., 2000). FGF9 also enhanced choline acetyltransferase activity 
in neurons (Kanda et al., 2000, Kanda et al., 1999). FGF9 treatment protected 
dopaminergic neurons from 1-methyl-4-phenylpyridinium toxicity and blocking 
endogenous FGF9 induced neuronal apoptosis (Huang et al., 2009, Huang and 
Chuang, 2010). Contrary to the findings of these studies, results from the previous 
chapter indicate FGF9 can also be pathogenic to neurons.  
Increases in FGF9 expression have been demonstrated in response to several 
CNS pathologies but the effects of prolonged over-expression on the CNS have 
not yet been investigated. The aim of this chapter was to investigate the effects of 
chronic over-expression of FGF9 in the CNS. Adeno Associated viral vectors 
(AAVs) are single stranded DNA viruses that require other viruses to replicate 
making them ideal transduction vectors (Naso et al., 2017). They have been used 
extensively in transduction studies as they do not cause disease or severe 
immune responses, they can infect dividing and quiescent cells, and their genes 
do not integrate into the host genome. This ability to infect non-dividing cells is 
especially useful when studying the brain as neurons do not undergo cell division 
(Yu et al., 2013). Adeno-associated virus serotype 6 (AAV6) is the most neuron-
specific of all AAV serotypes in rat brain (Salegio et al., 2013). Gene expression 
resulting from AAV6 gene transfer has also been shown to persist for several 
months (Yu et al., 2013) allowing the effects of long-term over expression of FGF9 
to be investigated. 
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To study the effects of chronic FGF9 treatment in isolation and delineate them 
from other factors at work in MS, an in vivo model of chronic over-expression was 
established. AAV6 containing FGF9 or enhanced green fluorescent protein (eGFP) 
sequences were injected into the cortex of Lewis rats as detailed in section 2.6.2. 
Gene expression was placed under control of the GFAP promoter in an attempt to 
target expression in astrocytes. Brains from these animals were harvested and 
processed for immunohistochemical/ immunofluorescence analysis ten days, thirty 
days, three months, and 9 months following the gene transfer procedure. 
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6.2 Results 
6.2.1 FGF9 expression appeared in neurons following AAV6 
infection 
The initial step in these experiments was to determine when FGF9 expression 
began and how long it persisted for in the cortex following gene transfer. Spinal 
cord motor neurons are known to be the main source of FGF9 in the CNS, 
therefore spinal cord sections were used as a positive control for FGF9 expression 
(Nakamura et al., 1997) (Figure 6.1 A). Brains from each time point, 10 days, 30 
days, 3 months, and 9 months post injection (PI) were stained for FGF9 
expression and analysed by immunofluorescence microscopy. No FGF9 staining 
was detected at the injection site 10 days PI (Figure 6.1 B). By 30 days PI, robust 
FGF9 staining was observed in cells morphologically identified as neurons (Figure 
6.1 C). At 3 months and 9 months PI (Figure 6.1 D, E) FGF9 was still being 
expressed around the injection site. 
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Figure 6.1. FGF9 was expressed by neurons following injection with AAV6-Fgf9 
vectors. Infections were performed using (AAV-6)-based vectors containing Egfp (pAAV-
egfp) and Fgf9 (AAV6-Fgf9) as described in section 2.6.2. Spinal cord motor neurons were 
used as a positive control for FGF9 staining (A) FGF9 was absent 10 days PI (B) but was 
robustly expressed by cells morphologically identified as neurons after 30 days (C), 3 
months (D), and 9 months (E). 
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6.2.2 FGF9 overexpression caused extensive demyelination 
After establishing that FGF9 expression is maintained throughout the full course of 
these experiments, the first question asked was what effect such chronic exposure 
would have on myelin in these animals. Cortical sections from each time point 
were stained with antibodies against five myelin proteins: CNPase, MAG, MBP, 
MOG, and PLP. 10 days PI, no differences between myelin adjacent to the 
injection site and the rest of the cortex were detected in AAV6-Fgf9 rats (Figure 
6.2 A). By 30 days PI, an area of reduced myelin density demarcated by a sharp 
border, shown in Figure 6.2 B, could be seen extending from the cortex into the 
white matter. After 3 months PI, the area surrounding the injection site was almost 
completely devoid of PLP staining (Figure 6.2 C). Little change was then observed 
at 9 months PI and the lesion remained completely demyelinated (Figure 6.2 D). 
To quantify these changes in myelination, FIJI (ImageJ) software was used to 
calculate DAB deposition for each of the myelin proteins in lesions from their first 
appearance at 30 days PI to 9 months as described in section 2.6.3. This method 
only allowed myelination to be quantified after the onset of lesion development, as 
a border must be visible to select out an area of myelin for analysis. At 1 month PI, 
lesions in AAV6-Fgf9 brains appear fairly normal with regards to myelination and a 
subtle area of myelin loss is only just identifiable compared to the surrounding grey 
and white matter. At this stage, the area of lesions covered by all five myelin 
proteins averaged around 40% (Figure 6.3). By 3 months, deposition of all myelin 
proteins had decreased, but to variable degrees: e.g. MBP covered 25% of the 
lesioned area at this stage while PLP stained in only 6%. There was little change 
in the area covered by each myelin protein at 9 months indicating that 
demyelination had reached its maximum by 3 months PI. Numbers of lesions 
stained at each time point varied between two and five so statistical analysis could 
not be performed on this data. 
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Figure 6.2. Representative images of progressive demyelination in AAV6-Fgf9 
lesions. Infections were performed using (AAV-6)-based vectors containing the Fgf9 
(pAAV-Fgf9) as described in section 2.6.2. Rats were euthanized at each time point and 
their brains were fixed and processed for immunohistochemical analysis. Sections from 
lesions at different time points were stained for the presence of five myelin proteins. 10 
days PI (A) PLP staining is normal and no lesion can be defined at the site of injection. By 
30 days, an area of disrupted PLP staining with a distinct border can be defined (B). At 3 
months these lesions have lost most or all PLP staining (C), which remains unchanged 9 
months PI (D).  
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Figure 6.3. Demyelination took place between one and three months following 
injection with AAV6-Fgf9. Sections from lesions at different time points were stained 
for the presence of five myelin proteins. Area of myelination per lesion was calculated 
using particle analyser in ImageJ, described in section 2.6.3. No lesions were detected 
10 days PI. The expression of each myelin protein correlates strongly at each stage of 
lesion development and decreases from a mean of 40% of lesion myelinated to 15% at 1 
month and 3 months respectively. 
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6.2.3 Demyelinated lesions accumulated β-APP+ axonal swellings 
over time  
To determine whether the axonal pathology observed in in vitro cultures treated 
with FGF9 also occurs in vivo, FGF9-overexpression lesions were stained for the 
presence of beta-amyloid precursor protein (β-APP+) axonal swellings. Sections 
from AAV6-egfp and AAV6-Fgf9 animals from each time point were stained and β-
APP+ swellings per mm2 were quantified by light microscopy. No β-APP+ swellings 
were found at the injection site in either treatment group 10 days PI (Figure 6.4 A, 
E). At no time point PI were β-APP+ axons detected in AAV6-egfp animals (Figure 
6.4 A – D). In one of three AAV6-Fgf9 animals at 30 days PI, β-APP+ axonal 
swellings were detected (Figure 6.4 F), suggesting lesion formation begins at 
around 30 days. By 3 months PI, all three animals in the AAV6-Fgf9 treatment 
group displayed β-APP+ axons. β-APP+ swellings were more numerous at 3 
months (Figure 6.4 G) and 9 months PI (Figure 6.4 H) suggesting chronic 
exposure to FGF9 causes a progressive axonal pathology. Quantification of β-
APP+ axonal swellings (Figure 6.5) found this to be the case: 1 month PI =110 ± 
190.5 β-APP count/mm2. 3 months PI = 383.3 ± 65.1 β-APP count/mm2. 9 months 
PI = 760 ± 72.1 β-APP count/mm2. 
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Figure 6.4. Representative images of β-APP staining in rat cortex following AAV6 
infection. No β-APP+ axons were detected in AAV6-egfp animals at 10 days, 30 days, 3 
months, or 9 months (A – D). AAV6-Fgf9 animals appear normal at 10 days PI (E) but 
have begun to display β-APP+ axons at 30 days (B) β-APP+ axons numbers continue to 
increase at 3 months (G) and 9 months (H) PI. 
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Figure 6.5. β-APP+ axonal swellings appeared 30 days PI in pAAV-Fgf9 lesions 
and accumulated as lesions persisted. Sections from  lesions at different time points 
were stained for the presence of β-APP. β-APP counts from three brains per time point 
were performed under a light microscope at 40X magnification and repeated once. 
Quantification of β-APP shows that axonal damage is absent before the onset of 
demyelination at 10 days but by 30 days 1 lesion had β-APP+ axonal swellings whose 
number increase at 3 months and 9 months PI. Data presented are the means ± SD, 
*P<0.05; **P<0.01 (one way ANOVA with Bonferroni’s multiple comparison test).  
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6.2.4 Astrocytes in FGF9-overexpressing lesions upregulated 
Sprouty2 but not FGF9 
Lesions in AAV6-Fgf9 rats share many characteristics with MS lesions such as 
demyelination and axonal pathology. To determine whether astrocytes were 
induced to express FGF9 in the rat model, as they have been shown to do in MS 
(Lindner et al., 2015), lesion sections were double-stained with FGF9 and GFAP 
antibodies. In vivo, GFAP staining is strongly associated with reactive gliosis 
(Pekny and Pekna, 2014). 10 days after injection with eGFP and FGF9 vectors, 
reactive astrocytes can be seen along the needle tract (Figure 6.6 A, B). A few 
reactive astrocytes persist in AAV6-egfp animals at 1 month and 3 months PI 
(Figure 6.6 C, E) but FGF9 staining is not detected at any time point in these 
animals. In contrast, AAV6-Fgf9 animals display a marked increase in astrocyte 
reactivity associated with expression of FGF9 at 1 month and 3 months PI (Figure 
6.6 D, F). No colocalization of FGF9 in GFAP+ astrocytes was observed, 
suggesting FGF9 overexpression and the resulting demyelination and axonal 
pathology are not drivers of astrocytic FGF9 expression.  
FGF signaling feedback inhibitor expression is associated with FGF9 expression 
and treatment in MS lesions and myelinating cultures respectively, as 
demonstrated in chapter 3. In AAV6-egfp animals, no FGF9 or Sprouty2 was 
detected 10 days, 30 days, or 3 months PI (Figure 6.7 A – C). 10 days PI no FGF9 
or Sprouty2 expression was detected in AAV6-Fgf9 animals (Figure 6.7 D). By 30 
days PI FGF9 expression is robust and astrocytes have become reactive. 
Astrocytic expression of Sprouty2 also greatly increases (Figure 6.7 E). Sprouty2 
expression persisted at 3 months in FGF9 over-expressing animals (Figure 6.7 F). 
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Figure 6.6. Astrocytes did not express FGF9 in AAV6-Fgf9 lesions. Sections from 
AAV6-egfp and AAV6-Fgf9 brains were double labelled with antibodies against FGF9 and 
GFAP. Some astrocytic GFAP upregulation is observed at 10 days PI along the needle 
tract in AAV6-egfp brains and this persists at 30 days and 3 months PI (A – C). No FGF9 
expression was detected in these animals. AAV6-Fgf9 brains display similar GFAP 
staining as AAV6-egfp controls, with no FGF9 expression at 10 days PI (D). 30 days (E) 
and 3 months (F) PI more extensive astrocyte activation is observed but this was not 
associated with astrocytic expression of FGF9. 
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Figure 6.7. Sprouty2 staining appeared in astrocytes in AAV6-Fgf9 lesions. Sections 
from AAV6-egfp and AAV6-Fgf9 brains were double labelled with antibodies against 
FGF9 and Sprouty2. No cells stained with either antibody in the controls or AAV6-Fgf9 
animals 10 days PI (A – D). Sprouty2 staining appeared in cells morphologically identified 
as astrocytes 30 days (E) and 3 months (F) after AAV6-Fgf9 injection. 
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6.3 Discussion 
Most of the data so far generated regarding FGF9 in the CNS has focused on its 
roles in embryonic development and cancer. The functions of FGF9 in the healthy 
human CNS are still relatively unclear and as FGF signaling is so complex, are 
unlikely to be fully understood any time soon. FGF9 was identified as a potential 
therapeutic target in MS through imaging of MS lesions and by testing FGFs in 
myelinating cultures (Lindner et al., 2015). FGF9 signaling in the CNS is so 
complex because of its interactions with neurons, astrocytes, and OLs (Chapter 3). 
It can also induce a plethora of direct and indirect effects by utilising multiple 
signaling pathways. As a result, there is likely to be a lot of functional overlap with 
other factors that are expressed in MS, such as FGF2 for example. In order to 
delineate the effects of dysregulated FGF9 signaling from the complexity that is 
the MS lesion signaling environment, the effects of FGF9 in the CNS have to be 
studied in the absence of complicating factors.  
Dr Claudia Wrsoz set up a model of chronic FGF9 overexpression in collaboration 
with Prof Christine Stadelmann’s research group at the University of Göttingen. 
(Lindner et al., 2015) proposed that FGF9 contributes to the pathogenesis of MS 
by preventing remyelination and promoting the recruitment of inflammatory cells 
via chemokine induction. Therefore, this model was established under the 
hypothesis that if FGF9-overexpressing animals were given EAE, higher levels of 
FGF9 would enhance inflammation and limit remyelination which would hamper 
functional recovery. However, immunohistological characterisation of the area 
surrounding the injection site in these animals revealed FGF9 overexpression to 
have profound detrimental effects, which resembled some of the histopathological 
features of MS lesions. 
Astrocytes were the intended target of FGF9 expression in this model as they are 
abundant in the CNS and were shown to express FGF9 in MS lesions (Lindner et 
al., 2015). FGF9 expression was placed under control of the GFAP promotor 
however, astrocytic expression of FGF9 was never detected at any time point 
following AAV6 injection, and neurons appeared to be the only cell type that 
expressed the growth factor (Figure 6.1). This is perhaps due to a leaky promotor 
and the high propensity of AAV6 vectors to preferentially infect neurons (Salegio et 
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al., 2013). Expression of FGF9 was still present after 9 months, as would be 
expected with AAV transduction (Zincarelli et al., 2008), however no expression 
was observed at 10 days (Figure 6.1 A). Gene expression following AAV6 
transduction has been shown as early as 3 days after treatment in mouse heart 
(Zincarelli et al., 2010) but  there is likely some variation in expression time 
depending on the type of cell being targeted and the gene being transduced. 
Robust FGF9 expression was detected at 30 days (Figure 6.1 B) so it is likely 
expression began soon after the 10-day time point. 
Lesion formation was first detected in FGF9 overexpressing rats 30 days PI as a 
slight decrease in DAB deposition and irregular distribution of myelin proteins 
surrounding the injection site (Figure 6.2 B). Lesions remained confined to the 
area surrounding the injection site and were progressively demyelinated. By 3 
months PI (Figure 6.2 C), virtually no myelin protein staining was detected within 
the lesioned area and myelin loss persisted until the end of the experiment at 9 
months (Figure 6.2 D). Myelin in AAV6-egfp animals appeared normal throughout 
the experiment. The sharp border between the demyelinated lesion and 
surrounding NAWM is likely due to the very limited diffusion distance of 
paracrine/autocrine FGFs; HSPGs on the surface of cells and the ECM prevent 
diffusion more than a few cell-widths from the site of secretion (Storey et al., 
1998). Quantification of myelin protein staining in FGF9 overexpressing lesions 
revealed demyelination occurred between 1 and 3 months PI and then little 
change occurred between 3 and 9 months PI (Figure 6.3). 
These results were interesting as previous studies have shown that FGF9 reduces 
myelin protein expression and differentiation in developing OLs (Cohen and 
Chandross, 2000), however, in mature OLs FGF9 only enhanced process 
elongation and did not induce de-differentiation (Fortin et al., 2005). Results in the 
last chapter showed that 10-day FGF9 treatment from DIV 28 - 38 did not induce 
demyelination in myelinating cultures (Figure 5.1). The difference between in vivo 
and in vitro findings is perhaps due to a timing discrepancy, as disruption of myelin 
did not become apparent until 30 days PI in AAV6-Fgf9 rats so perhaps longer 
treatment with FGF9 in vitro would cause demyelination. There may also be 
influence from the immune system in vivo which precipitated the observed 
demyelination. 
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These findings resemble those from (Butt and Dinsdale, 2005) who demonstrated 
that continuous injection of FGF2 into rat CSF disrupted mature OLs and caused 
demyelination. Chronic high levels of FGF9 appear to have a similar effect but 
demyelination occurred after just 3 days in the FGF2 experiments suggesting 
different mechanisms are involved. 
Axonal β-APP immunoreactivity is a commonly used marker for axonal injury 
(Sherriff et al., 1994). No β-APP+ axons were detected in AAV6-egfp brains at any 
time point and AAV6-Fgf9 brains at 10 days PI (Figure 6.4 A – E). β-APP+ axonal 
swellings appeared concurrent with the onset of demyelination in FGF9-over-
expressing lesions (Figure 6.4 F). β-APP+ axons were not detected in any sections 
in which myelin disturbances were not also apparent suggesting axonal pathology 
follows myelin disruption in this model. While demyelination peaked at 3 months PI 
in FGF9 over-expressing animals, β-APP+ axon counts doubled between 3 and 9 
months PI. This suggests high levels of FGF9 causes a slowly progressing axonal 
pathology. Loss of myelin and the associated trophic support and metabolic strain 
is a likely contributing factor to axonal pathology seen in these lesions (Nave, 
2010). As discussed in the introduction to this chapter, FGF9 has neuroprotective 
properties, and it is unclear if FGF9 is performing any of these functions in AAV6-
Fgf9 rats. It is possible the pro-survival functions of FGF9 in neurons are simply 
incapable of compensating for the impact of prolonged demyelination and 
astrocyte activation brought on by its over-expression. There may be a dose effect 
in that a certain concentration of FGF9 protects neurons in the brain and above 
this threshold becomes damaging, or FGF9 is protective in the short term but 
becomes pathogenic with chronic exposure. Hopefully, future experiments will be 
able to answer these questions. These results also support in vitro findings from 
the previous chapter that showed FGF9 could be detrimental to neurons and 
axons.   
Astrocyte activation, or reactive astrocytosis, is a common feature of MS lesions 
and is thought to exacerbate and mitigate pathogenesis in MS (Correale and 
Farez, 2015). (Lindner et al., 2015) demonstrated that inhibition of myelination by 
FGF9 is dependent on astrocytes and this effect was accompanied by a pro-
inflammatory chemokine response predicted to drive inflammation. Astrocyte 
activation was extensive in FGF9-over-expressing lesions, in which strong GFAP 
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reactivity was detected from 30 days PI and persisted to at least 3 months PI 
(Figure 6.6, 6.7). FGF9 staining did not colocalize with GFAP in AAV6-Fgf9 lesions 
suggesting FGF9 does not drive its own expression in astrocytes. These findings 
also indicate that myelin and axonal damage observed in AAV6-Fgf9 lesions do 
not drive FGF9 expression directly. This suggests that similar destruction in MS 
may also not be responsible for FGF9 expression associated with MS but further 
studies will be required to test this hypothesis. 
In Chapter 3, the FGF feedback inhibitors Sprouty2 and Sprouty4 were visualised 
mostly in astrocytes in MS lesions. FGF9 induced feedback inhibitor expression in 
myelinating cultures while FGF1 and FGF2 did not. Astrocytes upregulated 
feedback inhibitor expression at the mRNA and protein level only in response to 
FGF9. These findings suggested that feedback inhibitor expression in astrocytes is 
mainly a response to FGF9 signaling. Sprouty2 was visualised in astrocytes 
adjacent to FGF9-expressing neurons 30 days and 3 months PI in AAV6-Fgf9 
lesions (Figure 6.7). Astrocytic Sprouty2 expression corresponded with onset of 
demyelination and axonal pathology. As inhibition of myelination in vitro is 
astrocyte dependant and astrocytes respond to FGF9 in AAV6-Fgf9 lesions, it is 
tempting to speculate that demyelination in these lesions is also astrocyte 
dependant but further experiments will be required to determine if this is the case. 
Pinpointing the exact time within the first 30 days of FGF9 expression, astrocytic 
Sprouty2 expression, and demyelination take place, would reveal whether 
astrocytes are activated before or after the onset of demyelination.  
In MS, FGF9 is thought to contribute to pathogenesis by inhibiting remyelination 
and inducing pro-inflammatory chemokine production, both of which are 
dependent on astrocytes. By inducing FGF9-over-expression in rat cortex, results 
in this chapter have shown increased levels of FGF9 are sufficient to induce 
formation of demyelinated lesions with extensive axonal pathology, the two major 
hallmarks of MS. These lesions progressively demyelinated over months and were 
accompanied by a sustained astrocytic response. Data from Figure 5.12 
demonstrated FGF9 does not induce axonal pathology directly. This suggests 
FGF9 might be causing axonal damage via astrocytes in a similar fashion to how 
FGF9 inhibits myelination. In summary, these results combined with findings from 
the previous chapter support a role for FGF9 as a neurodegenerative agent in MS.  
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7 GENERAL DISCUSSION 
FGF signaling represents a relatively unexplored area of research in the study of 
MS pathogenesis. FGF9 has long been a factor of interest in the study of several 
cancers as it is a potent mitogen and survival factor that promotes tumorigenesis 
(Todo et al., 1998). Some studies have alluded to a role for FGF9 in the CNS as a 
protective factor in neurodegenerative diseases like Parkinson’s, ALS, and 
Alzheimer’s disease (Nakamura et al., 1998b, Nakamura et al., 1998a, Huang et 
al., 2009, Huang and Chuang, 2010). In these studies, the presence of FGF9 
protected neurons from death from a variety of toxic insults. FGF9 emerged as an 
interesting target in the study of demyelinating disease when it was found to inhibit 
myelination in a screen of myelinating cultures (Lindner et al., 2015). This effect 
was associated with the appearance of OLs displaying a premyelinating 
phenotype that also expressed mature myelin proteins. OLs in these experiments 
resembled OLs seen in chronic MS lesions (Chang et al., 2002). Further research 
led to the discovery that astrocyte-dependant mechanisms are responsible for 
inhibition of myelination seen with FGF9. Although FGF9 inhibited myelination, it 
promoted OPC proliferation, which is believed to be a beneficial process in trying 
to promote remyelination in MS. Despite these findings, relatively little is known 
about the functions of this pleiotropic growth factor in MS and experiments in the 
course of this thesis have set out to address this problem. In particular, this work 
has focused on elucidating which cell types respond to FGF9 signaling in the CNS. 
Experiments were performed to screen inflammatory factors associated with MS to 
determine whether any caused induction of FGF9 in CNS cells. The effects of 
long-term exposure to FGF9 were investigated in vitro and in vivo, and neuronal 
cultures were studies with regard to the effects of FGF9 on axonal integrity and 
transport.  
The first set of experiments performed in the course of this research went back 
into human brain samples used by Lindner et al. to try to determine the targets of 
FGF9 signaling in MS. MS brains displayed higher levels of FGF-feedback 
inhibitors, correlating with the presence of FGF9. The same cell types associated 
with FGF9 expression in MS, astrocytes and OLs, were found to express FGF-
feedback inhibitors. Feedback inhibitor expression was also more common in 
acute MS than chronic MS, as is FGF9. In acute lesions, astrocytes, OLs, and 
macrophages were FGF9+ and most often, these cells were Sprouty+ as well. 
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FGF9 was expressed at lower levels in chronic lesions and the same was true for 
the Sproutys. Expression of FGF9 and Sproutys was mostly limited to astrocytes 
in chronic lesions, likely due to the paucity of OLs and macrophages present at 
this stage of disease.  In summary, there was strong correlation between the cells 
expressing FGF9 and those expressing Sproutys in MS. These studies were 
limited in scope due to difficulty with using human tissue. Unlike with in vivo tissue 
or in vitro cells, there is often a long delay between death and fixation, which 
allows degradation of the tissue to take place and makes staining more difficult. Of 
the dozen antibodies specific for members of FGF-signaling pathways, only three 
were efficacious enough for staining. This limited the research that could be 
performed using archived MS brain samples.  
The expression of negative feedback inhibitors of FGF signaling, Sproutys and 
DUSPs, were then assessed in FGF-treated in vitro cultures. OLs and neurons 
responded similarly to FGF2 and FGF9 but astrocytes only upregulated feedback 
inhibitors in response to FGF9. This is despite the fact FGF1 and FGF2 are the 
most promiscuous FGFs and astrocytic responses to FGF1 and FGF2 have been 
demonstrated by other groups in the past  (Cassina et al., 2005, Gómez-Pinilla et 
al., 1995, Eclancher et al., 1996). In myelinating cultures, FGF9 induced feedback 
inhibitor expression while FGF1 and FGF2 did not, suggesting this may be a 
feature excusive to FGF9. Interestingly, FGF1 had almost no effect on any of the 
cells studied in these experiments. The reasons for discrepancies in feedback 
inhibitor expression are a mystery and warrant further investigation as these cell 
types are well documented to express FGFRs and feedback-inhibitor expression is 
a robust downstream signaling event following FGF-FGFR interactions, however 
this was not the case in these experiments. These findings were not anticipated as 
feedback inhibitor expression is the response most strongly associated with FGF 
signaling and the two are often intrinsically linked. Examining other aspects of FGF 
signaling in these cells, such as MAPK, AKT, and PLCγ activation should be 
investigated to determine if these cells were responding to FGF signaling at all. 
There may also be some discrepancy between previous studies that have shown 
FGF-feedback inhibitor expression mostly through in vivo staining and imaging, 
and these studies, which relied on in vitro cultures. Although myelinating cultures 
have all CNS cell types represented they are still very different from the in vivo 
environment, one major difference is these cultures are produced from embryos 
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and very young animals whereas most MS research focuses on the adult. These 
cultures also lack a functional immune and circulatory system which may impact 
reactions to different treatments. 
One crucial question regarding FGF9 in MS is why is it upregulated in the first 
place? The trigger or triggers for FGF9 expression are unknown in most contexts 
in which FGF9 has been investigated, but some clues have come from cancer 
studies. FGF9 induction has been shown in response to PGE2 (Wang et al., 2009), 
AhR activation (Chuang et al., 2006), and hypoxia (Chen et al., 2014). These 
factors along with a host of inflammatory and anti-inflammatory cytokines 
associated with MS were screened for their ability to induce FGF9 upregulation in 
myelinating cultures. None of the factors used in these experiments succeeded in 
upregulating FGF9 except hypoxia. Hypoxia was incredibly damaging to 
myelinating cultures as it killed neurons and OLs while sparing only astrocytes. 
Astrocytes survived hypoxia and reperfusion, and responded by increasing their 
expression of FGF9. Hypoxia is a well described component of MS pathogenesis 
(Lassmann, 2003) and these findings suggested it may also be involved in driving 
FGF9 expression by astrocytes in MS lesions. Colocalization studies of HIF1α in 
nuclei and FGF9 in cytoplasm of astrocytes in MS lesions could confirm whether 
hypoxia is indeed a trigger for FGF9 expression in MS. Macrophages polarised 
towards an anti-inflammatory phenotype were also induced to upregulate FGF9, at 
the mRNA level. This suggested an additional mechanism whereby FGF9 
expression could be induced by macrophages in a tissue repair context. This could 
also be investigated in MS as results from Chapter 3 showed that, where present, 
macrophages stained for the presence of FGF9. Future experiments should 
examine the phenotype of FGF9+ macrophages in MS lesions and determine 
whether there is a correlation between an anti-inflammatory phenotype and FGF9 
expression. In additional experiments looking at the effects of FGFs on 
macrophages directly, macrophages did not respond to FGF treatment by 
upregulating feedback inhibitor expression, or altering their polarization state or 
cytokine profile suggesting they are not targets of FGF signaling. 
Experiments performed in Chapter 5 attempted to address some basic questions 
about FGF9 and its effects on myelin using myelinating cultures. The most obvious 
consideration was whether FGF9 is a demyelinating factor. To test this query, 
Chapter 7 – General Discussion 182 
 
myelinating cultures were maintained until DIV 28, before treatment with FGF9 
was initiated. Myelinating cultures produce the majority of their myelin between 
DIV 18 and DIV 28 so this approach allowed for the effects of FGF9 on mature 
myelin to be observed, as opposed to previous research that focused on the effect 
of FGF9 treatment on primary myelination (Lindner et al., 2015). Using this model 
it was found that FGF9 did not induce demyelination in cultures after ten days 
suggesting that FGF9 is not a demyelinating factor. Withdrawing FGF9 from 
cultures that were treated from DIV 18 – 28, and maintaining them in control media 
for a further ten days had surprising results. Pre-treatment with FGF9 led to greatly 
increased myelin production, determined through greatly increased MOG+ staining, 
compared to control cultures at DIV 38. Analysis of these cultures under high 
power microscopy revealed the myelin produced following withdrawal of FGF9 at 
DIV 28 differed greatly from myelin in control cultures. This myelin had an irregular 
structure with large segments that were only loosely associated with axons, and a 
striking variety in the thickness of the myelin sheath along the length of one 
internode. This suggested there was a defect in differentiation and myelin 
production in OLs that have been exposed to FGF9, even when the factor is 
removed.  
Findings from the previous section raised the question: what happens to OPCs 
that are produced as a result of FGF9-induced proliferation? Can they go onto 
mature and myelinate or does FGF9 irreparably alter them in some way? In these 
cultures it appeared as though OLs had attempted to mature and myelinate but 
were unable to do so following the withdrawal of FGF9. Further staining and 
imaging studies revealed the presence of MOG+PLP+ OLs with the proteins 
randomly distributed throughout cell bodies and processes. This effect had not 
been described before and these cells somewhat resemble mature OLs that 
undergo de-differentiation when treated with FGF2 (Bansal and Pfeiffer, 1997). 
This suggested similar mechanisms might underlie the appearance of aberrant 
myelin in FGF9-treated cultures and the de-differentiation observed in FGF2-
treated OLs. Future studies along this line of enquiry should focus on the effects of 
FGF9 pre-treatment on OL maturation and myelination, and try to determine at 
which point in differentiation OLs begin to exhibit these unusual characteristics. As 
these effects were observed ten days after treatment was ended, these findings 
suggest exposure to high levels of FGF9 may render OLs produced from FGF9-
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induced proliferation unable to develop normally. This would have potential 
implications on the failure of remyelination observed in many MS cases. 
Examining axons in cultures from the previous section under confocal microscopy 
revealed that long-term treatment with FGF9 resulted in axonal loss and the 
appearance of axonal swellings. These findings somewhat resembled features of 
axonal transport deficit so axonal transporter gene expression was assessed in 
FGF9-treated myelinating cultures. The outcome of this experiment was a 
downregulation of axonal transporter genes following FGF9 treatment suggesting 
FGF9 may actually be detrimental to neurons, in contradiction to the current 
literature. Following these results, enriched neuronal cultures were generated and 
treated with FGF9 and these cultures displayed a reduction in total neuronal cell 
counts and axonal density. This effect could be overcome by the addition of FdU, 
a cytotoxic agent that kills proliferating cells. This showed the effects of FGF9 on 
neurons was indirect, and likely a result of astrocyte-dependant signaling or 
metabolic stress. Additionally, neurons express FGFR1 and FGFR4 while FGF9 is 
specific for FGFR2 and FGFR3 further supporting the hypothesis that FGF9 does 
not signal in neurons directly to mediate these detrimental effects. These 
experiments showed for the first time that FGF9 could be harmful to neurons while 
most other research has focused on its neuroprotective capabilities. To continue 
this line of experimentation, FGF9-treated astrocyte supernatants should be 
administered to neuronal cultures to determine whether a soluble astrocyte-
derived factor is responsible for these effects as is the case for myelination 
(Lindner et al., 2015). Following this the microarray from FGF9-treated myelinating 
cultures mentioned previously in this thesis should be screened for upregulated 
candidates that regulate axonal transport and neuronal survival. These factors 
could then be tested on neurons to see if the effects observed with FGF9 can be 
replicated. 
Chapter 6 focused on the over-expression of FGF9 in rat cortex. Unexpectedly, 
chronic over-expression of FGF9 induced demyelination and axonal pathology 
over the course of nine months. By 30 days, the formation of demyelinated lesions 
and the appearance of β-APP axonal swellings were apparent in FGF9-over 
expressing brains while brains injected with a control vector remained healthy 
throughout the experiment. These lesions had completely demyelinated by three 
Chapter 7 – General Discussion 184 
 
months and axonal β-APP swellings continued to accumulate until the end of the 
experiment at nine months. Lesions in FGF9 over-expressing animals were 
associated with Sprouty2 staining in astrocytes. These lesions displayed 
characteristics strikingly similar to MS lesions, such as demyelination, axonal 
pathology, astrocyte activation and Sprouty2 expression. This suggests that FGF9 
may be also be involved in MS lesion development, as well as failure of 
remyelination and axonal pathology and further in vivo  research should focus on 
more robustly examining lesion development in FGF9-overexpressing cortex. 
Future in vivo experiments should also address the potential roles of FGF9 in EAE 
as one of the most widely used models of MS.  
Taken together, the results shown in this thesis support the hypothesis that FGF9 
can mediate a host of detrimental effects on cells of the CNS and may be a more 
prominent factor in MS lesion development and progression than previously 
thought. Before commencement of experiments in this thesis, FGF9 was believed 
to contribute to remyelination failure in MS and promote inflammation via 
inflammatory chemokine expression but this research expands on the potential 
detrimental mechanisms of FGF9 in the CNS. In in vitro and in vivo models, FGF9 
has been shown to negatively impact OL differentiation, myelination, axonal 
integrity, and neuronal numbers. This work also showed astrocytes appear to be 
particularly receptive to FGF9 signaling compared to other cell types in the CNS. 
Astrocytes also produce FGF9 in response to hypoxia, a common feature of MS 
lesions. Infiltrating macrophages are also sources of FGF9 in MS lesions and 
experiments shown here suggest this is largely a feature of repair-oriented 
macrophages. In addition to inhibiting myelination, FGF9 was shown to perturb 
myelination by OPCs generated as a result of FGF9 treatment. This suggests 
FGF9 induces long lasting changes in cells of the OPC lineage that interfere with 
maturation. Chronic over-expression of FGF9 also led to the formation of 
demyelinating lesions. In summary, these experiments show that, in a variety of 
model systems, FGF9 is involved in demyelination and axonal damage as well as 
inhibition of myelination, the three major characteristic of MS. 
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8 APPENDICES 
8.1 Positive control stainings for Sprouty, DUSP, and FGF9 
antibodies 
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Figure 8.1. Positive control stainings for FGF9 antibodies used in 
immunohistochemistry and immunofluorescence. Antibodies against FGF9 were 
tested on tissues known to express each protein according to the Human Protein Atlas 
(https://www.proteinatlas.org/) and antibody specification sheets. Abcam FGF9 was 
more effective for immunohistochemistry while Abnova FGF9 was more effective for 
immunofluorescence. 
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Figure 8.2. Positive control stainings for antibodies used in immunohistochemistry 
and immunofluorescence. Antibodies against Sprouty2 (A, B), Sprouty4 (C, D), DUSP5 
(E, F), and DUSP6 were tested on tissues known to express each protein according to 
the Human Protein Atlas (https://www.proteinatlas.org/) and antibody specification 
sheets.  
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8.2 Cell culture purity analysis 
To assess their purity, astrocyte monolayers were stained with antibodies against 
markers of CNS cells (Figure 8.3). Monolayers were fixed at DIV 7 as this is when 
they are used for experiments or seeded with spinal cord progenitors to generate 
myelinating cultures. Astrocytes were not counted directly in this experiment as 
their density and irregular shape made this too difficult to do accurately. The only 
contaminating cell type was found to be OL lineage cells due to the prevalence of 
Olig2 staining in astrocyte monolayers.  
As enriched neuronal cultures were used in experiments involving FGF9, a potent 
proliferative factor, it was important to investigate purity in the cultures. NeuN+ 
cells, signifying neuronal differentiation, appeared at DIV 3 and then remained at a 
steady level (Figure 8.4 B). As with astrocyte monolayers, OL lineage cells were 
the main contaminating cell type, proliferating exponentially between DIV 3 – 10 
(Figure 8.4 C). Astrocytes were rare in neuronal cultures but were detected from 
DIV5 and continued to proliferate to DIV 10 (Figure 8.4 D). Microglia were very 
rare or absent in most of the cultures examined (Figure 8.4 E). 
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Figure 8.3. Quantification of different cell types in astrocyte monolayers. 
Astrocyte monolayers were generated as described in section 2.2.1.2 and fixed for 
staining at DIV 7. Monolayers were stained with antibodies against cell nuclei (DAPI) 
OL lineage cells (Olig2), neurons (NeuN), and microglia (Iba1). Olig2
+ 
 cells were the 
most abundant contaminating cell type in astrocyte monolayers while neurons and 
microglia were never detected. This experiment was performed three times. 
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Figure 8.4. Quantification of different cell types in enriched neuronal cultures. 
Neurons were purified as described in section 2.2.5.8 and cultured in neuro-basal 
medium from 1 to 10 days before being fixed and processed for immunofluorescence. 
Cultures were stained for Olig2, NeuN, Iba1, and GFAP to identify oligodendrocytes, 
neurons, microglia, and astrocytes respectively. Cell numbers from each time point were 
quantified by manual counting except for Olig2 and DAPi counts which were done using 
CellProfiler. Overall cell numbers remained fairly constant from DIV1-10 (A). NeuN
+
 cells 
are present from DIV1 but reach and remain at their peak from DIV3 (B) Olig2+ cells 
begin appearing at DIV3 and these numbers increase rapidly by DIV 10 (C). Astrocytes 
appear around DIV5 and quickly proliferate by DIV10. Microglia were very rarely seen at 
any time in the cultures (E). This experiment was performed once. 
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8.3 FGF9 induced proliferation in astrocytes 
Low-density astrocyte cultures were generated as described in section 2.2.2. After 
1 week in culture, astrocytes were treated with 100 ng/mL FGF1, 2, or 9 for 3 
days. Astrocyte numbers were quantified by counting DAPI nuclei per field of view 
using CellProfiler. FGF9 induced a significant proliferative response by 3 days 
while FGF1 and FGF2 had no effect on cell numbers. C = 98.4 ± 36.5 cells/FOV, 
FGF9 = 160.5 ± 59 cells/FOV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.5 FGF9 induced proliferation in astrocytes in vitro. Low-density astrocyte 
cultures were generated as described in section 2.2.2 and treated for 72 hours with 100 
ng/mL FGF1, 2, or 9. Cells were fixed and stained and DAPI-positive nuclei were 
quantified using CellProfiler. Following FGF9 treatment cell numbers were increased 50% 
where as FGF1 and FGF2 appeared to have a slight but insignificant proliferative effect. 
This experiment was performed three times. ***, p < 0.001, (one-way ANOVA with 
Dunnett's Multiple Comparison Test). 
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8.4 Expression of FGFs and feedback inhibitors in EAE 
To investigate the expression and functions of FGF9 in EAE, Lewis rats were 
immunised against MOG. 100 μL complete Freund’s adjuvant containing 50 μg 
MOG1-125 was injected into rats subcutaneously at the base of the tail (n = 6).  
Animals were monitored for symptoms of EAE and sacrificed at the peak of the 
second phase of disease. Clinical scores and weights from control and EAE 
animals are shown in Figure 8.6. Animals were scored based on the criteria laid 
out in section 2.6.1.1. Symptoms first appeared at day 10 PI and peaked at a 
score of four on day 13. Weight decreased by an average of 35g in EAE rats by 
this time point. This was followed by a brief recovery period and clinical scores 
decreased to an average of two. By day 21, all but one animal in the EAE group 
developed severe disease and the experiment was stopped. Animals in both 
groups were sacrificed and the lumbar portions of their spinal cords were prepared 
for qPCR and immunohistological analysis. 
The first studies looked at expression of inflammatory markers in EAE vs control 
spinal cords. The polarized macrophage markers Nos2 and Arg1 were not up or 
down regulated in EAE cords compared to controls (Figure 8.7 A). Expression of 
inflammatory cytokine genes, Tnfa, and Ifny were significantly up regulated in EAE 
cords (Tnfa = 17.7 ± 13.4 fold, Ifny = 51.4 ± 72.6 fold). Expression of Fgf1 and 
Fgf9 did not vary strongly from control levels (Figure 8.7 B). Fgf2 expression was 
slightly elevated, 2.2 ± 0.7 fold. FGF feedback inhibitor genes, Spry2 and Dusp5 
were unchanged in EAE spinal cords (Figure 8.7 C). Spry4 was down regulated -
2.4 ± 1.1 fold, while Dusp6 was up regulated 5.5 ± 3.2 fold.  
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Figure 8.6. MOG
1-125
 induced EAE caused biphasic disease in Lewis rats. 10 12-
week-old female Lewis rats were immunised with 100 μL complete Freund’s adjuvant 
containing 50 μg MOG
1-125
 as described in section 2.6.1. Animals began showing 
symptoms and losing weight 10 days PI and the first phase of disease peaked at day 13. 
Animals partially recovered until day 16 when the second phase began. At day 21 some 
of the animals progressed to a clinical score of 6 so the experiment was stopped at this 
stage and the animals euthanized. 
Chapter 8 – Appendices 194 
 
 
 
 
 
 
Figure 8.7. FGF and feedback inhibitor expression was variable in EAE.  The 
lumbar regions of spinal cords from EAE and control rats were harvested and 
processed for qPCR as described in section2.6.1.2. qPCRs were ran with Gapdh as a 
house keeping control. CT values from 3 controls were averaged for each gene 
analysed and this value was used as the control. There was no change in Nos2 or Arg1 
expression in EAE (A) but Tnfa and Ifny were significantly up regulated. Fgf2 expression 
was increased while expression of Fgf1 and Fgf9 were not significantly up or down 
regulated (B). Spry4 expression was decreased slightly and Dusp6 was significantly up 
regulated while Spry2 and Dusp5 expression were unaffected by EAE (C). Data 
presented are the means ± SD. *, p < 0.05, **, p < 0.01 (Two-tailed T test of delta CT 
values).  
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8.5 FGF9 and Sprouty2 were associated with macrophages in 
EAE 
Results from the previous section suggest that FGF signaling is not a major 
feature of MOG induced EAE. To determine whether any changes in FGF9 
expression could be detected, EAE cords were fixed and prepared for 
immunohistochemistry. Sections were stained with antibodies against FGF9 and 
Sprouty2 in combination with GFAP, the OL markers P25 and Olig2, and the 
macrophage/microglia markers ED1 and IBA1. FGF9 staining was extensive in 
White matter regions and was not associated with GFAP in EAE (Figure 8.8 A) or 
P25 (Figure 8.8 B). There was strong colocalization of FGF9 and ED1 surrounding 
blood vessels indicating that infiltrating macrophages are producing FGF9 (Figure 
8.8 C). Sprouty2 staining did not colocalize in astrocytes (Figure 8.8 D) stained in 
a few OL nuclei (Figure 8.8 E) and macrophage/microglia cell bodies (Figure 8.8 
F). Due to time constraints further analysis was not performed. 
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Figure 8.8. FGF9 and Sprouty2 expression was visualised in macrophages/ 
microglia in EAE. Spinal cords from EAE rats were perfused with PFA and the lumbar 
portion prepared for immunohistochemistry as described in section2.6.1.2. Sections were 
double labelled with antibodies against FGF9 or Sprouty2 in combination with markers for 
astrocytes, OLs, and macrophages. FGF9 staining did not colocalize with GFAP (A) or the 
OL marker P25 (B), but was seen in ED1+ macrophages (C). Sprouty2 was also not 
detected in astrocytes (D) but did stain in OLs (E) and macrophages (F). 
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